

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 September 2001 (13.09.2001)

PCT

(10) International Publication Number
WO 01/66690 A2

(51) International Patent Classification⁷: C12N

(21) International Application Number: PCT/US01/07143

(22) International Filing Date: 5 March 2001 (05.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/187,107	6 March 2000 (06.03.2000)	US
60/188,916	13 March 2000 (13.03.2000)	US
60/236,874	3 October 2000 (03.10.2000)	US
60/237,846	3 October 2000 (03.10.2000)	US

(71) Applicants (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, Philadelphia, PA 19103
(US). **SMITHKLINE BEECHAM P.L.C.** [GB/GB]; New
Horizons Court, Great West Road, Brentford, Middlesex
TW8 9EP (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **AGARWAL,**
Pankaj [IN/US]; 251 West DeKalb Pike, King of Prussia,

PA 19406 (US). **MURDOCH, Paul, R.** [GB/GB]; New
Frontiers Science Park South, Third Avenue, Harlow,
Essex CM19 5AW (GB). **RIZVI, Safia, K.** [PK/US];
4617 Pine Street, Philadelphia, PA 19143 (US). **SMITH,**
Randall, F. [US/US]; 4138 Presidential Drive, Lafayette
Hill, PA 19444 (US). **XIANG, Zhaoying** [CN/US]; 2413
Ridgeway, Fort Lee, NJ 07024 (US).

(74) Agents: **GIMMI, Edward, R.** et al.; SmithKline Beecham
Corporation, Corporate Intellectual Property, UW2220,
709 Swedeland Road, P.O. Box 1539, King of Prussia, PA
19406-0939 (US).

(81) Designated States (national): JP, US.

(84) Designated States (regional): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE, TR).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/66690 A2

(54) Title: NOVEL COMPOUNDS

(57) Abstract: Polypeptides and polynucleotides of the genes set forth in Table I and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing polypeptides and polynucleotides of the genes set forth in Table I in diagnostic assays.

Novel Compounds

Field of Invention

5 This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in diagnosis and in identifying compounds that may be agonists, antagonists that are potentially useful in therapy, and to production of such polypeptides and polynucleotides. The polynucleotides and polypeptides of the present invention also relate to proteins with signal sequences which allow them to be secreted
10 extracellularly or membrane-associated (hereinafter often referred collectively as secreted proteins or secreted polypeptides).

Background of the Invention

15 The drug discovery process is currently undergoing a fundamental revolution as it embraces "functional genomics", that is, high throughput genome- or gene-based biology. This approach as a means to identify genes and gene products as therapeutic targets is rapidly superseding earlier approaches based on "positional cloning". A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.

20 Functional genomics relies heavily on high-throughput DNA sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.

25 Proteins and polypeptides that are naturally secreted into blood, lymph and other body fluids, or secreted into the cellular membrane are of primary interest for pharmaceutical research and development. The reason for this interest is the relative ease to target protein therapeutics into their place of action (body fluids or the cellular membrane). The natural pathway for protein secretion into extracellular space is the endoplasmic reticulum in
30 eukaryotes and the inner membrane in prokaryotes (Palade, 1975, Science, 189, 347; Milstein, Brownlee, Harrison, and Mathews, 1972, Nature New Biol., 239, 117; Blobel, and Dobberstein, 1975, J. Cell. Biol., 67, 835). On the other hand, there is no known natural pathway for exporting a protein from the exterior of the cells into the cytosol (with the exception of pinocytosis, a mechanism of snake venom toxin intrusion into cells). Therefore
35 targeting protein therapeutics into cells poses extreme difficulties.

The secreted and membrane-associated proteins include but are not limited to

all peptide hormones and their receptors (including but not limited to insulin, growth hormones, chemokines, cytokines, neuropeptides, integrins, kallikreins, lamins, melanins, natriuretic hormones, neutropins, neurotropins, pituitary hormones, pleiotropins, prostaglandins, secretogranins, selectins, thromboglobulins, thymosins),

5 the breast and colon cancer gene products, leptin, the obesity gene protein and its receptors, serum albumin, superoxide dismutase, spliceosome proteins, 7TM (transmembrane) proteins also called as G-protein coupled receptors, immunoglobulins, several families of serine proteinases (including but not limited to proteins of the blood coagulation cascade, digestive enzymes), deoxyribonuclease I, 10 etc.

Therapeutics based on secreted or membrane-associated proteins approved by FDA or foreign agencies include but are not limited to insulin, glucagon, growth hormone, chorionic gonadotropin, follicle stimulating hormone, luteinizing hormone, calcitonin, adrenocorticotrophic hormone (ACTH), vasopressin, interleukines,

15 interferones, immunoglobulins, lactoferrin (diverse products marketed by several companies), tissue-type plasminogen activator (Alteplase by Genentech), hyaluronidase (Wydase by Wyeth-Ayerst), dornase alpha (Pulmozyme by Genentech), Chymodictin (chymopapain by Knoll), alglucerase (Ceredase by Genzyme), streptokinase (Kabikinase by Pharmacia) (Streptase by Astra), etc. This 20 indicates that secreted and membrane-associated proteins have an established, proven history as therapeutic targets. Clearly, there is a need for identification and characterization of further secreted and membrane-associated proteins which can play a role in preventing, ameliorating or correcting dysfunction or disease, including but not limited to diabetes, breast-, prostate-, colon cancer and other malignant tumors, 25 hyper- and hypotension, obesity, bulimia, anorexia, growth abnormalities, asthma, manic depression, dementia, delirium, mental retardation, Huntington's disease, Tourette's syndrome, schizophrenia, growth, mental or sexual development disorders, and dysfunctions of the blood cascade system including those leading to stroke. The 30 proteins of the present invention which include the signal sequences are also useful to further elucidate the mechanism of protein transport which at present is not entirely understood, and thus can be used as research tools.

Summary of the Invention

The present invention relates to particular polypeptides and polynucleotides of the 35 genes set forth in Table I, including recombinant materials and methods for their production. Such polypeptides and polynucleotides are of interest in relation to methods of treatment of

certain diseases, including, but not limited to, the diseases set forth in Tables III and V, hereinafter referred to as "diseases of the invention". In a further aspect, the invention relates to methods for identifying agonists and antagonists (e.g., inhibitors) using the materials provided by the invention, and treating conditions associated with imbalance of polypeptides and/or polynucleotides of the genes set forth in Table I with the identified compounds. In still a further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate activity or levels the genes set forth in Table I. Another aspect of the invention concerns a polynucleotide comprising any of the nucleotide sequences set forth in the Sequence Listing and a polypeptide comprising a polypeptide encoded by the nucleotide sequence. In another aspect, the invention relates to a polypeptide comprising any of the polypeptide sequences set forth in the Sequence Listing and recombinant materials and methods for their production. Another aspect of the invention relates to methods for using such polypeptides and polynucleotides. Such uses include the treatment of diseases, abnormalities and disorders (hereinafter simply referred to as diseases) caused by abnormal expression, production, function and or metabolism of the genes of this invention, and such diseases are readily apparent by those skilled in the art from the homology to other proteins disclosed for each attached sequence. In still another aspect, the invention relates to methods to identify agonists and antagonists using the materials provided by the invention, and treating conditions associated with the imbalance with the identified compounds. Yet another aspect of the invention relates to diagnostic assays for detecting diseases associated with inappropriate activity or levels of the secreted proteins of the present invention.

Description of the Invention

In a first aspect, the present invention relates to polypeptides the genes set forth in Table I. Such polypeptides include:

- (a) an isolated polypeptide encoded by a polynucleotide comprising a sequence set forth in the Sequence Listing, herein when referring to polynucleotides or polypeptides of the Sequence Listing, a reference is also made to the Sequence Listing referred to in the Sequence Listing;
- (b) an isolated polypeptide comprising a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;
- (c) an isolated polypeptide comprising a polypeptide sequence set forth in the Sequence Listing;
- (d) an isolated polypeptide having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;

- (e) a polypeptide sequence set forth in the Sequence Listing; and
- (f) an isolated polypeptide having or comprising a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to a polypeptide sequence set forth in the Sequence Listing;
- 5 (g) fragments and variants of such polypeptides in (a) to (f).

Polypeptides of the present invention are believed to be members of the gene families set forth in Table II. They are therefore of therapeutic and diagnostic interest for the reasons set forth in Tables III and V. The biological properties of the polypeptides and polynucleotides of the genes set forth in Table I are hereinafter referred to as "the biological activity" of 10 polypeptides and polynucleotides of the genes set forth in Table I. Preferably, a polypeptide of the present invention exhibits at least one biological activity of the genes set forth in Table I.

Polypeptides of the present invention also include variants of the aforementioned polypeptides, including all allelic forms and splice variants. Such polypeptides vary from the 15 reference polypeptide by insertions, deletions, and substitutions that may be conservative or non-conservative, or any combination thereof. Particularly preferred variants are those in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acids are inserted, substituted, or deleted, in any combination.

20 Preferred fragments of polypeptides of the present invention include an isolated polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids from an amino acid sequence set forth in the Sequence Listing, or an isolated polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids truncated or deleted from an amino acid sequence set forth in the Sequence 25 Listing. Preferred fragments are biologically active fragments that mediate the biological activity of polypeptides and polynucleotides of the genes set forth in Table I, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also preferred are those fragments that are antigenic or immunogenic in an animal, especially in a human.

30 Fragments of a polypeptide of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these variants may be employed as intermediates for producing the full-length polypeptides of the invention. A polypeptide of the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to 35 include an additional amino acid sequence that contains secretory or leader sequences, pro-

sequences, sequences that aid in purification, for instance multiple histidine residues, or an additional sequence for stability during recombinant production.

Polypeptides of the present invention can be prepared in any suitable manner, for instance by isolation from naturally occurring sources, from genetically engineered host cells comprising expression systems (*vide infra*) or by chemical synthesis, using for instance automated peptide synthesizers, or a combination of such methods. Means for preparing such polypeptides are well understood in the art.

In a further aspect, the present invention relates to polynucleotides of the genes set forth in Table I. Such polynucleotides include:

- 10 (a) an isolated polynucleotide comprising a polynucleotide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polynucleotide sequence set forth in the Sequence Listing;
- 15 (b) an isolated polynucleotide comprising a polynucleotide set forth in the Sequence Listing;
- (c) an isolated polynucleotide having at least 95%, 96%, 97%, 98%, or 99% identity to a polynucleotide set forth in the Sequence Listing;
- (d) an isolated polynucleotide set forth in the Sequence Listing;
- (e) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;
- 20 (f) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide set forth in the Sequence Listing;
- (g) an isolated polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;
- 25 (h) an isolated polynucleotide encoding a polypeptide set forth in the Sequence Listing;
- (i) an isolated polynucleotide having or comprising a polynucleotide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to a polynucleotide sequence set forth in the Sequence Listing;
- (j) an isolated polynucleotide having or comprising a polynucleotide sequence encoding a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to a polypeptide sequence set forth in the Sequence Listing; and
- 30 polynucleotides that are fragments and variants of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.

Preferred fragments of polynucleotides of the present invention include an isolated polynucleotide comprising an nucleotide sequence having at least 15, 30, 50 or 100

contiguous nucleotides from a sequence set forth in the Sequence Listing, or an isolated polynucleotide comprising a sequence having at least 30, 50 or 100 contiguous nucleotides truncated or deleted from a sequence set forth in the Sequence Listing.

Preferred variants of polynucleotides of the present invention include splice variants, 5 allelic variants, and polymorphisms, including polynucleotides having one or more single nucleotide polymorphisms (SNPs).

Polynucleotides of the present invention also include polynucleotides encoding polypeptide variants that comprise an amino acid sequence set forth in the Sequence Listing and in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, 10 from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acid residues are substituted, deleted or added, in any combination.

In a further aspect, the present invention provides polynucleotides that are RNA transcripts of the DNA sequences of the present invention. Accordingly, there is provided an RNA polynucleotide that:

15 (a) comprises an RNA transcript of the DNA sequence encoding a polypeptide set forth in the Sequence Listing;

 (b) is a RNA transcript of a DNA sequence encoding a polypeptide set forth in the Sequence Listing;

 (c) comprises an RNA transcript of a DNA sequence set forth in the Sequence Listing; or

20 (d) is a RNA transcript of a DNA sequence set forth in the Sequence Listing; and RNA polynucleotides that are complementary thereto.

The polynucleotide sequences set forth in the Sequence Listing show homology with the polynucleotide sequences set forth in Table II. A polynucleotide sequence set forth in the Sequence Listing is a cDNA sequence that encodes a polypeptide set forth in the Sequence Listing. A polynucleotide sequence encoding a polypeptide set forth in the Sequence Listing may be identical to a polypeptide encoding a sequence set forth in the Sequence Listing or it may be a sequence other than a sequence set forth in the Sequence Listing, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes a polypeptide set forth in the Sequence Listing. A polypeptide of a sequence set forth in the Sequence Listing is related to other proteins of the gene families set forth in Table II, having homology and/or structural similarity with the polypeptides set forth in Table II. Preferred polypeptides and polynucleotides of the present invention are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore,

preferred polypeptides and polynucleotides of the present invention have at least one activity of the genes set forth in Table I.

Polynucleotides of the present invention may be obtained using standard cloning and screening techniques from a cDNA library derived from mRNA from the tissues set forth in Table IV (see for instance, Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)).

Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

10 When polynucleotides of the present invention are used for the recombinant production of polypeptides of the present invention, the polynucleotide may include the coding sequence for the mature polypeptide, by itself, or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide

15 portions. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. A polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-
20 translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

Polynucleotides that are identical, or have sufficient identity to a polynucleotide sequence set forth in the Sequence Listing, may be used as hybridization probes for cDNA and genomic DNA or as primers for a nucleic acid amplification reaction (for instance, PCR).

25 Such probes and primers may be used to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes (including genes encoding paralogs from human sources and orthologs and paralogs from species other than) that have a high sequence similarity to sequences set forth in the Sequence Listing, typically at least 95% identity. Preferred probes and primers will
30 generally comprise at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50, if not at least 100 nucleotides. Particularly preferred probes will have between 30 and 50 nucleotides. Particularly preferred primers will have between 20 and 25 nucleotides.

35 A polynucleotide encoding a polypeptide of the present invention, including homologs from species other than , may be obtained by a process comprising the steps of screening a library under stringent hybridization conditions with a labeled probe having a

sequence set forth in the Sequence Listing or a fragment thereof, preferably of at least 15 nucleotides; and isolating full-length cDNA and genomic clones containing the polynucleotide sequence set forth in the Sequence Listing. Such hybridization techniques are well known to the skilled artisan. Preferred stringent hybridization conditions include

- 5 overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA; followed by washing the filters in 0.1x SSC at about 65°C. Thus the present invention also includes isolated polynucleotides, preferably with a nucleotide sequence of at least 100, obtained by
- 10 screening a library under stringent hybridization conditions with a labeled probe having the sequence set forth in the Sequence Listing or a fragment thereof, preferably of at least 15 nucleotides.

The skilled artisan will appreciate that, in many cases, an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide does not extend all the way through to the 5' terminus. This is a consequence of reverse transcriptase, an enzyme with inherently low "processivity" (a measure of the ability of the enzyme to remain attached to the template during the polymerisation reaction), failing to complete a DNA copy of the mRNA template during first strand cDNA synthesis.

There are several methods available and well known to those skilled in the art to

- 20 obtain full-length cDNAs, or extend short cDNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman et al., Proc Nat Acad Sci USA 85, 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon (trade mark) technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon (trade mark)
- 25 technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the "missing" 5' end of the cDNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using 'nested' primers, that is, primers designed to anneal within the amplified product (typically an adapter specific
- 30 primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the known gene sequence). The products of this reaction can then be analyzed by DNA sequencing and a full-length cDNA constructed either by joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.

Recombinant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems comprising a polynucleotide or polynucleotides of the present invention, to host cells which 5 are genetically engineered with such expression systems and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

For recombinant production, host cells can be genetically engineered to incorporate 10 expression systems or portions thereof for polynucleotides of the present invention. Polynucleotides may be introduced into host cells by methods described in many standard laboratory manuals, such as Davis et al., *Basic Methods in Molecular Biology* (1986) and Sambrook *et al.* (*ibid*). Preferred methods of introducing polynucleotides into host cells include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, 15 transvection, micro-injection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as 20 *Streptococci*, *Staphylococci*, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila S2* and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, *e.g.*, vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast 25 chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any 30 system or vector that is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host may be used. The appropriate polynucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, (*ibid*). Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the translated protein into the

lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.

If a polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. In 5 this event, the cells may be harvested prior to use in the screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

Polypeptides of the present invention can be recovered and purified from recombinant 10 cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins 15 may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis, isolation and/or purification.

Polynucleotides of the present invention may be used as diagnostic reagents, through 20 detecting mutations in the associated gene. Detection of a mutated form of a gene is characterized by the polynucleotides set forth in the Sequence Listing in the cDNA or genomic sequence and which is associated with a dysfunction. Will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of 25 techniques well known in the art.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from 30 blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or it may be amplified enzymatically by using PCR, preferably RT-PCR, or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled nucleotide sequences of the genes set forth in Table I. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase 35 digestion or by differences in melting temperatures. DNA sequence difference may also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (see, for instance, Myers *et al.*,

Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc Natl Acad Sci USA (1985) 85: 4397-4401).

An array of oligonucleotides probes comprising polynucleotide sequences or

5 fragments thereof of the genes set forth in Table I can be constructed to conduct efficient screening of *e.g.*, genetic mutations. Such arrays are preferably high density arrays or grids. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability, see, for example, M. Chee *et al.*, Science, 274, 610-613
10 (1996) and other references cited therein.

Detection of abnormally decreased or increased levels of polypeptide or mRNA expression may also be used for diagnosing or determining susceptibility of a subject to a disease of the invention. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for
15 example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radio-immunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

20 Thus in another aspect, the present invention relates to a diagnostic kit comprising:

(a) a polynucleotide of the present invention, preferably the nucleotide sequence set forth in the Sequence Listing, or a fragment or an RNA transcript thereof;
25 (b) a nucleotide sequence complementary to that of (a);
(c) a polypeptide of the present invention, preferably the polypeptide set forth in the Sequence Listing or a fragment thereof; or
(d) an antibody to a polypeptide of the present invention, preferably to the polypeptide set forth in the Sequence Listing.

30 It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly diseases of the invention, amongst others.

The polynucleotide sequences of the present invention are valuable for chromosome localisation studies. The sequences set forth in the Sequence Listing are specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an
35 important first step in correlating those sequences with gene associated disease. Once a

sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (co-inheritance of physically adjacent genes). Precise human chromosomal localisations for a genomic sequence (gene fragment etc.) can be determined using Radiation Hybrid (RH) Mapping (Walter, M. Spillett, D., Thomas, P., Weissenbach, J., and Goodfellow, P., (1994) A method for constructing radiation hybrid maps of whole genomes, *Nature Genetics* 7, 22-28). A number of RH panels are available from Research Genetics (Huntsville, AL, USA) e.g. the GeneBridge4 RH panel (Hum Mol Genet 1996 Mar;5(3):339-46 A radiation hybrid map of the human genome. Gyapay G, Schmitt K, Fizames C, Jones H, Vega-Czarny N, Spillett D, Muselet D, Prud'Homme JF, Dib C, Auffray C, Morissette J, Weissenbach J, Goodfellow PN). To determine the chromosomal location of a gene using this panel, 93 PCRs are performed using primers designed from the gene of interest on RH DNAs. Each of these DNAs contains random human genomic fragments maintained in a hamster background (human / hamster hybrid cell lines). These PCRs result in 93 scores indicating the presence or absence of the PCR product of the gene of interest. These scores are compared with scores created using PCR products from genomic sequences of known location. This comparison is conducted at <http://www.genome.wi.mit.edu/>.

The polynucleotide sequences of the present invention are also valuable tools for tissue expression studies. Such studies allow the determination of expression patterns of polynucleotides of the present invention which may give an indication as to the expression patterns of the encoded polypeptides in tissues, by detecting the mRNAs that encode them. The techniques used are well known in the art and include *in situ* hybridization techniques to clones arrayed on a grid, such as cDNA microarray hybridization (Schena *et al*, *Science*, 270, 467-470, 1995 and Shalon *et al*, *Genome Res*, 6, 639-645, 1996) and nucleotide amplification techniques such as PCR. A preferred method uses the TAQMAN (Trade mark) technology available from Perkin Elmer. Results from these studies can provide an indication of the normal function of the polypeptide in the organism. In addition, comparative studies of the normal expression pattern of mRNAs with that of mRNAs encoded by an alternative form of the same gene (for example, one having an alteration in polypeptide coding potential or a regulatory mutation) can provide valuable insights into the role of the polypeptides of the present invention, or that of inappropriate expression thereof in disease. Such inappropriate expression may be of a temporal, spatial or simply quantitative nature.

A further aspect of the present invention relates to antibodies. The polypeptides of the invention or their fragments, or cells expressing them, can be used as immunogens to produce antibodies that are immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the 5 polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against polypeptides of the present invention may be obtained by administering the polypeptides or epitope-bearing fragments, or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal 10 antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., *Nature* (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, *Immunology Today* (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies, such as those described in 15 U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography. 20 Antibodies against polypeptides of the present invention may also be employed to treat diseases of the invention, amongst others.

Polypeptides and polynucleotides of the present invention may also be used as vaccines. Accordingly, in a further aspect, the present invention relates to a method for inducing an immunological response in a mammal that comprises inoculating the mammal 25 with a polypeptide of the present invention, adequate to produce antibody and/or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said animal from disease, whether that disease is already established within the individual or not. An immunological response in a mammal may also be induced by a method comprises delivering a polypeptide of the present invention *via* a vector directing expression 30 of the polynucleotide and coding for the polypeptide *in vivo* in order to induce such an immunological response to produce antibody to protect said animal from diseases of the invention. One way of administering the vector is by accelerating it into the desired cells as a coating on particles or otherwise. Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid. For use a vaccine, a polypeptide or a nucleic 35 acid vector will be normally provided as a vaccine formulation (composition). The

formulation may further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous, intra-muscular, intravenous, or intra-dermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions that may contain 5 anti-oxidants, buffers, bacteriostats and solutes that render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions that may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to 10 use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

Polypeptides of the present invention have one or more biological functions that are 15 of relevance in one or more disease states, in particular the diseases of the invention hereinbefore mentioned. It is therefore useful to identify compounds that stimulate or inhibit the function or level of the polypeptide. Accordingly, in a further aspect, the present invention provides for a method of screening compounds to identify those that stimulate or 20 inhibit the function or level of the polypeptide. Such methods identify agonists or antagonists that may be employed for therapeutic and prophylactic purposes for such diseases of the invention as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, collections of chemical 25 compounds, and natural product mixtures. Such agonists or antagonists so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the polypeptide; a structural or functional mimetic thereof (see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)) or a small molecule. Such small molecules preferably have a molecular weight below 2,000 daltons, more preferably between 300 and 1,000 daltons, and most preferably between 400 and 700 daltons. It is preferred that these small molecules are organic molecules.

30 The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof, by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve measuring or detecting (qualitatively or 35 quantitatively) the competitive binding of a candidate compound to the polypeptide against a labeled competitor (*e.g.* agonist or antagonist). Further, these screening methods may test

whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide.

Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed.

5 Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring an activity of the genes set forth in Table I in the mixture, and comparing activity of the mixture of the genes set forth in Table I to a control mixture which contains no candidate compound.

10 Polypeptides of the present invention may be employed in conventional low capacity screening methods and also in high-throughput screening (HTS) formats. Such HTS formats include not only the well-established use of 96- and, more recently, 384-well micotiter plates but also emerging methods such as the nanowell method described by Schullek *et al.*, *Anal Biochem.*, 246, 20-29, (1997).

15 Fusion proteins, such as those made from Fc portion and polypeptide of the genes set forth in Table I, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D. Bennett *et al.*, *J Mol Recognition*, 8:52-58 (1995); and K. Johanson *et al.*, *J Biol Chem*, 270(16):9459-9471 (1995)).

20 The polynucleotides, polypeptides and antibodies to the polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be 25 used to discover agents that may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

A polypeptide of the present invention may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the 30 polypeptide is labeled with a radioactive isotope (for instance, ¹²⁵I), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify 35 agonists and antagonists of the polypeptide that compete with the binding of the polypeptide

to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

Examples of antagonists of polypeptides of the present invention include antibodies or, in some cases, oligonucleotides or proteins that are closely related to the ligands, substrates, receptors, enzymes, etc., as the case may be, of the polypeptide, *e.g.*, a fragment of the ligands, substrates, receptors, enzymes, etc.; or a small molecule that bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.

Screening methods may also involve the use of transgenic technology and the genes set forth in Table I. The art of constructing transgenic animals is well established. For example, the genes set forth in Table I may be introduced through microinjection into the male pronucleus of fertilized oocytes, retroviral transfer into pre- or post-implantation embryos, or injection of genetically modified, such as by electroporation, embryonic stem cells into host blastocysts. Particularly useful transgenic animals are so-called "knock-in"

15 animals in which an animal gene is replaced by the human equivalent within the genome of that animal. Knock-in transgenic animals are useful in the drug discovery process, for target validation, where the compound is specific for the human target. Other useful transgenic animals are so-called "knock-out" animals in which the expression of the animal ortholog of a polypeptide of the present invention and encoded by an endogenous DNA sequence in a cell 20 is partially or completely annulled. The gene knock-out may be targeted to specific cells or tissues, may occur only in certain cells or tissues as a consequence of the limitations of the technology, or may occur in all, or substantially all, cells in the animal. Transgenic animal technology also offers a whole animal expression-cloning system in which introduced genes are expressed to give large amounts of polypeptides of the present invention

25 Screening kits for use in the above described methods form a further aspect of the present invention. Such screening kits comprise:

- (a) a polypeptide of the present invention;
- (b) a recombinant cell expressing a polypeptide of the present invention;
- (c) a cell membrane expressing a polypeptide of the present invention; or
- 30 (d) an antibody to a polypeptide of the present invention;

which polypeptide is preferably that set forth in the Sequence Listing.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

35 **Glossary**

The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

"Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an

5 Fab or other immunoglobulin expression library.

"Isolated" means altered "by the hand of man" from its natural state, *i.e.*, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials 10 of its natural state is "isolated", as the term is employed herein. Moreover, a polynucleotide or polypeptide that is introduced into an organism by transformation, genetic manipulation or by any other recombinant method is "isolated" even if it is still present in said organism, which organism may be living or non-living.

15 "Secreted protein activity or secreted polypeptide activity" or "biological activity of the secreted protein or secreted polypeptide" refers to the metabolic or physiologic function of said secreted protein including similar activities or improved activities or these activities with decreased undesirable side-effects. Also included are antigenic and immunogenic activities of said secreted protein.

20 "Secreted protein gene" refers to a polynucleotide comprising any of the attached nucleotide sequences or allelic variants thereof and/or their complements.

"Polynucleotide" generally refers to any polyribonucleotide (RNA) or polydeoxyribonucleotide (DNA), which may be unmodified or modified RNA or DNA.

25 "Polynucleotides" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also includes 30 DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces 35 relatively short polynucleotides, often referred to as oligonucleotides.

"Polypeptide" refers to any polypeptide comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres.

"Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain

5 amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide

10 backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may

15 result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, biotinylation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation,

20 demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for instance,

25 Proteins - Structure and Molecular Properties, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., Post-translational Protein Modifications: Perspectives and Prospects, 1-12, in Post-translational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", Meth Enzymol, 182, 626-646, 1990, and Rattan *et al.*, "Protein

30 Synthesis: Post-translational Modifications and Aging", Ann NY Acad Sci, 663, 48-62, 1992).

"Fragment" of a polypeptide sequence refers to a polypeptide sequence that is shorter than the reference sequence but that retains essentially the same biological function or activity as the reference polypeptide. "Fragment" of a polynucleotide sequence refers to a

polynucleotide sequence that is shorter than the reference sequence set forth in the Sequence Listing.

"Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains the essential properties thereof. A typical variant of a polynucleotide differs in nucleotide sequence from the reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from the reference polypeptide. Generally, alterations are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, insertions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. Typical conservative substitutions include Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe and Tyr. A variant of a polynucleotide or polypeptide may be naturally occurring such as an allele, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis. Also included as variants are polypeptides having one or more post-translational modifications, for instance glycosylation, phosphorylation, methylation, ADP ribosylation and the like. Embodiments include methylation of the N-terminal amino acid, phosphorylations of serines and threonines and modification of C-terminal glycines.

"Allele" refers to one of two or more alternative forms of a gene occurring at a given locus in the genome.

"Polymorphism" refers to a variation in nucleotide sequence (and encoded polypeptide sequence, if relevant) at a given position in the genome within a population.

"Single Nucleotide Polymorphism" (SNP) refers to the occurrence of nucleotide variability at a single nucleotide position in the genome, within a population. An SNP may occur within a gene or within intergenic regions of the genome. SNPs can be assayed using Allele Specific Amplification (ASA). For the process at least 3 primers are required. A common primer is used in reverse complement to the polymorphism being assayed. This common primer can be between 50 and 1500 bps from the polymorphic base. The other two (or more) primers are identical to each other except that the final 3' base wobbles to match one of the two (or more) alleles that make up the polymorphism. Two (or more) PCR

reactions are then conducted on sample DNA, each using the common primer and one of the Allele Specific Primers.

"Splice Variant" as used herein refers to cDNA molecules produced from RNA molecules initially transcribed from the same genomic DNA sequence but which have undergone alternative RNA splicing. Alternative RNA splicing occurs when a primary RNA transcript undergoes splicing, generally for the removal of introns, which results in the production of more than one mRNA molecule each of that may encode different amino acid sequences. The term splice variant also refers to the proteins encoded by the above cDNA molecules.

10 "Identity" reflects a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, determined by comparing the sequences. In general, identity refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of the two polynucleotide or two polypeptide sequences, respectively, over the length of the sequences being compared.

15 "% Identity" - For sequences where there is not an exact correspondence, a "% identity" may be determined. In general, the two sequences to be compared are aligned to give a maximum correlation between the sequences. This may include inserting "gaps" in either one or both sequences, to enhance the degree of alignment. A % identity may be determined over the whole length of each of the sequences being compared (so-called global 20 alignment), that is particularly suitable for sequences of the same or very similar length, or over shorter, defined lengths (so-called local alignment), that is more suitable for sequences of unequal length.

25 "Similarity" is a further, more sophisticated measure of the relationship between two polypeptide sequences. In general, "similarity" means a comparison between the amino acids of two polypeptide chains, on a residue by residue basis, taking into account not only exact correspondences between a between pairs of residues, one from each of the sequences being compared (as for identity) but also, where there is not an exact correspondence, whether, on an evolutionary basis, one residue is a likely substitute for the other. This likelihood has an associated "score" from which the "% similarity" of the two sequences can then be 30 determined.

Methods for comparing the identity and similarity of two or more sequences are well known in the art. Thus for instance, programs available in the Wisconsin Sequence Analysis Package, version 9.1 (Devereux J et al, Nucleic Acids Res, 12, 387-395, 1984, available from Genetics Computer Group, Madison, Wisconsin, USA), for example the programs BESTFIT 35 and GAP, may be used to determine the % identity between two polynucleotides and the %

identity and the % similarity between two polypeptide sequences. BESTFIT uses the "local homology" algorithm of Smith and Waterman (J Mol Biol, 147, 195-197, 1981, Advances in Applied Mathematics, 2, 482-489, 1981) and finds the best single region of similarity between two sequences. BESTFIT is more suited to comparing two polynucleotide or two 5 polypeptide sequences that are dissimilar in length, the program assuming that the shorter sequence represents a portion of the longer. In comparison, GAP aligns two sequences, finding a "maximum similarity", according to the algorithm of Needleman and Wunsch (J Mol Biol, 48, 443-453, 1970). GAP is more suited to comparing sequences that are approximately the same length and an alignment is expected over the entire length.

10 Preferably, the parameters "Gap Weight" and "Length Weight" used in each program are 50 and 3, for polynucleotide sequences and 12 and 4 for polypeptide sequences, respectively. Preferably, % identities and similarities are determined when the two sequences being compared are optimally aligned.

Other programs for determining identity and/or similarity between sequences are also 15 known in the art, for instance the BLAST family of programs (Altschul S F et al, J Mol Biol, 215, 403-410, 1990, Altschul S F et al, Nucleic Acids Res., 25:389-3402, 1997, available from the National Center for Biotechnology Information (NCBI), Bethesda, Maryland, USA and accessible through the home page of the NCBI at www.ncbi.nlm.nih.gov) and FASTA (Pearson W R, Methods in Enzymology, 183, 63-99, 1990; Pearson W R and Lipman D J, 20 Proc Nat Acad Sci USA, 85, 2444-2448, 1988, available as part of the Wisconsin Sequence Analysis Package).

Preferably, the BLOSUM62 amino acid substitution matrix (Henikoff S and Henikoff J G, Proc. Nat. Acad. Sci. USA, 89, 10915-10919, 1992) is used in polypeptide sequence comparisons including where nucleotide sequences are first translated into amino acid 25 sequences before comparison.

Preferably, the program BESTFIT is used to determine the % identity of a query polynucleotide or a polypeptide sequence with respect to a reference polynucleotide or a polypeptide sequence, the query and the reference sequence being optimally aligned and the parameters of the program set at the default value, as hereinbefore described.

30 "Identity Index" is a measure of sequence relatedness which may be used to compare a candidate sequence (polynucleotide or polypeptide) and a reference sequence. Thus, for instance, a candidate polynucleotide sequence having, for example, an Identity Index of 0.95 compared to a reference polynucleotide sequence is identical to the reference sequence except that the candidate polynucleotide sequence may include on average up to five differences per 35 each 100 nucleotides of the reference sequence. Such differences are selected from the group

consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion. These differences may occur at the 5' or 3' terminal positions of the reference polynucleotide sequence or anywhere between these terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more 5 contiguous groups within the reference sequence. In other words, to obtain a polynucleotide sequence having an Identity Index of 0.95 compared to a reference polynucleotide sequence, an average of up to 5 in every 100 of the nucleotides of the in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 10 0.98 and 0.99.

Similarly, for a polypeptide, a candidate polypeptide sequence having, for example, an Identity Index of 0.95 compared to a reference polypeptide sequence is identical to the reference sequence except that the polypeptide sequence may include an average of up to five differences per each 100 amino acids of the reference sequence. Such differences are selected 15 from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion. These differences may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between these terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. In 20 other words, to obtain a polypeptide sequence having an Identity Index of 0.95 compared to a reference polypeptide sequence, an average of up to 5 in every 100 of the amino acids in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

25 The relationship between the number of nucleotide or amino acid differences and the Identity Index may be expressed in the following equation:

$$n_a \leq x_a - (x_a \cdot I),$$

in which:

30 n_a is the number of nucleotide or amino acid differences,

x_a is the total number of nucleotides or amino acids in a sequence set forth in the Sequence Listing,

I is the Identity Index,

• is the symbol for the multiplication operator, and

in which any non-integer product of x_a and I is rounded down to the nearest integer prior to subtracting it from x_a .

"Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a reference

5 sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the two sequences as hereinbefore defined. Falling within this generic term are the terms "ortholog", and "paralog". "Ortholog" refers to a polynucleotide or polypeptide that is the functional equivalent of the polynucleotide or polypeptide in another species. "Paralog" refers to a polynucleotide or polypeptide that within the same species

10 which is functionally similar.

"Fusion protein" refers to a protein encoded by two, often unrelated, fused genes or fragments thereof. In one example, EP-A-0 464 533-A discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, employing an immunoglobulin Fc region as a

15 part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for example, improved pharmacokinetic properties [see, e.g., EP-A 0232 262]. On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified.

All publications and references, including but not limited to patents and patent

20 applications, cited in this specification are herein incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety in the manner described above for publications and references.

Table I.

Gene Name	GSK Gene ID	Nucleic Acid SEQ ID NO's	Corresponding Protein SEQ ID NO's
sbg101452SLITa	101452	SEQ ID NO:1	SEQ ID NO:27
sbg29046CYSa	29046a	SEQ ID NO:2	SEQ ID NO:28
sbg29046CYSb	29046b	SEQ ID NO:3 SEQ ID NO:4	SEQ ID NO:29 SEQ ID NO:30
sbg37149SLITb	37149	SEQ ID NO:5	SEQ ID NO:31
sbg36267SLIta	36267	SEQ ID NO:6	SEQ ID NO:32
sbg35579MELAa	35579	SEQ ID NO:7 SEQ ID NO:8	SEQ ID NO:33 SEQ ID NO:34
SBh69447. Triglyceride Lipase	69447	SEQ ID NO:9	SEQ ID NO:35
SBh86614.Tryp1	86614	SEQ ID NO:10 SEQ ID NO:11	SEQ ID NO:36 SEQ ID NO:37
sbg106886DELTAAa	106886	SEQ ID NO:12	SEQ ID NO:38
sbg35779THYa	35779	SEQ ID NO:13	SEQ ID NO:39
sbg15130INHa	15130	SEQ ID NO:14 SEQ ID NO:15	SEQ ID NO:40 SEQ ID NO:41
SBh26548.homebox	26548	SEQ ID NO:16	SEQ ID NO:42
sbg26991CERUa	26991	SEQ ID NO:17	SEQ ID NO:43
sbg35851PEROa	35851	SEQ ID NO:18 SEQ ID NO:19	SEQ ID NO:44 SEQ ID NO:45
sbg36274SLITa	36274	SEQ ID NO:20	SEQ ID NO:46
sbg34575SLITa	34575	SEQ ID NO:21	SEQ ID NO:47
SBh71706.NIAP	71706	SEQ ID NO:22 SEQ ID NO:23	SEQ ID NO:48 SEQ ID NO:49
SBh77492.Breast Specific BS200	77492	SEQ ID NO:24 SEQ ID NO:25	SEQ ID NO:50 SEQ ID NO:51
sbg115305LRRa	115305	SEQ ID NO:26	SEQ ID NO:52

Table II

Gene Name	Gene Family	Closest Polynuclotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbg101452SLIta	Slit-like membrane glycoprotein	GB:AL138498 Submitted (07-DEC-2000) by Genoscope - Centre National de Sequençage : BP 191 91006 EVRY cedex - FRANCE	KIAA1246 protein;gi:6330833 Submitted (04-OCT-1999) by Osamu Ohara, Kazusa DNA Research Institute, Laboratory of DNA Technology; 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan	Membrane-bound
sbg29046CYSa	Cystatin	GB:AL121894 Submitted on Feb 18,2000 by Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK	Human cystatin family member gi :9944240 Submitted (25-OCT-2000) Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Secreted
sbg29046CYSb	Cystatin	GB:AL121894 Submitted on Feb 18,2000 by Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK	Novel human cystatin-related protein geneseqp:Y53771 (KARO-) KAROLINSKA INNOVATIONS AB WO9958565-A1, 18-NOV-99	Secreted
sbg37149SLItb	Slit-like membrane glycoprotein	GB:Z94160 Submitted on Dec8, 1999, Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Human putative leucine rich protein gi:3191975 Submitted (08-DEC-1999) Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Membrane-bound
sbg36267SLIta	Slit 3-like membrane glycoprotein	GB:AL080239 Submitted on Jan10, 2000, by Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Human KIAA0918 protein, gi :4240325 Nagase,T., Ishikawa,K., Suyama,M., Kikuno,R., Hiroswa,M., Miyajima,N., Tanaka,A., Kotani,H., Nomura,N. and Ohara,O. DNA Res. 5 (6), 355-364 (1998)	Membrane-bound
sbg35579MELAa	Brain-specific transmembrane glycoprotein	GB:AC018477 Submitted (12-DEC-1999) by Human Genome Sequencing Center, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA	Human KIAA1484 protein, gi: 7959229 Nagase,T., Kikuno,R., Ishikawa,K., Hiroswa,M. and Ohara,O. DNA Res. 7 (2), 143-150 (2000).	Membrane-bound
SBh69447. Triglyceride Lipase	Triglyceride lipase	GB:AC011277 Submitted (05-OCT-1999) by Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA	Human gastric lipase, gi:4758676 Bodmer,M.W., Angal,S., Yarranton,G.T., Harris,T.J., Lyons,A., King,D.J., Pieroni,G., Riviere,C., Verger,R. and Lowe,P.A. Biochim. Biophys. Acta 909 (3), 237-244 (1987)	Secreted

Table II Cont

Gene Name	Gene Family	Closest Polynucleotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
SBh86614.Tryp1	Serine protease	JGI:RPCI-11± 388M20 Found at Joint Genome Institute	Human PRO351 protein, geneseqp:Y41704 GENENTECH INC WO9946281-A2, 16-SEP-99	Secreted
sbg106886DELTa	DELTAA	GB:AC021391 Submitted on JAN 16, 2000, Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA	Rat preadipocyte factor , gi: 802014 Carlsson,C., Tomehave,D., Lindberg,K., Galante,P., Billestrup,N., Michelsen,B., Larsson,L.I. and Nielsen,J.H. Endocrinology 138 (9), 3940-3948 (1997)	Secreted
sbg35779THYa	Thyroxine binding globulin	GB:AL132990 Submitted (27-JAN-2000) by Genoscope – Centre National de Sequencage :BP 191 91006 EVRY cedex	Human PRO1337 GENENTECH INC WO200012708-A2, 09-MAR-00	Secreted
sbg15130INHa	Leukocyte protease inhibitor	SC:Z93016 Submitted (31-JUL-2000) Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Human serine protease inhibitor, geneseqp:Y28645 Human Genome Sci Inc WO199940183-A1, 12-AUG-99	Secreted
SBh26548.homebox	LBX, HOX, DLX	GB:AC005041 Sulston,J.E. and Waterston,R. Genome Res. 8 (11), 1097-1108 (1998)	Mouse lady bird-like homeobox 2 homolog, gi: 6754512 Chen,F., Liu,K.C. and Epstein,J.A. Mech. Dev. (1999).	Nucleus
sbg26991CERUa	Ceruloplasmin precursor	GB:AC010909 Submitted (26-SEP-1999) by Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA	Human ceruloplasmin, gi: 1070458 Takahashi,N., Ortel,T.L. and Putnam,F.W. Proc. Natl. Acad. Sci. U.S.A. 81 (2), 390-394 (1984).	Secreted
sbg35851PEROa	Slit-like membrane glycoprotein	GB:AF038458 Submitted (12-DEC-1997) Human Genome Center, Lawrence Livermore National Laboratory, 7000 East Ave., Livermore, CA 94551, USA	Human KIAA1246 protein,gi:6330833 Submitted (04-OCT-1999) by Osamu Ohara, Kazusa DNA Research Institute, Laboratory of DNA Technology; 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan	Membrane-bound
sbg36274SLIta	Slit-like membrane glycoprotein	GB:AL109653 Submitted (22-NOV-1999) Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Human novel protein, gi: 11877257 Submitted (20-JAN-2000) Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA	Membrane-bound

Table II Cont

Gene Name	Gene Family	Closest Polynucleotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbg34575SLJTa	Slit-like membrane glycoprotein	GB:AC005343 Submitted (31-JUL-1998) by Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.	pineal gland specific gene-1 protein, geneseq: W09405 Huaman Genome Sci Inc WO9639158-A1, 12-DEC-96	Membrane-bound
SBh71706.NIAP	Apoptosis inhibitory protein	GB:AL121653 Submission (29-FEB-2000) by Genoscope.	Human hypothetical protein, weakly similar to mouse neuronal apoptosis inhibitory protein 2, gi:9367840 Submitted (15-JUL-2000) by Dept. Genetica Molecular, Institut de Recerca Oncologica (IRO), Hospital Duran i Reynals, Av. Gran Via s/n Km 2,7 L'Hospitalet de Llobregat, 08907 Barcelona, Catalunya, SPAIN.	Cytosolic
SBh77492.Breast Specific BS200	EGF-related protein	SC:Z82214,GB:Z99756 Submitted (08-DEC-1999) by Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Mouse EGF-related protein SCUBE1, gi: 10998440 Submitted (08-JUN-2000) Mammalian Genetics Unit, MRC Harwell, Chilton, Didcot, Oxon OX11 0RD, United Kingdom.	Secreted
sbg115305LRRa	Lucine-rich repeat (LRR)	GB:AC023484 Submitted (14-FEB-2000) Human Genomic Center, Institute of Genetics, Chinese Academy of Sciences, Datun Road, Beijing, Beijing 100101, P.R.China	Muse leucine rich repeat protein 1, gi:678724 Taguchi A, Wanaka A, Mori T, Matsumoto K, Imai Y, Tagaki T, Tohyama M, 1996, Brain Res Mol Brain Res;35:31-4.	Membrane-bound

Table III.

Gene Name	Uses	Associated Diseases
sbg101452SLITa	An embodiment of the invention is the use of sbg101452SLITa, a member of the slit protein family, for diagnosis and treatment of nervous and muscular diseases. This is because other members of the slit protein family may be necessary for CNS development. In addition, sbg101452SLITa shows homology to leucine-rich repeat proteins, which demonstrates significant functions in neural development. It is thus possible that similar molecules play a crucial role in the morphogenesis of the mammalian nervous system (Taniguchi H, Tohyama M, Takagi T. <i>Brain Res Mol Brain Res</i> 1996 Feb;36(1):45-52).	Gastrointestinal ulceration, Zollinger-Ellison syndrome, congenital microvillus atrophy, skin diseases
sbg29046CYSa	An embodiment of the invention is the use of sbg29046CYSa to inhibit tumor formation and metastasis and may also be involved in natural tissue remodeling events such as bone resorption and embryo implantation. Close homologs of sbg29046CYSa are cysteine protease inhibitors known as cystatins. Cystatins and their target proteases have been associated with tumor formation and metastasis, but also are involved in natural tissue remodeling events such as bone resorption and embryo implantation (Tohonen V., Osterlund C., and Nordqvist K., 1998 <i>Proc Natl Acad Sci U S A</i> 95(24):14208-13). Cystatin is a natural and specific inhibitor of the cysteine proteases generating in cancer invasion. The level of cystatin determination in serum and tissue extracts can be the clinical diagnostic and prognostic parameters in human cancers (Kos J., Stabuc B., Cimerman N., and Brunner N., 1998. <i>Clin Chem</i> 44(12):2556-7).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing, inflammation metastasis, amyloid angiopathies, and progressive myoclonus epilepsy
sbg29046CYSb	An embodiment of the invention is the use of sbg29046CYSb to inhibit tumor formation and metastasis and may also be involved in natural tissue remodeling events such as bone resorption and embryo implantation. Close homologs of sbg29046CYSa are cysteine protease inhibitors known as cystatins. Cystatins and their target proteases have been associated with tumor formation and metastasis, but also are involved in natural tissue remodeling events such as bone resorption and embryo implantation (Tohonen V., Osterlund C., and Nordqvist K., 1998 <i>Proc Natl Acad Sci U S A</i> 95(24):14208-13). Cystatin is a natural and specific inhibitor of the cysteine proteases generating in cancer invasion. The level of cystatin determination in serum and tissue extracts can be the clinical diagnostic and prognostic parameters in human cancers (Kos J., Stabuc B., Cimerman N., and Brunner N., 1998. <i>Clin Chem</i> 44(12):2556-7).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing, inflammation metastasis, amyloid angiopathies, and progressive myoclonus epilepsy
sbg37149SLITb	An embodiment of the invention is the use of sbg37149SLITb, a member of human slit-like proteins, which may be necessary for CNS development, and therefore can be useful for diagnosis and treatment of nervous and muscular diseases. In addition, sbg37149SLITb shows similarity to leucine-rich repeat proteins, and may also demonstrate significant functions in neural development. It has been shown that expression of slit genes is associated with neuronal migration in the developing forebrain (Hu H, <i>Neuron</i> 703-11,1999). It is thus possible that sbg37149SLITb plays a crucial role in the morphogenesis of the mammalian nervous system (Taniguchi H, Tohyama M, Takagi T. <i>Brain Res Mol Brain Res</i> 1996 Feb;36(1):45-52)	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing, inflammation, and diseases in spinal cord, thyroid gland, ovary, prostate, renal gland, small intestine, heart, trachea, thymus, lymph node, and muscular system

Table III Cont

Gene Name	Uses	Associated Diseases
sbg36267SLITa	An embodiment of the invention is the use of sbg36267SLITa to treat gastrointestinal ulceration as well as prevention and treatment of diseases in spinal cord, thyroid gland, ovary, prostate, renal gland, small intestine, heart, trachea, thymus, lymph node, muscular system and colon. sbg36267SLITa is exploitable in similar ways to a close homolog human KIAA0918 protein, which is functionally related to cell signaling/communication, cell structure/motility and nucleic acid management. A close homolog of sbg36267SLITa is PRO266 and human slit 3 mature protein.	Gastrointestinal ulceration, diseases in spinal cord, thyroid gland, ovary, prostate, renal gland, small intestine, heart, trachea, thymus, lymph node, muscular system and colon
sbg35579MELAa	An embodiment of the invention is the use of sbg35579MELAa. The closest homologue to this novel protein is human KIAA1484 protein which is derived from brain-specific cDNA library and functionally related to cell signaling/communication, cell structure/motility and nucleic acid management. Other close homologs to sbg35579MELAa are human KIAA1246, also derived from brain-specific cDNA library and human brain-specific transmembrane glycoprotein B09968. B09968 has a typical PDZ protein binding motif and functions as a cellular signal transducer, useful in developing drugs for treating nervous diseases	Gastrointestinal ulceration, diseases in spinal cord, thyroid gland, ovary, prostate, renal gland, small intestine, heart, trachea, thymus, lymph node, muscular system and colon.
SBh69447. Triglyceride Lipase	An embodiment of the invention is the use of SBh69447. Triglyceride Lipase, a member of gastric lipases, for oral administration to treat lipase deficiency in cystic fibrosis and pancreatitis. Some gastric lipases are also useful therapeutically for absorption of ingested fat in patients with mucoviscidiosis of fat and defective transesterification (WO8601532-A).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing, inflammation, gastric lipase deficiency, cystic fibrosis, Pancreatitis, altered absorption of fat, gastrointestinal disorders, defective biocatalysis, mucoviscidosis, poor enzymatic bioconversion of fat, cystic fibrosis, pancreatitis diseases
SBh86614.Tryp1	An embodiment of the invention is the use of SBh86614.Tryp1, a member of the mast cell protease/ tryptase family, for treatment of undesirable clot formation such as myocardial infarction, during angioplasty and all surgical procedures that require decreased blood clot formation and may also be involved in tumor growth and fertility. Other homologs of the mast cell protease/ tryptase family have been identified in WO9836054-A1 and WO9824886-A1.	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorder, inflammation, blood coagulation disorders, cancers and cellular adhesion disorders, deep vein thrombosis, myocardial infarction
sbg106886 DELTAa	An embodiment of the invention is the use of sbg106886DELTAA in cellular interactions and fetal development. Close homologs of sbg106886DELTAA are involved in cell-to-cell communications in mammalian embryos through the Notch signaling pathway, and therefore may have a role in cellular interactions (Artavanis-Tsakonas et al., 1995, Science 268: 225-232). It has been shown that mouse Delta1 protein is essential for normal somitogenesis and neuronal differentiation, and Delta1 expression can be detected during organogenesis and fetal development (Beckers J., Clark A., Wunsch K., Hrabe De Angelis M., Gossler A. 1999, Mech Dev 84:165-8).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing, inflammation

Table III Cont.

Gene Name	Uses	Associated Diseases
sbg35779THY _a	An embodiment of the invention is the use of sbg35779THY _a , a secreted protein, in the diagnosis and also in the treatment of thyroid and liver diseases, treatment of septic shock, pancreatitis, coagulation disorders, and microbial diseases. Close homologs of sbg35779THY _a are Mutant Human alpha-1-antichymotrypsin with Arg(358) and Alpha-1-antichymotrypsin (Leu358Arg).	Thyroid and liver diseases, septic shock, pancreatitis, coagulation disorders, microbial diseases
sbg15130INH _a	An embodiment of the invention is the use of sbg15130INH _a , a secreted protein, in developing products for treating e.g. immune disorders, cancers, inflammation, transplant rejection or infections. A close homolog of sbg15130INH _a is mouse and rat secretory leukocyte protease inhibitors (SLPI). Transfection of macrophages with SLPI have been shown to suppress LPS-induced activation of NF-kappa B and production of nitric oxide and TNF alpha (Jin,F.Y., Nathan,C., Radzioch,D. and Ding,A. Cell 88 (3), 417-426 (1997)).	Immune disorders, cancers, inflammation, transplant rejection or infections, disorders in fetal development
SBh26548.home-box	An embodiment of the invention is the use of SBh26548 homebox to enhance bone thickness and increase bone density at the site of application or may affect developmental conditions if expressed in the thymus or T cells. Close homologs of SBh26548 homebox are members of HOX and DLX (US5850002-A and WO9943784-A2).	Autoimmune disorder, hematopoietic disorder, wound healing disorder, cancer, inflammation, viral and bacterial infection, autosomal dominant disorder, bone defects, osteoporosis, trauma, periodontal defects
sbg26991CERU _a	An embodiment of the invention is the use of sbg26991CERU _a to reduce the loss of essential ferroxidases. Copper is an essential trace metal which plays a fundamental role in the biochemistry of the human nervous system. Close homologs of sbg26991CERU _a are Ceruloplasmins. Ceruloplasmins are plasma metalloproteins that contains 95% of the copper found in human plasma and inherited loss of this essential ferroxidase is associated with progressive neurodegeneration of the retina and basal ganglia (Waggoner DJ, Bartnikas TB, Gitlin JD, 1999 Neurobiol Dis 6(4):221-30). Ceruloplasmin deficiency leads to iron accumulation and causes damage to a variety of tissues and organs. Serum ceruloplasmin determination can be part of diagnostic procedures of Wilson's disease, an inherited copper storage disease.	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorder, inflammation, and progressive neurodegeneration of the retina and basal ganglia
sbg35851PERO _a	An embodiment of the invention is the use of sbg35851PERO _a , a member of the slit protein family, for diagnosis and treatment of nervous and muscular diseases. In addition, sbg35851PERO _a shows homology to leucine-rich repeat proteins, which demonstrates significant functions in neural development. It is thus possible that similar molecules play a crucial role in the morphogenesis of the mammalian nervous system (Taniguchi H, Tohyama M, Takagi T. Brain Res Mol Brain Res 1996 Feb;36(1):45-52).	Cancer, Gastrointestinal ulceration, Zollinger-Ellison syndrome, congenital microvillus atrophy, skin diseases, diseases associated with nervous system.
sbg36274SLIT _a	An embodiment of the invention is the use of sbg36274SLIT _a , a member of human slit-like proteins, which may be necessary for CNS development, and therefore can be useful for diagnosis and treatment of nervous and muscular diseases. A close homolog of sbg36274SLIT _a is insulin-like growth factor. Insulin-like growth factors may be used to treat patients with growth hormone receptor deficiency (GHRD) (Fielder PJ, Gargosky SE, Vaccarello M, Wilson K, Cohen P, Diamond F, Guevara-Aguirre J, Rosenbloom AL, and Rosenfeld RG 1993. Acta Paediatr Suppl 388:40-3).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorder, inflammation, gastrointestinal ulceration, and diseases in spinal cord, thyroid gland, ovary, prostate, renal gland, small intestine, heart, trachea, thymus, lymph node, and muscular system

TABLE III Cont

Gene Name	Uses	Associated Diseases
sbg34575SLITa	An embodiment of the invention is the use of sbg34575SLITa, a member of human slit-like proteins, which may be necessary for CNS development, and therefore can be useful for diagnosis and treatment of nervous and muscular diseases. A close homolog of sbg34575SLITa is leucine-rich repeat proteins(BAA85972, mouse 1SLR), which also demonstrates significant functions in neural development (Nagasaki, A., Kudo, J., Noda, S., Mashima, Y., Wright, A., Oguchi, Y., and Shimizu, N. <i>Genomics</i> 61 (1), 37-43, 1999). It has been shown that expression of slit genes is associated with neuronal migration in the developing forebrain (Hu H, <i>Neuron</i> 23:703-11,1999). It is thus possible that similar molecules play a crucial role in the morphogenesis of the mammalian nervous system (Taniguchi H, Tohyama M, Takagi T. <i>Brain Res Mol Brain Res</i> 1996 36(1):45-52).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorder, inflammation, gastrointestinal ulceration, and diseases in spinal cord, thyroid gland, ovary, prostate, small intestine, heart, trachea, thymus, lymph node, muscular system and colon
SBh71706.NIAP	An embodiment of the invention is the use of SBh71706.NIAP in the suppression of apoptosis. Related polypeptides have been used for treating regulation of cellular proliferation and differentiation and cell survival. The NIAP prevent motor neuron apoptosis induced by a variey of signals. These proteins do contain 3 BIR(Baculoviral Inhibitionof apoptosis protein repeats (LISTON,P. <i>Nature</i> 379 (6563), 349-353 (1996).	Autoimmune disorder, hematopoietic disorder, wound healing disorder, viral and bacterial infection, cancer, AIDS, amyotrophic lateral sclerosis, infertility, human spinal muscular atrophy and neurodegenerative disorder
SBh77492.Breast Specific BS200	An embodiment of the invention is the use of SBh77492.Breast Specific BS200 in regulating vascular smooth muscle cell proliferation. A close homolog of SBh77492.Breast Specific BS200 is EEGF protein. EEGF protein is useful for enhancing neurological functions or treating neoplasia and other disorders (LI HS and OLSEN H, New isolated extracellular/epidermal growth factor, Patent Accession Number W79739, HUMAN GENOME SCI INC).	Cancer, autoimmune disorders, wound healing disorders, infections, and hematopoietic disorders
sbgl15305LRRa	An embodiment of the invention is the use of sbgl15305LRRa, a Leucine-rich repeat (LRR) protein, in neuronal development and the adult nervous systems as cell adhesion molecules. Close homologs of sbgl15305LRRa are connectin, slit, chaoptin, and toll. These LRR proteins possibly have important roles in neuronal development and the adult nervous systems as cell adhesion molecules (Taguchi A, Wanaka A, Mori T, Matsumoto K, Imai Y, Tagaki T, Tohyama M, 1996, <i>Brain Res Mol Brain Res</i> 35:31-4). Leucine-rich repeat protein family has been implicated in protein-protein interactions, such as cell adhesion or receptor-ligand binding. At least one LRR was shown to be specifically expressed on B cells, suggesting its role in immunization (Miyake K, Yamashita Y, Ogata M, Sudo T, Kimoto M, 1995. <i>J Immunol</i> 154:3333-40). Some studies have shown that brain injury can cause over expression of neuronal LRR, suggesting that neuronal LRR may be an important component of the pathophysiological response to brain injury (Ishii N, Wanaka A, Tohyama M, <i>Brain Res Mol Brain Res</i> 1996 Aug;40(1):148-52).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorder, inflammation, gastrointestinal ulceration, diseases in spinal cord, thyroid gland, heart, trachea, thymus, lymph node, muscular system, and nervous system

Table IV. Quantitative, Tissue-specific mRNA expression detected using SybrMan

Quantitative, tissue-specific, mRNA expression patterns of the genes were measured using SYBR-Green Quantitative PCR (Applied Biosystems, Foster City, CA; see Schmittgen T.D. et al., Analytical Biochemistry 285:194-204, 2000) and human cDNAs prepared from various human tissues. Gene-specific PCR primers were designed using the first nucleic acid sequence listed in the Sequence List for each gene. Results are presented as the number of copies of each specific gene's mRNA detected in 1ng mRNA pool from each tissue. Two replicate mRNA measurements were made from each tissue RNA.

Gene Name	Tissue-Specific mRNA Expression (copies per ng mRNA; avg. \pm range for 2 data points per tissue)									
	Brain	Heart	Lung	Liver	Kidne y	Skeletal muscle	Intestin e	Spleen/ lymph	Placen ta	Testis
sbg10145 2SL1Ta	3389 \pm 33	174 \pm 11	187 \pm 29	-6 \pm 2	112 \pm 4	64 \pm 5	159 \pm 7	147 \pm 8	209 \pm 37	563 \pm 37
sbg29046 CYSa	338 \pm 60	385 \pm 69	735 \pm 29	138 \pm 41	592 \pm 36	218 \pm 25	186 \pm 35	348 \pm 52	839 \pm 65	46124 \pm 22605
sbg29046 CYSb	951 \pm 69	1121 \pm 74	358 \pm 110	364 \pm 44	871 \pm 128	1133 \pm 203	347 \pm 101	612 \pm 18	601 \pm 12	591 \pm 51
sbg37149 SLITb	4989 \pm 18	51 \pm 10	457 \pm 41	148 \pm 12	769 \pm 90	17 \pm 2	31 \pm 11	37 \pm 14	10 \pm 6	346 \pm 10
sbg36267 SLIta	2976 \pm 186	258 \pm 8	127 \pm 30	2 \pm 0	1374 \pm 13	2188 \pm 72	44 \pm 1	81 \pm 5	113 \pm 4	242 \pm 1
sbg35579 MELAa	4630 \pm 1163	5518 \pm 506	6114 \pm 1422	1701 \pm 140	5876 \pm 1366	4017 \pm 291	1918 \pm 25	4310 \pm 279	5247 \pm 1	3589 \pm 148
SBh69447 Trigly- ceride Lipase	1 \pm 0	5 \pm 1	6 \pm 6	-7 \pm 6	3 \pm 0	1 \pm 0	-2 \pm 3	4 \pm 1	200 \pm 8	18 \pm 7
SBh86614 .Tryp1	742 \pm 82	392 \pm 18	487 \pm 24	642 \pm 6	576 \pm 12	369 \pm 53	234 \pm 15	547 \pm 25	662 \pm 2	550 \pm 4
sbg10688 6 DELTAAa	1308 \pm 49	520 \pm 19	340 \pm 66	127 \pm 11	418 \pm 24	264 \pm 39	130 \pm 21	269 \pm 21	538 \pm 99	558 \pm 116
sbg35779 THYa	2 \pm 1	2 \pm 1	21 \pm 1	-4 \pm 8	2 \pm 1	-5 \pm 8	26 \pm 2	886 \pm 38	7 \pm 2	6 \pm 5
sbg15130I NHa	4 \pm 1	6 \pm 2	209 \pm 2	-4 \pm 6	42 \pm 1	-2 \pm 8	9 \pm 5	14 \pm 0	12 \pm 4	133 \pm 9
SBh26548 .home- box	56 \pm 3	85 \pm 5	111 \pm 18	273 \pm 1	149 \pm 12	80 \pm 17	86 \pm 12	88 \pm 8	120 \pm 49	81 \pm 35
sbg26991 CERUa	1 \pm 0	4 \pm 2	2 \pm 2	1 \pm 3	4 \pm 0	-1 \pm 0	4 \pm 0	2 \pm 2	9 \pm 0	26 \pm 8
sbg35851 PEROa	83 \pm 20	31 \pm 1	37 \pm 17	29 \pm 5	53 \pm 14	35 \pm 8	17 \pm 4	25 \pm 13	36 \pm 9	38 \pm 3
sbg36274 SLITa	8770 \pm 345	598 \pm 8	591 \pm 57	7 \pm 5	518 \pm 82	75 \pm 9	253 \pm 13	2847 \pm 37	13 \pm 1	278 \pm 6
sbg34575 SLIta	2045 \pm 346	2 \pm 0	5 \pm 0	-14 \pm 2	-2 \pm 4	-4 \pm 3	0 \pm 0	26 \pm 7	10 \pm 0	45 \pm 6
SBh71706 .NIAP	251 \pm 9	535 \pm 25	1055 \pm 55	122 \pm 36	144 \pm 7	322 \pm 15	149 \pm 5	1081 \pm 67	740 \pm 27	387 \pm 17
SBh77492 .Breast Specific BS200	154 \pm 4	134 \pm 4	1954 \pm 135	325 \pm 57	981 \pm 13	60 \pm 6	700 \pm 15	1246 \pm 5	586 \pm 30	2614 \pm 69
sbg11965 2TYRa	43 \pm 11	132 \pm 21	25 \pm 8	10 \pm 7	122 \pm 15	24 \pm 10	22 \pm 11	30 \pm 8	15 \pm 15	615 \pm 4
sbg11530 SLRRa	7057 \pm 326	289 \pm 1	1122 \pm 88	111 \pm 4	547 \pm 5	6178 \pm 84	361 \pm 12	896 \pm 8	377 \pm 18	9121 \pm 120

Table V. Additional diseases based on mRNA expression in specific tissues

Tissue Expression	Additional Diseases
Brain	Neurological and psychiatric diseases, including Alzheimers, parasupranuclear palsey, Huntington's disease, myotonic dystrophy, anorexia, depression, schizophrenia, headache, amnesias, anxiety disorders, sleep disorders, multiple sclerosis
Heart	Cardiovascular diseases, including congestive heart failure, dilated cardiomyopathy, cardiac arrhythmias, Hodgson's Disease, myocardial infarction, cardiac arrhythmias
Lung	Respiratory diseases, including asthma, Chronic Obstructive Pulmonary Disease, cystic fibrosis, acute bronchitis, adult respiratory distress syndrome
Liver	Dyslipidemia, hypercholesterolemia, hypertriglyceridemia, cirrhosis, hepatic encephalopathy, fatty hepatocirrhosis, viral and nonviral hepatitis, Type II Diabetes Mellitis, impaired glucose tolerance
Kidney	Renal diseases, including acute and chronic renal failure, acute tubular necrosis, cystinuria, Fanconi's Syndrome, glomerulonephritis, renal cell carcinoma, renovascular hypertension
Skeletal muscle	Eulenburg's Disease, hypoglycemia, obesity, tendinitis, periodic paralyses, malignant hyperthermia, paramyotonia congenita, myotonia congenita
Intestine	Gastrointestinal diseases, including Myotonia congenita, Ileus, Intestinal Obstruction, Tropical Sprue, Pseudomembranous Enterocolitis
Spleen/lymph	Lymphangiectasia, hypersplenism, angiomas, ankylosing spondylitis, Hodgkin's Disease, macroglobulinemia, malignant lymphomas, rheumatoid arthritis
Placenta	Choriocarcinoma, hydatidiform mole, placenta previa
Testis	Testicular cancer, male reproductive diseases, including low testosterone and male infertility
Pancreas	Diabetic ketoacidosis, Type 1 & 2 diabetes, obesity, impaired glucose tolerance

What is claimed is:

1. An isolated polypeptide selected from the group consisting of:
 - (a) an isolated polypeptide encoded by a polynucleotide comprising a sequence set forth in Table I;
 - (b) an isolated polypeptide comprising a polypeptide sequence set forth in Table I; and
 - (c) a polypeptide sequence of a gene set forth in Table I.
2. An isolated polynucleotide selected from the group consisting of:
 - (a) an isolated polynucleotide comprising a polynucleotide sequence set forth in Table I;
 - (b) an isolated polynucleotide of a gene set forth in Table I;
 - (c) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide set forth in Table I;
 - (d) an isolated polynucleotide encoding a polypeptide set forth in Table I;
 - (e) a polynucleotide which is an RNA equivalent of the polynucleotide of (a) to (d); or a polynucleotide sequence complementary to said isolated polynucleotide.
3. An expression vector comprising a polynucleotide capable of producing a polypeptide of claim 1 when said expression vector is present in a compatible host cell.
- 20 4. A process for producing a recombinant host cell which comprises the step of introducing an expression vector comprising a polynucleotide capable of producing a polypeptide of claim 1 into a cell such that the host cell, under appropriate culture conditions, produces said polypeptide.
- 25 5. A recombinant host cell produced by the process of claim 6.
6. A membrane of a recombinant host cell of claim 7 expressing said polypeptide.
- 30 7. A process for producing a polypeptide which comprises culturing a host cell of claim 7 under conditions sufficient for the production of said polypeptide and recovering said polypeptide from the culture.

SEQUENCE LISTING

<110> SMITHKLINE BEECHAM CORPORATION
SMITHKLINE BEECHAM p.l.c.

<120> NOVEL COMPOUNDS

<130> GP50016

<140> TO BE ASSIGNED

<141> 2001-03-05

<150> 60/187,107

<151> 2000-03-06

<150> 60/236,874

<151> 2000-10-03

<150> 60/188,916

<151> 2000-03-13

<150> 60/237,846

<151> 2000-10-03

<160> 52

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 2301

<212> DNA

<213> Homo sapiens

<400> 1

atggaaaaag ttcttttta tctgtttctc attggcatag cagtgaaagc tcagatctgt	60
ccaaagcgtt gtgtctgtca gatttgtct cctaatttg caaccctttg tgccaagaaa	120
ggcctttat ttgttccacc aaacattgac agaagaactg tggaactgctg gttggcagac	180
aattttgtta caaatattaa aaggaaagat ttgccaata tgaccagctt ggtggacctg	240
actctatcca ggaatacaat aagtttattt acacctcatg ctttcgtctga cctacgaaat	300
ttgagggctt tgcatttcaa tagcaacaga ttgactaaaa ttacaaatga tatgttcagt	360
ggctttcca atcttcatca ttgtactg aacaacaatc agctgacttt aatttcctct	420

<210> 2

<211> 445

<212> DNA

<213> *Homo sapiens*

<400> 2

aatgctgggc ctgcgtgga agggaggtct gtcctggcg ctgctgctgc ttctctttagg 60
ctccccagatc ctgctgatct atgcctggca tttccacgag caaaggact gtgatgaaca 120
caatgtcatg gtcgttacc tccctgccac agtggagttt gctgtccaca cattcaacca 180

acagagcaag gactactatg cctacagact ggggcacate ttgaattcct ggaaggagca	240
ggtggagtcc aagactgtat tctcaatgga gctactgctg gggagaacta ggtgtggaa	300
atttgaagac gacattgaca actgcattt ccaagaaaagc acagagctga acaatacttt	360
cacctgcttc ttcaccatca gcaccaggcc ctggatgact cagttcagcc tcctgaacaa	420
gacctgcttg gagggattcc actga	445

<210> 3
 <211> 477
 <212> DNA
 <213> Homo sapiens

<400> 3	
atgtggagtc tgccgccgag cagggtctg tccgtgcgc cactgctgct tctttcagc	60
ttccagttcc tggttaccta tgcttggctt ttccaagagg aagaggagtg gaatgaccaa	120
aaacaaaattg ctgttatct ccctcccacc ctggagtttgc cctgtacac attcaacaag	180
cagagcaagg actggatgc ctacaagctg gtgcctgtcc tggcttcctg gaaggagcag	240
ggttatgata agatgacatt ctccatgaat ctgcaactgg gcagaaccat gtgtggaaa	300
tttgaagatg acattgacaa ctgcccctt caagagagcc cagagctgaa caatgttaaga	360
caagacacca gcttccctcc tggatacagc tggatgatgcc gcatgggttgc tggcggac	420
acagacactgc acctgcttct tcaccattgg aatagagccc tggaggacac ggtttga	477

<210> 4
 <211> 444
 <212> DNA
 <213> Homo sapiens

<400> 4	
atgtggagtc tgccgccgag cagggtctg tccgtgcgc cactgctgct tctttcagc	60
ttccagttcc tggttaccta tgcttggctt ttccaagagg aagaggagtg gaatgaccaa	120
aaacaaaattg ctgttatct ccctcccacc ctggagtttgc cctgtacac attcaacaag	180
cagagcaagg actggatgc ctacaagctg gtgcctgtcc tggcttcctg gaaggagcag	240
ggttatgata agatgacatt ctccatgaat ctgcaactgg gcagaaccat gtgtggaaa	300
tttgaagatg acattgacaa ctgcccctt caagagagcc cagagctgaa caatacctgc	360
acctgcttct tcaccattgg aatagagccc tggaggacac ggtttgacct ctggacaag	420
acgtgctcag gcggcattc ctga	444

<210> 5
 <211> 2463
 <212> DNA
 <213> Homo sapiens

<400> 5

atgctgcgcc	tggggctgtg	cgcggcggcg	ctgctgtgcg	tgtgccggcc	gggtgccgtg	60
cgtgccact	gctggctcat	tgagggcgac	aagggtacg	tgtggctggc	catttgcagc	120
cagaaccagc	cgcctacga	gaccatccc	cagcacatca	atagcaccgt	gcacgacctg	180
cggctcaacg	agaacaagct	caaaggcg	cttacttct	cgctcaaccg	cttggaaac	240
ctcaccgacc	tcaacctcac	caagaacgag	atctcctaca	tcgaggacgg	tgcccttc	300
ggccagtcga	gcctgcagg	cctgcagct	ggctacaaca	agctcagcaa	cctgacggag	360
ggcatgctgc	gaggcatgag	ccgcctgcag	ttccctttt	tccagcacaa	cctcatcgag	420
gtgggtacgc	ccaccgc	ctccgagtgc	ccgagcctca	tcagcatcga	cctgtcctcc	480
aaccgcctca	gccgcctgga	cggtgccacc	tttgcagcc	tcgcccagc	gtgggtgtgt	540
gagctggccg	gcaacccctt	caactgtgag	tgcgacctct	tcggcttc	ggcctggctg	600
gtgggtttca	acaacgtcac	caagaactac	gaccgcctgc	agtgtgagtc	gccgcgggag	660
tttgcggct	acccgctgt	ggtgccccgg	ccctaccaca	gcctcaacgc	cataccgta	720
ctccaggc	agtgtcgaa	tggctcgct	ccgcggccgg	ccgtgagcca	ccccacgccc	780
tactccaccg	acgcccagag	ggagccagac	gagaactcgg	gcttcaaccc	cgacgagatc	840
ctttcggtgg	agccgcggc	ctcgccacc	acggatgcgt	cggcaggg	agccatcaag	900
ctgaccacg	tcacgttac	ctcgccacc	ctgggtgtca	tcatccaca	ccctacagc	960
aagatgtaca	tcctcg	tgc	gtacaacaac	agctacttct	ccgacgtcat	1020
aacaagaagg	agatcg	gt	gtggacaaa	ctgcggcgc	acactgagta	1080
gtgac	ctgc	tg	gcaacacag	ccgccc	gac	1140
gac	cc	cc	ccggagactt	ggcgc	cc	1200
atc	ctt	ttt	gc	cc	at	1260
aag	ggc	gg	ggc	gt	gt	1320
atg	cg	ct	gt	ct	gt	1380
gag	c	cc	cc	cc	cc	1440
ctg	ccc	acc	gg	gg	gg	1500
aactat	atcg	ggg	gg	gg	gg	1560
ctcc	ccgg	ctt	ggc	cc	gg	1620
gtgg	aca	gtt	cc	cc	cc	1680
tctt	tct	cc	cc	cc	cc	1740
ctcc	ctt	cc	cc	cc	cc	1800
ttcc	ttt	cc	cc	cc	cc	1860
gac	cc	cc	cc	cc	cc	1920
aagg	tctt	cc	cc	cc	cc	1980
tccaa	gtt	cc	cc	cc	cc	2040
ccgg	cc	cc	cc	cc	cc	2100
ccgg	cc	cc	cc	cc	cc	2160
ccgg	cc	cc	cc	cc	cc	2220
tccac	ctt	cc	cc	cc	cc	2280
tccat	cc	cc	cc	cc	cc	2340
tact	cc	cc	cc	cc	cc	2400
cgcc	cc	cc	cc	cc	cc	2460
cgcc	cc	cc	cc	cc	cc	2463
tga						

<210> 6
 <211> 2601
 <212> DNA
 <213> Homo sapiens

<400> 6

atgaccattg	aaaaaatgtt	ttcttttat	tttttagatt	atttctctt	attcagaagc	60
atacagttgt	ttgctgattg	caagaagatg	tttctgtggc	tgtttctgat	tttgcagcc	120
ctgatttctt	cgacaaaatgc	agattctgac	atatcggtgg	aaatttgcaa	tgtgtgttcc	180
tgcgtgtcag	ttgagaatgt	gctctatgtc	aactgtgaga	aggtttcagt	ctacagacca	240
aatcagctga	aaccacccgt	gtctaaattt	tatcacctca	atttccaaaa	taatttttta	300
aatattctgt	atccaaatac	attcttgaat	ttttcacatg	cagtctccct	gcatctgggg	360
aataataaac	tgcagaacat	tgagggagga	gcctttcttg	ggctcagtgc	attaaagcag	420
ttgcacttga	acaacaatga	attaaagatt	ctccgagctg	acactttcct	tggcatagag	480
aacttggagt	atctccaggc	tgactacaat	ttaatcaagt	atattgaacg	aggagccctc	540
aataagctcc	acaaaactgaa	agtttcattt	cttaatgaca	atctgatttc	attccttccct	600
gataatattt	tccgattcgc	atcttgcacc	catctggata	tacgagggaa	cagaatccag	660
aagctccctt	atatcggtt	tctggaacac	attggccgtg	tcgttgaatt	gcaactggaa	720
gataaccctt	ggaactgttag	ctgtgatttta	ttgcctttaa	aagcttggct	ggagaacatg	780
ccatataaca	tttacatagg	agaagctatc	tgtgaaactc	ccagtgactt	atatggaagg	840
cttttaaaag	aaaccaacaa	acaagagcta	tgtcccatgg	gcaccggcag	tgattttgac	900
gtgcgcatcc	tgcctccatc	tcagctggaa	aatggctaca	ccactcccaa	tggtcacact	960
acccaaacat	ctttacacag	attagtaact	aaaccaccaa	aaacaacaaa	tccttccaag	1020
atctctggaa	tcgttgcagg	caaagccctc	tccaaaccgca	atctcagtca	gattgtgtct	1080
taccaacaa	gggtgcctcc	tctaacacct	tgccggcac	cttgcttctg	caaaaacacac	1140
ccttcagatt	tgggactaag	tgtgaactgc	caagagaaaa	atatacagtc	tatgtctgaa	1200
ctgataccga	aacctttaaa	tgcgaagaag	ctgcacgtca	atggcaatag	catcaaggat	1260
gtggacgtat	cagacttcac	tgactttgaa	ggactggatt	tgcttcattt	aggcagcaat	1320
caaattacag	tgattaaggg	agacgttattt	cacaatctca	ctaatttacg	caggctataat	1380
ctcaatggca	atcaaattga	gagactctat	cctgaaatat	tttcaggtct	tcataaacctg	1440
cagtatctgt	atttggaata	caatttgatt	aaggaaatct	cagcaggcac	ctttgactcc	1500
atgccaattt	tgcagttact	gtacttaaac	aataatctcc	taaagagcct	gcctgtttac	1560
atctttccg	gagcaccctt	agctagactg	aacctgagga	acaacaaatt	catgtacctg	1620
cctgtcagtg	gggtccttga	tcagttgcaa	tctttcacac	agattgactt	ggagggcaac	1680
ccatggact	gtacttgcata	cttggggca	ttaaagctgt	gggtggagaa	gttgagcgcac	1740
gggattgttg	tgaaagaact	gaaatgtgag	acgcctgttc	agtttgccaa	cattgaactg	1800
aagtccctca	aaaatgaaat	cttatgtccc	aaacttttaa	ataagccgtc	tgaccatcc	1860
acaagccctg	cacctgccat	tacattcacc	actcctttgg	gtcccattcg	aagtccctcc	1920
gttggggccag	tgcctctgtc	tatTTTATC	ttaagtatct	tagtggcct	catttaacg	1980
gtgtttgttg	cttttgcct	tcttggggaa	gtcctgcgac	gcaacaagaa	acccacagtg	2040
aagcacgaag	gcctggggaa	tcctgactgt	ggctccatgc	agctgcagct	aaggaagcat	2100

gaccacaaaa ccaataaaaa agatggactg agcacagaag ctttcattcc acaaactata	2160
gaacagatga gcaagagcca cacttgtggc ttgaaaagagt cagaaactgg gttcatgttt	2220
tcagatcctc caggacagaa agttgttagt agaaatgtgg ccgacaagga gaaagattta	2280
ttacatgttag ataccaggaa gagactgagc acaaattgtat agctggatga attattccct	2340
agcaggatt ccaatgttt tattcaagaat ttctttgaaa gcaaaaagga gtataatagc	2400
ataggtgtca gtggcttga gatccgctat ccagaaaaac aaccagacaa aaaaagtaag	2460
aagtcaactga taggtggcaa ccacagtaaa attgtgtgg aacaaaggaa gagtgagttat	2520
tttgaactga aggcgaaact gcagagttcc cctgactacc tacaggtcct tgaggagcaa	2580
acagcttga acaagatcta g	2601

<210> 7

<211> 1602

<212> DNA

<213> Homo sapiens

<400> 7

atggctccag gacccttctc ctggccctc ctctcgccgc cgcccgctgc cctgccc	60
ctgctgctgc tctggcgccc ggcacatctcggt ggccagccct gccccggccg ctgcacatctgc	120
cagaacgtgg cgcccacact gacaatgtcg tgcccaaga ccggcttgcgt ctttgtgccc	180
cccgccatcg accggcgctg ggtggagctg cggctcaccg acaacttcat cgccgcccgtg	240
cgccgcccggc acttcgcca catgaccaggc ctgggtgcacc tcactctctc ccggAACACC	300
atcgccagg tggcagctgg cgccttcgccc gacctgcgtg ccctccggc cctgcacac	360
gacagcaacc gcctggcgaa ggtgcgcggc gaccagctcc gcggccttggg caacctccgc	420
cacctgatcc ttggaaacaa ccagatccgc cgggtggagt cggccgcctt tgacgccttc	480
ctgtccaccc tggaggaccc ggatctgtcc tacaacaacc tggaggccct gccgtgggag	540
gcggtggggcc agatgggtgaa cctaaacacc ctcacgcgtt accacaaccc catcgaccac	600
atcgccggagg ggacccctgt gcagcttcac aagctggtcc gtctggacat gacccctccac	660
cgccctgcata aactccccc cgacggctc ttcttgagggt cgccaggcacc cggggcccaag	720
ccggccaccc cgctgaccgt cagcttcggc ggcaacccccc tgcactgcaa ctgcagctg	780
ctctggctgc ggcggctgac ccgcgaggac gacttagaga cctgcgccac gcccgaacac	840
ctcaccggacc gctacttcgt gtccatcccc gaggaggagt ttctgtgtga gcccccgctg	900
atcacacggc aggcgggggg ccggggccctg gtgggtggaaag gccaggccgt gacccctgc	960
tgccgagcgg tgggtgaccc cgagccgtg gtgcactggg tggcacctga tggccggctg	1020
ctggggaaact ccagccggac ccgggtccgg ggggacggga cgctggatgt gaccatcacc	1080
accttgaggg acagtggcac cttcacttgt atgcctccca atgctgtgg ggaagcgacg	1140
gcgcgggtgg aggtgtgcgt ggtacctctg cctctgtatgg caccggccccc ggctgcccc	1200
ccgcctctca ccgagccccc ctccctgcac atgcctccacgc cggcagacc aggtgccaac	1260
gattctgcgg ctgagcgtcg gctctggca gccgagctca cctcgaactc cgtctcatc	1320
cgctggccag cccagaggcc tgcgtggaa atacgcatgt accaggttca gtacaacagt	1380
tccgttcatgt actccctctg ctacagcttgc gcctccctca tgcacattgt agagcaccag	1440
ttaaatgctt cagtcatctg cttggcttca cctggagatg ccagccggc tggagcttt	1500
tccctacctg tggagagccct cagctccctgg ctgtcagatc ttcaccggaga aacctgcctc	1560

ttggcctcca tctctgcctt tccagtgttt tcttggccat ag	1602
<210> 8	
<211> 2316	
<212> DNA	
<213> Homo sapiens	
<400> 8	
atggctccag gacccttctc ctcggccctc ctctcgccgc cgcccgctgc cctgcccctt	60
ctgctgctgc tctggcgccc ggcatctcggt ggccagccct gccccggccg ctgcacatctgc	120
cagaacgtgg cggccacact gacaatgctg tgcgccaaga ccggcttgct ctttgtgccc	180
cccgccatcg accggcgctg ggtggagctg cggctcaccc acaacttcat cgccgcccgtg	240
cgccgcccggag acttcgccaa catgaccaggc ctggtgacacc tcactctctc cggaaacacc	300
atcgccagg tggcagctgg cgccttcgccc gacctgcgtg ccctccgggc cctgcacactg	360
gacagcaacc gcctggcgga ggtgcgcggc gaccagctcc gccgcctggg caacctccgc	420
cacctgatcc ttggaaaccaa ccagatccgc cgggtggagt cggcggcctt tgacgccttc	480
ctgtccaccc tggaggaccc ggatctgtcc tacaacaacc tggaggccct gccgtggag	540
gcggtggggcc agatggtcaa cctaaacacc ctcacgctgg accacaaccc catcgaccac	600
atcgccggagg ggacccctgt gcagcttcac aagctggtcc gtctggacat gacctccaa	660
cgcctgcata aactcccccc cgacgggctc ttctcgaggt cgccaggcac cgggccccaa	720
ccgcccaccc cgctgaccgt cagcttcggc ggcaacccccc tgcactgcaa ctgcgagctg	780
ctctggctgc ggcggctgac ccgcgaggac gacttagaga cctgcgccac gcccgaacac	840
ctcaccgacc gctacttctg gtccatcccc gaggaggagt ttctgtgtga gcccccgctg	900
atcacacggc aggcgggggg ccggccctg gtgggtggaaag gccaggcggt gagcctgcgc	960
tgccgagcgg tgggtgaccc cgagccggtg gtgcactggg tggcacctga tggcggctg	1020
ctgggaaact ccagccggac ccgggtccgg ggggacggga cgctggatgt gaccatcacc	1080
accttggagg acagtggcac cttcacttgt atcgctccaa atgctgctgg ggaagcgacg	1140
gcccggctgg aggtgtgcgt ggtacccctg cctctgtatgg caccggccccc ggctgcccc	1200
ccgcctctca ccgagccccc ctcctctgac atcgccacgc cggcagacc aggtgccaac	1260
gattctgcgg ctgagcgctg gtcgtggca gccgagctca cctcgaactc cgtgctcatc	1320
cgctggccag cccagagggc tggccggcaac gcgagttgtac accaggttca gtacaacagt	1380
tccgttgatg actccctctgt ctacaggatg atccctgtcca ccagtcagac cttcctgg	1440
aatgacctgg cggccggccg tgcctacgac ttgtgcgtgc tggcgtctca cgacgacggg	1500
gccacagcgc tgccggcaac gcgagttgtac ggctgtgtac agttcaccac cgctgggat	1560
ccggcgcctt gccgcccgt gaggggccat ttcttggcg gcaccatgtat catcgccatc	1620
ggggggctca tgcgtccctc ggtcctcgctc ttcatcgatc tgctcatgtat ccgtataag	1680
gtgtatggcg acggggacag ccgcccgtc aagggttcca ggtcgctccc ggggtcagc	1740
cacgtgtgtc cgcagaccaa cggcgcaggc acaggcgccgg cacaggcccc ggccctgccc	1800
gcccaggacc actacgagac gctgcgcgg gtggagttccc aggctgcccc cgccgtcgc	1860
gtcgaggcca aggccatgga ggccgagacg gcatccgcgg agccggaggt ggtccttgga	1920
cgttctctgg cggcgtccggc cacctcgctg tgcctgtgc catccgagga aacttccggg	1980
gaggaggctc gggccgcggt gggccctcga aggagccat ccggccccc gtagccacca	2040

acctcggcgc cccctactct agctctagtt cctgggggag ccgcggcccg gcccaggccg	2100
cagcagcgct attcgttcga cggggactac ggggcactat tccagagcca cagttacccg	2160
cgccgcgccc ggcggacaaa gcgcacccgg tccacgcccgc acctggacgg ggctggaggg	2220
ggcgcggccg gggaggatgg agacctgggg ctgggctccg ccagggcgtg cctggcttc	2280
accagcaccg agtggatgct ggagagtacc gtgtga	2316

<210> 9

<211> 1200

<212> DNA

<213> Homo sapiens

<400> 9

atgtggcagc tttagcagc agcatgctgg atgcttcttc ttggatctat gtatggttat	60
gacaagaaag gaaacaatgc aaaccctgaa gctaataatga atattagcca gattatttct	120
tactggggtt atccttatga agagtatgat gttacaacaa aagatggta tattcttgg	180
attatagga ttccacatgg aagaggatgc ccagggagga cagctccaaa gcctgctgtg	240
tatttgcagc atggcttaat tgcacatgcg agtaact'gga tttgcaacct gcccaacaac	300
agtttggctt tccttctggc agatagtggt tatgacgtgt ggttgggaa cagccgagga	360
aacacttggt ccagaaaaca ccttaaattt tcacccaaat caccagaata ctggccttc	420
agtttggatg agatggctaa atatgacctt ccagccacaa tcaattttat catagagaaa	480
actggacaga agcgactcta ctacgtggc cactcacaag gcaccaccat agctttata	540
gcattttcta caaacccaga actggctaaa aagattaaga tatttttgc actggctcca	600
gttgcacag ttaaatacac ccaaagtccct atgaaaaaac taacaaccct ttccaggcga	660
gtagtttaagg ttttgggggg tgacaaaatg ttccaccctc atacattgtt tgaccaattc	720
attgccacca aagtgtgcaa tcgaaagcta ttccgtcgta tttgcagcaa ctccctattt	780
actctgagtg gatttgcattt gcaaaactta aatatgagtc gcttggatgt ttatttgcata	840
cacaatcctg cggaaacatc tggtcagaat atgctgcact gggctcaggc ttttaattct	900
ggtcagctcc aagctttga ttggggaaac tctgtatcaga acatgatgca ctccaccag	960
cttacacccctc cttaatacaa cattactaag atcgaagttc caacagaat atgaaatgg	1020
ggacaggaca ttgtggctga tcccaaggat gttgaaaatt tacttcctca aattgctaac	1080
tttatttttata acaagctgat tccacactac aatcatgtgg attttaccc tggagaggat	1140
gcacccctcagg aaatttacca agacctaattt atattgtgg aagaatattt acaaattaa	1200

<210> 10

<211> 768

<212> DNA

<213> Homo sapiens

<400> 10

atcggtgggg gctcaaacgc gcagccggc acctggcctt ggcaagttag cctgcaccat	60
ggaggtggcc acatctgcgg gggctccctc atcgccccct cctgggtcct ctccgctgct	120
cactgtttca tgacggggcg gcagtaccgc tgcccgagaa cccgcccac gcgcctcgcc	180

ctgcctacca ggaaaaggag gagggcctat aaccactaca gccagggctc agacctggcc	240
ctgctgcagc tcgcccaccc cacgacccac acacccctct gcctgccccca gcccgcctat	300
cgcttccctt ttggagcctc ctgctggcc actggctggg atcaggacac cagtatgccc	360
ccgtctcttt caccagctcc tgggacccta cgcaatctgc gcctgcgtct catcagtgc	420
ccacatgtt actgtatcta caaccagctg caccagcgac acctgtccaa cccggcccg	480
cctggatgc tatgtggggg ccccaagcct ggggtgcagg gcccctgtca gggcttgttt	540
ggggcaccac tggtgcatga ggtgaggggc acatggttcc tggccgggct gcacagtttc	600
ggagatgctt gccaaggccc cgccaggccc gcggtcttca ccgcgtcccc tgctatgagg	660
actgggtcag cagttggac tcggcaggc tacttcgccg aggaaccaga gcccggggct	720
gagcctggaa gtcgcctggc caacataaga cccttctctc tccagtga	768

<210> 11

<211> 906

<212> DNA

<213> Homo sapiens

<400> 11

atggagactg ctgggagtga ttgggttgcg ggaggccac tgacccaggc ctctcacc	60
tcagagtgcg ggaaggcccc gcggccaggc gctggccctt gggaggccca ggtgatggtg	120
ccaggatcca gaccctgcca tggggcgctg gtgtctgaaa gctgggtctt ggacac	180
agctgttttc tggagcaagt aacacacaca ctttgggtct gcagaatgac tcgcgttgg	240
gcctttgtg ccaggaggag gggacctggt ttctggctgg aatcagagac ttcccagt	300
gctgtctact tgcccaggcct ctataaccac tacagccagg gctcagaccc ggccctgct	360
cagctcgcccc acccccacgac ccacacaccc ctctgcctgc cccagccgc ccac	420
ccctttggag cctcctgctg ggccactggc tggatcagg acaccagtga tgccctgg	480
accctacgca atctgcgcct gcgtctcata agtcgccccca catgtaactg tatctaca	540
cagctgcacc agcgacaccc gtccaaacccg gcccggcctg ggatgctatg tggggcccc	600
cagctgggg tgcagggccc ctgtcaggc ttgtttgggg caccactggt gcatgagg	660
aggggcacat gttccctggc cgggctgcac agtttggag atgcttgcac agggccccc	720
aggccggcgg tttcaccgc gtcctgtct atgaggactg ggtcagcagt ttggactcg	780
caggtctact tcggcgagga accagagccc gaggctgagc ctggaaagctg cttggccaac	840
ataagtatgt gcccccccccc ctcctgcca aaccctgcct ctccaggacc ttctctctc	900
cagtga	906

<210> 12

<211> 1152

<212> DNA

<213> Homo sapiens

<400> 12

atgcccagcg gctgccgctg cctgcacatctc gtgtgcctgt tgcattctt gggggctccc	60
ggtcagcctg tccgagccga tgactgcgc tccactgtg acctggccca cggctgctgt	120

gcacctgacg	gctcctgcag	gtgtgacccg	ggctgggagg	ggctgcactg	tgagcgctgt	180
gtgaggatgc	ctggctgcca	gcacggtacc	tgccaccagc	catggcagtg	catctgccac	240
agtggctggg	caggcaagtt	ctgtgacaaa	gatgaacata	tctgtaccac	gcagtc	300
tgccagaatg	gaggccagtg	catgtatgac	gggggcggtg	agtaccattg	tgtgtgctta	360
ccaggttcc	atgggcgtga	ctgcgagcgc	aaggctggac	cctgtgaaca	ggcaggctcc	420
ccatgccgca	atggcgggca	gtgccaggac	gaccagggct	ttgctctcaa	cttcacgtgc	480
cgctgcttgg	tggtgtttgt	gggtgcccgc	tgtgaggtaa	atgtggatga	ctgcctgatg	540
cggccttgc	ctaacggtgc	cacctgcctt	gacggcataa	accgcttctc	ctgcctctgt	600
cctgagggct	ttgctggacg	cttctgcacc	atccaacctgg	atgactgtgc	cagccgccc	660
tgccagagag	ggcccccgtg	tcgggaccgt	gtccatgact	tcgactgcct	ctgccccagt	720
ggctatggtg	gcaagacttg	tgagcttgc	ttacctgtcc	cagacccccc	aaccacagtg	780
gacacccctc	tagggcccac	ctcagctgt	gtggtaacctg	ccacggggcc	agccccccac	840
agcgcagggg	ctggctctgt	gcggatctca	gtgaaggagg	tggtgcggag	gcaagaggct	900
gggctaggtg	agcctagctt	ggtgccctgt	gtgggttttg	gggcccctcac	tgctgccc	960
gttctggcta	ctgtgttgct	gaccctgagg	gcctggcgcc	gggggtgtctg	ccccctggaa	1020
ccctgttgc	accctgcccc	acactatgct	ccagcgtgcc	aggaccagga	gtgtcaggtt	1080
agcatgctgc	cagcagggt	ccccctgcca	cgtgacttgc	cccctgagcc	tggaaagacc	1140
acagcactgt	ga					1152

<210> 13
 <211> 1254
 <212> DNA
 <213> Homo sapiens

<400> 13						
atggcatctt	acctttatgg	agtactctt	gctgttgcc	tctgtgtcc	aatctactgt	60
gtgtccccgg	ccaatgcccc	cagtgcatac	ccccgcctt	cctccacaaa	gagcacc	120
gcctcacagg	tgtattccct	caacaccgac	tttgccttc	gcctataaccg	caggctggtt	180
ttggagaccc	cgagtcagaa	catcttcttc	tcccctgtga	gtgtctccac	ttccctggcc	240
atgcctccc	ttggggccca	ctcagtcacc	aagacccaga	ttctccaggg	cctgggcttc	300
aacctcacac	acacaccaga	gtctgccatc	caccaggct	tccagcacct	gttcaactca	360
ctgactgttc	ccagcaaaga	cctgacctt	aagatggaa	gtgccc	cgtcaagaag	420
gagctgcagc	tgcaggcaaa	tttctggc	aatgtcaaga	ggctgtatga	agcagaagtc	480
ttttctacag	atttctccaa	cccctccatt	gcccaggcga	ggtcaacag	ccatgtgaaa	540
aagaagaccc	aagggaaaggt	tgtagacata	atccaaggcc	ttgaccttct	gacggccatg	600
gttctggta	accacattt	ctttaaagcc	aagtggaga	agcccttca	ccctgaatat	660
acaagaaaga	acttcccatt	cctggggc	gagcaggtca	ctgtgc	cccatgtatg	720
caccagaaag	agcagttcgc	ttttgggtg	gatacagagc	tgaactgctt	tgtgtgcag	780
atggattaca	agggagatgc	cgtggcc	tttgccttc	ctagcaaggg	caagatgagg	840
caactggAAC	aggccttgc	agccagaaca	ctgagaaagt	ggagccactc	actccagaaa	900
aggtggatag	aggtgttcat	ccccagattt	tccatttctg	cctcctacaa	tctggaaacc	960
atcccccga	agatggcat	ccaaaatgtc	tttgacaaaa	atgctgattt	ttctggatt	1020

gcaaagagag actccctgca ggtttctaaa gcaacccaca aggctgtgct ggatgtcagt	1080
gaagagggca ctgaggccac agcagctacc accaccaagt tcatagtccg atcgaaggat	1140
ggccctctt acttcaactgt ctccctcaat aggaccttcc tcatgtatgtat tacaataaaa	1200
gccacagacg gtattcttt tctagggaaa gtggaaaatc ccactaaatc ctag	1254

<210> 14
 <211> 732
 <212> DNA
 <213> Homo sapiens

<400> 14	
atggggtcca gcagcttctt ggccatcg gtgtctctcg ttcttgac cctggggct	60
gtggaggag ttaaagaggg tatagagaaa gcaggggtt gcccagctga caacgtacgc	120
tgcttcaagt ccgatccccc ccagtgtcac acagaccagg actgtctggg ggaaaggaag	180
tgttggtacc tgcactgtgg cttcaagtgt gtgattcctg tgaaggaact ggaagaaggt	240
cagcgcttat tacataaccg tgagcttctt ccagctgcaa tattaggaga ttctttaca	300
gagaaatcgg gggctgccc gccagatgtat gggccctgccc tcctatcggt gcctgaccag	360
tgcgttggaa acagccagtgc tcccttgacc aggaagtgt gctacagagc ttgttccgc	420
cagtgtgtcc ccagggtctc tggtaatgc ctcccttcca ctttgctgac catccaagcc	480
ccaaagcttca gggccagtgg gcaaggacgg agtcacccca gttccctgtg ttgcagtggaa	540
gctgggcagc tgcccagagg accaactgcg ctgcctcagc cccatgaacc acctgtgtca	600
caaggactca gactgctcg gaaaaagcg atgctgccac agcgcctgca ggccggattt	660
ccgggatcct gccagaggtt cggcttctgg gtgcccaggc caggtgcctc ccctctccga	720
gcccagctct aa	732

<210> 15
 <211> 558
 <212> DNA
 <213> Homo sapiens

<400> 15	
atggggtcca gcagcttctt ggccatcg gtgtctctcg ttcttgac cctggggct	60
gtggaggag ttaaagaggg tatagagaaa gcaggggtt gcccagctga caacgtacgc	120
tgcttcaagt ccgatccccc ccagtgtcac acagaccagg actgtctggg ggaaaggaag	180
tgttggtacc tgcactgtgg cttcaagtgt gtgattcctg tgaaggaact ggaagaagtt	240
ccctgtgttgc agtgaagct gggcagctgc ccagaggacc aactgcgtg cctcagcccc	300
atgaaccacc tgcgtcacaa ggactcagac tgctcgccca aaaagcgatg ctgccacagc	360
gcctgcgggc gggattgcgg ggatcctgcc agaggtacgg ctcctgggtg cccagggcag	420
gtgcctcccc tctccgagcc cagctctaat actttcttca ttgctacaag cttaacagga	480
tgcctccccca gaagtcagga cttccatgg ccaggattag gaaactggat aggggttggaa	540
ggagtcctgc taggtga	558

<210> 16

<211> 597

<212> DNA

<213> Homo sapiens

<400> 16

atgaactcgg gacgcgagcc	ccgaacaccc	cgacactct	taagcatcgc	agacatccta	60
gccccgcgca	tggcccccg	agcacccctct	gcgcgcgcagc	ttccagagtc	gggtccgggt
ccaaacgtcgc	cgctgtgcgc	gctggaggag	ctgactagta	aaactttccg	180
gcgcgcgc	tgcagccctc	tgaaggcgg	gcaggtccgg	acgcgcgtgg	240
ttcggccgca	aacggcgcaa	gtcacgcact	gcgttcaccg	cgcaacaggt	300
gagcggcgct	tcgttcca	gaagtacctg	gcgcgcgtccg	acgcgagacgg	360
cgactcggcc	tggccaacgc	gcaggtggtc	acttggttcc	agaacccggcg	420
aagcgcgatg	tggaggagat	gcgcgcgcac	gtcgcctcgc	tacgcgcgtt	480
gtcctgtgca	gcttagca	gcccgaaggc	gctccagatc	ccggccctctg	540
gccccccctg	actcccgcc	ccacctgtca	gacgaggaga	tacaggtgga	597

<210> 17

<211> 993

<212> DNA

<213> Homo sapiens

<400> 17

atggtatgga	aaagagagaa	tttctacaag	gaggtcaagc	gaggaagagc	60
aaaaggcttt	gtattttcaa	tattgatact	gataatacat	ttcaaaaggat	120
ccatcctgg	tgggattttt	aggtccaatg	attaaagcag	agactggaga	180
gtacatgtaa	aaaataatgc	ttcaagagct	tatagttatc	atcctcatgg	240
tccaaagaaa	atgaagggtc	tatctatcct	gataatacga	caggcctgca	300
gaatatctgg	agccagggaa	acaatatacc	tacaagtgg	atgtagaaga	360
cctggcccca	atgacagtaa	ttgtgtgaca	agaatttacc	attcccatat	420
agagatgtag	cttcgggact	tattggacca	atactgactt	gtaaaagagc	480
tacatctatg	gaaatctgcc	caatctcacc	atgtgtgctg	aagataggg	540
tttggggca	tgggtggcgt	ggctgacata	caccccgct	ccactccgcgg	600
atctctcgga	atcacagaaa	ggacaccatt	atgctttcc	cctcctca	660
ttcatgggtgg	ccaaggcccc	tggagtgtgg	atgctgggat	gccagataca	720
atattacttt	tgcgtgatac	aaagtcagag	aacttccaag	tggttagtgc	780
catttcctta	caaatgaaga	gacctatatac	caagaagaga	gtatgcaggc	840
gtaagtaatt	gccagaaaacc	ttcaacagaa	gcctttgtta	ctgggacaca	900
tactatattg	ctgctaaaga	aattcttgg	aactatgctc	tatctggat	960
actaaaaaaaaa	attnaacagc	agctggaagg	taa		993

<210> 18

<211> 1440

<212> DNA

<213> Homo sapiens

<400> 18

atggccatcc	tcccgttgt	cctgtgcctg	ctgcccgtgg	cccctgcctc	atccccaccc	60	
cagtca	gcca	cacccagccc	atgtccccgc	cgctgcgcgt	gccagacaca	gtcgctgccc	120
ctaagcgtgc	tgtgcccagg	ggcaggcctc	ctgttcgtgc	caccctcgct	ggaccgcgg	180	
gcagccgagc	tgccggctggc	agacaacttc	atgcctcccg	tgcgccgcgg	cgacactggcc	240	
aacatgacag	gcctgctgca	tctgacgcctg	tgcggaaaca	ccatccgcca	cgtggctgccc	300	
ggcgccctcg	ccgacactgcg	ggccctgcgt	gccctgcacc	tggatggcaa	ccggctgacc	360	
tcactggcg	agggccagct	gcgcggcctg	gtcaacttgc	gccacctcat	cctcagcaac	420	
aaccagctgg	cagcgtggc	ggccggcgcc	ctggatgatt	gtgccgagac	actggaggac	480	
ctcgacctct	cctacaacaa	cctcgagcag	ctgcccctggg	aggccctggg	ccgcctgggc	540	
aacgtcaaca	cgttggcct	cgaccacaac	ctgctggctt	ctgtgcccgc	cggcgcgtttt	600	
tcccgccctgc	acaagctggc	ccggctggac	atgacctcca	accgcctgac	cacaatccca	660	
cccgacccac	tcttctcccg	cctgcccctg	ctcgccaggc	cccggggctc	gcccgcctct	720	
gcccctggtc	tggccttgg	cgggaaacccc	ctgcactgca	actgcgagct	ggtgtggctg	780	
cgtcgccctgg	cgccggagga	cgacactcgag	gcctgcgcgt	ccccacactgc	tctgggcccgc	840	
cgtacttct	gggcgggtggg	cgaggaggag	tttgcgtgcg	agccgcggcgt	ggtgactcac	900	
cgctcaccac	ctctggctgt	gcccgcagg	cgccggcgtg	ccctgcgcgt	ccggggcagt	960	
ggggacccag	agccccgtgt	gcgttgggtg	tcacccagg	gccggctgct	aggcaactca	1020	
agccgtgccc	gcgccttccc	caatggacg	ctggagctgc	tggtcaccga	gccgggtgat	1080	
ggtggcatct	tcacctgcat	tgcggccaat	gcagctggcg	aggccacagc	tgctgtggag	1140	
ctgactgtgg	gtccccacc	acctcctcag	ctagccaaca	gcaccagctg	tgaccccccgc	1200	
cgggacgggg	atcctgatgc	tctcacccttca	ccctccgcgt	cctctgcctt	tgccaagggt	1260	
gccgacactg	ggcccccctac	cgaccgtggc	gtccaggtga	ctgagcacgg	ggccacagct	1320	
gtctttgtcc	agtggccgga	tcagcggct	atccccggca	tccgcattgt	ccagatccag	1380	
tacaacagct	cggctgatga	catcctcg	tacaggtgca	gggtccag	actggggtag	1440	

<210> 19

<211> 1887

<212> DNA

<213> Homo sapiens

<400> 19

atggccatcc	tcccgttgt	cctgtgcctg	ctgcccgtgg	cccctgcctc	atccccaccc	60	
cagtca	gcca	cacccagccc	atgtccccgc	cgctgcgcgt	gccagacaca	gtcgctgccc	120
ctaagcgtgc	tgtgcccagg	ggcaggcctc	ctgttcgtgc	caccctcgct	ggaccgcgg	180	
gcagccgagc	tgccggctggc	agacaacttc	atgcctcccg	tgcgccgcgg	cgacactggcc	240	
aacatgacag	gcctgctgca	tctgacgcctg	tgcggaaaca	ccatccgcca	cgtggctgccc	300	
ggcgccctcg	ccgacactgcg	ggccctgcgt	gccctgcacc	tggatggcaa	ccggctgacc	360	

tcactggcg	agggccagct	gcgcggcctg	gtcaacttgc	gccacccat	cctcagcaac	420
aaccagctgg	cagcgctggc	ggccggcgc	ctggatgatt	gtgccgagac	actggaggac	480
ctcgacctct	cctacaacaa	cctcgagcag	ctgcccctggg	aggccctggg	ccgcctggc	540
aacgtcaaca	cgttgggcct	cgaccacaac	ctgctggctt	ctgtgcccgc	cgcgctttt	600
tcccgcctgc	acaagctggc	ccggctggac	atgacctcca	accgcctgac	cacaatccca	660
cccgaccac	tcttctcccg	cctgcccctg	ctcgccaggc	cccggggctc	gcccgcctct	720
gcccctggc	tggccctttgg	cgggaacccc	ctgcactgca	actgcgagct	ggtgtggctg	780
cgtcgctgg	cgcgggagga	cgacctcgag	gcctgcgcgt	ccccacctgc	tctgggcggc	840
cgtacttct	ggcggtgggg	cgaggaggag	tttgtctgcg	agccgcggct	ggtgactcac	900
cgtcaccac	ctctggctgt	gcccgcagg	cggccggctg	ccctgcgcgt	cgggcagtg	960
ggggacccag	agccccgtgt	gcgttgggtg	tcaccccagg	gccggctgct	aggcaactca	1020
agccgtcccc	gcgccttccc	aatgggacg	ctggagctgc	tggtcaccga	gcccgggtat	1080
ggtggcatct	tcacctgcat	tgcgccaaat	gcagctggcg	aggccacagc	tgctgtggag	1140
ctgactgtgg	gtccccccacc	acctcctcag	ctagccaaca	gcaccagctg	tgaccccccgg	1200
cgggacgggg	atcctgatgc	tctcaccaca	ccctccgcgt	cctctgcctc	tgccaaggt	1260
gccgacactg	ggcccccata	cgaccgtggc	gtccaggtga	ctgagcacgg	ggccacagct	1320
gctcttgc	agtggccgga	tcagcggct	atcccgggca	tccgcata	ccagatccag	1380
tacaacagct	cggctgatga	catcctcg	tacaggatga	tcccggcga	gagccgcgt	1440
ttccctgctga	cggacactggc	gtcaggccgg	acctacgatc	tgtgcgtgt	cgcgtgtat	1500
gaggacagcg	ccacggggct	cacggccacg	cggcctgtgg	gctgcgccc	cttctccacc	1560
gaacctgcgc	tgccggccatg	cggggcgc	cacgctccct	tccctggcgg	cacgatgatc	1620
atcgcgc	gccccgtcat	cgtagecctcg	gtactggct	tcatcttct	getgtaatg	1680
cgttacaagg	tgcacggcgg	ccagcccccc	ggcaaggcca	agattcccgc	gctgttagc	1740
agcggttgc	cccagaccaa	cggcccccctg	ggcccccacgc	ccacgcccgc	cccgcccccc	1800
ccggagcccg	cggcgctcag	ggcccacacc	gtggtccagc	tggactgcga	gccctggggg	1860
cccgccacg	aacctgtggg	accctag				1887

<210> 20

<211> 2538

<212> DNA

<213> Homo sapiens

<400> 20

atgctgagcg	gcgttgggt	cctcagtgt	ttaaccgtgg	ccggatctt	acagacagag	60
agtgcaaaa	ctgccaaaga	catttgc	atccgcgttc	tgtgcgaaga	aaaggaaaac	120
gtactgaata	tcaactgtga	gaacaaagga	tttacaacag	ttagcctgct	ccagcccccc	180
cagtatcgaa	tctatcgat	ttttctcaat	ggaaacctct	tgacaagact	gtatccaaac	240
gaatttgc	attactccaa	cgcgtgact	cttcacctag	gtaacaacgg	gttacaggag	300
atccgaacgg	gggcattcag	tggcctgaaa	actctcaaaa	gactgcata	caacaacaac	360
aagcttgaga	tattgaggg	ggacaccc	ctaggcctgg	agagcctgga	gtatctccag	420
gccgactaca	attacatcg	tgccatcgag	gtggggcat	tcaacaact	taacaagctc	480
aaagtgc	tccatgc	caaccc	cttgcactgc	ccagcaatgt	gttccgc	540

gtcctgctga cccacttaga cctcaggggg aataggctaa aagtaatgcc	600
gtccttgaac atattggagg gatcatggag attcagctgg aggaaaatcc atggaattgc	660
acttgtgact tacttcctct caaggcctgg ctagacacca taactgtttt tgtgggagag	720
attgtctgtg agactccctt taggttgcac gggaaagacg tgaccagct gaccaggcaa	780
gacctctgtc ccagaaaaag tgccagtat tccagtcaga ggggcagcca tgctgacacc	840
cacgtccaaa ggctgtcacc tacaatgaat cctgctctca acccaaccag ggctccgaaa	900
gccagccggc cgcccaaaat gagaatcgat ccaactcctc gagtactgt gtcaaaggac	960
aggcaaagtt ttggacccat catgggtac cagaccaagt ctctgtgcc tctcacctgt	1020
cccagcagct gtgtctgcac ctctcagacg tcagacaatg gtctgaatgt aaactgcaa	1080
gaaaggaagt tcaactaatat ctctgacctg cagcccaaaac cgaccagtcc aaagaaaactc	1140
tacctaacag ggaactatct tcaaactgtc tataagaatg acctctttaga atacagttct	1200
ttggacttac tgcacttagg aaacaacagg attgcagtca ttcaggaagg tgcccttaca	1260
aacctgacca gtttacgca gacttatctg aatggcaatt accttgaagt gctgtaccct	1320
tctatgtttt atggactgca gagctgtcaa tatctctatt tagagtataa tgtcattaag	1380
gaaatataacg ctctgaccc ttatgtttt attaacctac agctactgtt tctgaacaac	1440
aaccttcttc ggtccttacc tgataatata ttggggggg cggccctaac caggtgaat	1500
ctgagaaaca accattttc tcacctgccc gtggaaagggg ttctggatca gctccggct	1560
ttcatccaga tagatctgca ggagaacccc tgggactgta cctgtgacat catggggctg	1620
aaagactgga cagaacatgc caatccccct gtcatcatta atgaggtgac ttgcgaatct	1680
cctgctaagc atgcaggggaa gatactaaaa ttctggggg gggaggctat ctgtccagac	1740
agccaaact tgtcagatgg aaccgtcttgc tcaatgaatc acaatacaga cacacctgg	1800
tcgcttagtgc tgcgttccatg ttccatcttctt gaaactacaca ctgaaggttcc actgtctgtc	1860
ttaattctgg gattgcttgt tgttttcattt ttatctgtct gttttggggc tggtttattc	1920
gtctttgtct tgaaacgccc aaaggagtg ccgagcgttc ccaggaatac caacaactta	1980
gacgttaagct ccttcaatt acagtatggg tcttacaaca ctgagactca cgataaaaca	2040
gacggccatg tctacaacta tatccccca cctgtgggtc agatgtgcca aaacccctac	2100
tacatgcaga aggaaggaga cccagtagcc tattaccgaa acctgcaaga gttcagctat	2160
agcaacctgg aggagaaaaa agaagagcca gccacacctg cttacacaat aagtgccact	2220
gagctgctag aaaagcaggc cacaccaaga gaggctgagc tgctgtatca aatattgtct	2280
gagcgagtca aggaacttcc cagcgcaggc ctatgttccact ataactttt taccttacct	2340
aaaaggcagt ttggcccttc ctatgaatct cgacgccc accaagacag aatcaataaa	2400
accgtttat atggaactcc cagaaatgc ttgtggggc agtcaaaaacc caaccaccct	2460
ttactgcaag ctaagccgca atcagaaccg gactacctcg aagttctgga aaaacaaaact	2520
gcaatcagtc agctgtga	2538

<210> 21

<211> 1050

<212> DNA

<213> Homo sapiens

<400> 21

atggggatca cctgctggat cgccctgtat gctgtggagg ccctccccac ctgccccttc

60

tcctgcaagt	gtgacagccg	cagcctggag	gtggactgca	gtggccttgg	cctcaccacg	120
gtgccccccag	acgtgcccgc	agccacccga	accctcttgc	tcttgaacaa	taagctgagt	180
gccctgccaa	gctgggctt	cgccaacctc	tccagcctgc	agcggttgg	cctgtccaac	240
aacttcctgg	acgggctgcc	cgctccatt	ttcggggacc	tgacgaatct	gactgagctt	300
cagctgctca	ataacagcat	caggaccctg	gacagggacc	tgctgeggca	ctcgccgctg	360
ctccgcccacc	tggacctgtc	catcaacggc	ctggcccagt	tgccccctgg	tctttcgac	420
gggctcctgg	ctctgcgtc	cctctcgctt	cgctccaacc	gtctgcagaa	tctggaccgg	480
ctgacatttgc	aacccttagc	aaacctgcag	ctgctgcagg	tcggggataa	cccctggag	540
tgtactgtat	acctgcgtga	gttcaaacac	tggatggagt	ggttctccta	ccgaggggg	600
cgcttggacc	agcttgcctg	caccctgccc	aaggagctga	ggggaaagga	catgcggatg	660
gtccccatgg	agatgttcaa	ctactgctcc	cagctggagg	acgagaatag	ctcagctggg	720
ctggatattc	ctgggccacc	ctgcaccaag	gccagtcag	agcctgctaa	gcccaagccc	780
ggggctgagc	cggagccgga	gcccagcaca	gcctgcccac	agaagcagag	gcacccggcc	840
gcgagcgtga	ggcgagccat	ggcacggtg	atcattgcag	gggtcgtgtg	cggcgtcgtc	900
tgcacatcatga	tggtggtgcc	cgctgcctat	ggctgcatac	acgcctccct	catggccaag	960
taccacccggg	agctaaaaaa	gcccagccc	ctgatggggg	accccgaggg	cgagcacgag	1020
gaccagaagc	agatctcttc	tgtggcctga				1050

<210> 22

<211> 2215

<212> DNA

<213> Homo sapiens

<400> 22

atgggaatga	ctgttataaaa	gcaaatcaca	gatgacctat	ttgtatggaa	tgttctgaat	60
cgcgaagaag	taaacatcat	ttgctgcag	aagggtggagc	aggatgctgc	tagagggatc	120
attcacatga	ttttgaaaaaa	gggttcagag	tccctgttaacc	tctttcttaa	atcccttaag	180
gagtggaact	atcctctatt	tcaggacttg	aatggacaaaa	gtcttttca	tcagacatca	240
gaaggagact	tggacgattt	ggctcaggat	ttaaaggact	tgtaccatac	cccatctttt	300
ctgaactttt	atcccttgg	tgaagatatt	gacattattt	ttaacttcaa	aagcaccttc	360
acagaacctg	tcctgtggag	gaaggaccaa	caccatcacc	gcgtggagca	gctgaccctg	420
aatggcctcc	tgcaggctct	tcagagcccc	tgcatcattt	aaggggaaatc	tggcaaaggc	480
aagtccactc	tgctgcagcg	aattgccatg	ctctgggct	ccggaaagtg	caaggctctg	540
accaagttca	aattcgtctt	cttcctccgt	ctcagcaggg	cccagggtgg	acttttgaa	600
accctctgt	atcaactcct	ggatatacct	ggcacaatca	ggaagcagac	attcatggcc	660
atgtgcgtga	agctgcggca	gagggttctt	ttccttcttg	atggctacaa	tgaattcaag	720
ccccagaact	gcccagaaat	cgaagccctg	ataaaaggaaa	accaccgctt	caagaacatg	780
gtcatcgatca	ccactaccac	tgagtgcctg	aggcacatac	ggcagtttgg	tgcctgact	840
gctgaggtgg	gggatatacgt	agaagacagc	gcccaggctc	tcatccgaga	agtgcgtatc	900
aaggagctt	ctgaaggctt	gttgcctcaa	attcagaaat	ccaggtgctt	gaggaatctc	960
atgaagaccc	ctctctttgt	ggtcatcaact	tgtgcaatcc	agatgggtga	aagtgagttc	1020
cacttcaca	cacaaacaac	gctgttccat	accttctatg	atctgttcat	acagaaaaac	1080

aaacacaaac ataaagggtgt ggctgcaagt gacttcattc ggagcctgga ccactgtgga	1140
gacctagctc tggaggggtgt gttcccccac aagtttgatt tcgaactgca ggatgtgtcc	1200
agcgtgaatg aggatgtcct gctgacaact gggctccctct gtaaaatatac agctcaaagg	1260
ttcaagccaa agtataaaatt ctttcacaag tcattccagg agtacacagc aggacgaaga	1320
ctcagcagtt tattgacgtc tcatgagcca gaggaggtga ccaagggaa tggttacttg	1380
cagaaaatgg tttccatttc ggacattaca tccacttata gcagcctgct ccgtacacc	1440
tgtgggtcat ctgtgaaagc caccaggct gttatgaagc acctcgcagc agtgtatcaa	1500
cacggctgcc ttctcgact ttccatcgcc aagaggcctc tctggagaca ggaatcttg	1560
caaagtgtga aaaacaccac tgagcaagaa attctgaaag ccataaacat caattccttt	1620
gtagagtgtg gcatccattt atatcaagag agtacatcca aatcagccct gagccaagaa	1680
tttgaagctt tctttcaagg taaaagcttataatcaact cagggAACat ccccgattac	1740
ttatTTGact tctttgaaca tttgccaat tggcaagtg ccctggactt cattaaactg	1800
gactttatg ggggagctat ggcttcatgg gaaaaggctg cagaagacac aggtgaaatc	1860
cacatggaag aggccccaga aacctacatt cccagcaggg ctgtatctt gttttcaac	1920
tggaagcagg aattcaggac tctggaggc acactccggg atttcagcaa gttgaataag	1980
caagatatac gatatctgg gaaaatattc agtctgcca caagcctcag gctgcaaata	2040
aagagatgtg ctgggtgtgc tggaagcctc agtttggtcc tcagcacctg taagaacatt	2100
tattctctca tggtggaaagc cagtcctcaccatagaag atgagaggca catcacatct	2160
gtaacaaacc tggaaacccctt gagtattcat gacctacaga atcaacggct gcccc	2215

<210> 23

<211> 3213

<212> DNA

<213> Homo sapiens

<400> 23

atgtacaaaa gccttaacat tgacgagtgt gatttgcatt cctggctgga tttgcctgcc	60
gagaaacctt taggggtgt taatcggtc tgctgggct tcattcaggaa caaggggtac	120
atgtacccct tggactactt gaatttcata aaggacaata gccgaccctt tattcaaaga	180
atggaaatga ctgttataaa gcaaatcaca gatgacctat ttgtatggaa tggctgaat	240
cgcgaagaag taaacatcat ttgctgcag aaggtggagc aggtgctgc tagaggatc	300
attcacatga ttttggaaaaa gggttcagag tcctgttaacc tctttcttaa atcccttaag	360
gagtttggact atcctctatt tcaggacttg aatggacaaa gtcttttca tcagacatca	420
gaaggagact tggacgatt ggctcaggat ttaaaggact tggaccatac cccatcttt	480
ctgaactttt atcccttgg tgaagatatt gacattattt ttaacttgaa aagcaccttc	540
acagaacctg tcctgtggag gaaggaccaa caccatcacc gcgtggagca gctgaccctg	600
aatggcctcc tgcaggctct tcagaccccc tgcatttcattt aagggaaatc tggcaaaggc	660
aagtccactc tgctgcagcg aattgccatg ctctgggct ccggaaagtg caaggctctg	720
accaagttca aattcgtctt ctccctccgt tcagcaggc cccaggggtgg actttttgaa	780
accctctgtg atcaactcct ggatataccct ggcacaatca ggaaggcagac attcatggcc	840
atgctgctga agctgcggca gagggttctt ttcccttctt atggctacaa tgaattcaag	900
ccccagaact gcccagaat cgaaggccctg ataaaggaaa accaccgctt caagaacatcg	960

gtcatcgta ccaactaccac	tgagtgcctg	aggcacatac	ggcagttgg	tgccctgact	1020
gctgagggtgg	gggatatgac	agaagacagc	gcccaggctc	tcatccgaga	1080
aaggagcttgc	ctgaaggctt	gttgctccaa	attcagaaat	ccaggtgctt	1140
atgaagaccc	ctctctttgt	ggtcatca	tgtgcaatcc	agatgggtga	1200
cactctcaca	cacaaacaac	gctgtccat	accttctatg	atctgttgc	1260
aaacacaaac	ataaagggtgt	ggctgcaagt	gacttcattc	ggagccttgg	1320
gacctagctc	tggagggtgt	gttctccac	aagtttgatt	tcgaactgca	1380
agcgtgaatg	aggatgtcct	gctgacaact	gggctccctc	gtaaatatac	1440
ttcaagccaa	agtataaaatt	cttcacaag	tcattccagg	agtacacagc	1500
ctcagcagtt	tattgacgtc	tcatgagcca	gaggaggtga	ccaaggggaa	1560
cagaaaatgg	tttccatttc	ggacattaca	tccacttata	gcagcctgct	1620
tgtgggtcat	ctgtgaaagc	caccagggt	gttatgaaagc	acctcgcagc	1680
cacggctgcc	ttctcggact	ttccatcgcc	aagaggcctc	tctggagaca	1740
caaagtgtga	aaaacaccac	tgagcaagaa	attctgaaag	ccataaaacat	1800
gtagagtgtg	gcatccattt	atatacagag	agtacatcca	aatcagccct	1860
tttgaagctt	tcttcaagg	taaaagctta	tatataact	cagggacat	1920
ttatattgact	tctttgaaca	tttgccaaat	tgtgcaagt	ccctggactt	1980
gacttttatg	ggggagctat	ggcttcatgg	gaaaaggctg	cagaagacac	2040
cacatggaaag	aggccccaga	aacctacatt	cccagcaggg	ctgtatctt	2100
tggaaggcagg	aattcaggac	tctggaggc	acactccggg	atttcagcaa	2160
caagatatac	gatatctggg	gaaaatattc	agctctgcca	caagcctcag	2220
aagagatgtg	ctgggtgtgg	tggaaagcctc	agtttggtcc	tcagcacctg	2280
tattctctca	tgggaaagc	cagtccctc	accatagaag	atgagaggca	2340
gtaacaaacc	tgaaaacctt	gagtattcat	gacctacaga	atcaacgct	2400
ctgactgaca	gcttggtaa	cttgaagaac	cttacaaagc	tcataatgga	2460
atgaatgaag	aagatgctat	aaaactagct	gaaggcctga	aaaacctgaa	2520
ttatattcatt	tgacccactt	gtctgacatt	ggagagggaa	tggattacat	2580
ctgtcaagt	aaccctgtga	ccttgaagaa	attcaattag	tctcctgct	2640
aatgcagtga	aaatcctagc	tcagaatctt	cacaatttgg	tcaaactgag	2700
ttatcagaaa	attacctgga	aaaagatgga	aatgaagctc	ttcatgaact	2760
atgaacgtgc	tagaacagct	caccgcactg	atgctccct	ggggctgtga	2820
agcctgagca	gcctgttcaa	acatttggag	gaggtcccac	aactcgtcaa	2880
aaaaactgga	gactcacaga	taacagagatt	agaattttag	gtgcatttt	2940
cctctgaaaa	acttccagca	gttgaatttg	gccccaaatc	gtgtgaggcag	3000
cttgccttca	tgggtgtatt	tgagaatctt	aagcaattag	tgttttttga	3060
aaagaatttc	tacctgatcc	agcattagtc	agaaaaactta	gccaagtgtt	3120
actttctgc	aagaagctag	gcttgggg	tggcaatttg	atgatgatga	3180
attacaggtg	cttttaaact	agtaactgct	taa		3213

<210> 24

<211> 1464

<212> DNA

<213> Homo sapiens

<400> 24

atgccgcctt	tgccacagt	gtccttcct	cgtccagacc	actgccatgt	gactttcg	60
accctaagt	gtgactcc	caagaagagg	cggcgtggcc	gcaagtcccc	atccaaggag	120
gtgtcccaca	tcacagcaga	gtttgagatc	gagacaaaga	tggaagaggc	ctcagacaca	180
tgcaagcgg	actgcttgc	gaagcgagca	gaacagagcc	tgcaggccgc	catcaagacc	240
ctgcgcaagt	ccatcgccg	gcagcagt	tatgtccagg	tctcaggcac	tgagtacgag	300
gtagcccaga	ggccagccaa	ggcgcgtgg	gggcaggggg	catgtggcgc	agggcagg	360
ctacaggaca	gcaaatgcgt	tgcctgtgg	cctggcaccc	acttcggtgg	tgagctcggc	420
cagtgtgtgt	catgtatgcc	aggaacatac	caggacatgg	aaggccagct	cagttgcaca	480
ccgtgcccc	gcagcgacgg	gcttggtctg	cctggtgc	gcaacgtgtc	ggaatgtg	540
ggcaagtgcg	ggcctagaag	gagaggcttc	ttctcgccg	atggcttcaa	gccctgccc	600
gcctgcccc	tgggcacgta	ccagcctgag	cccgccgc	ccggctgctt	ccccgtg	660
gggggtttgc	tcaccaaaca	cgaaggcacc	accccttcc	aggactgcg	ggctaaagt	720
cactgctcc	ccggccacca	ctacaacacc	accacccacc	gctgcatcc	ctgccccgtc	780
ggcacctacc	agcccgagtt	tggccagaac	cactgc	cctgtccgg	caacacc	840
acagacttcg	atggctccac	caacgtcaca	cactgcaaaa	accagcact	ggcggcgg	900
cttggtgact	acaccggcta	catcgagtc	cccaactacc	ctggcgacta	cccaagccaa	960
gctgaatgcg	tctggcacat	cgccctccc	ccaaagcg	ggatcctcat	cgtggcc	1020
gagatcttcc	tgcctatcga	ggatgagtgc	ggcgatgtt	tggatcatg	gaagagtgc	1080
tctccacgt	ccatcaccac	ctatgagacc	tgcctagac	acgagaggcc	catgccttcc	1140
accccccgt	cccgcaagct	ctggatcc	tccaaatcca	atgaaggca	cagcggcaaa	1200
ggcttccaag	tgcctatgt	cacctacgat	gaggactacc	agcaactcat	agaggacatc	1260
gtgcgcgt	ggcgcctgta	cgcctcg	aaccaccagg	aaatttgaa	agacaagaag	1320
ctgatcaagg	cccttcc	cgtgcgtgg	catccccaga	actacttcaa	gtacacagcc	1380
caggaatcca	aggagatgtt	cccacggtcc	ttcatcaa	tgctgcgtc	caaagtgt	1440
cggttcctgc	ggccctacaa	ataa				1464

<210> 25

<211> 2897

<212> DNA

<213> Homo sapiens

<400> 25

atgggcgcgg	cggccgtgc	ctggcactt	tgcgtgct	tggccctgg	cacacgcgg	60
cggctggccg	ggggcagcgg	gctccaggt	tcagtc	tggatgagt	ctcagagg	120
acagatgact	gccacatcga	tgccatctgt	cagaacacgc	ccaa	gtgtgagaat	180
tgcaagccag	gctacaaggg	ggaaggcaag	cagtgt	acattgac	gtgtgagaat	240
gactactaca	atgggggctg	tgtccacg	tgc	cccg	ctacagg	300
acctgcttgc	atggcttcat	gctggcacac	gatgg	actgc	tgtggc	360
tgtcaggaca	ataatgg	ctgccc	atctgc	atgc	cagctac	420

tgtcagtgcc acagtggctt cttcccttagt gacaaccagc atacctgcac ccaccgcctcc	480
aatagggtta tgaactgcac gaacaaagac catggctgtg cccacatctg ccggggagacg	540
cccaaagggtg gggtggcctg cgactgcagg cccggctttg accttgcacca aaaccagaag	600
gactgcacac taacctgtaa ttatggaaac ggaggctgcc agcacagctg tgaggacaca	660
gacacaggcc ccacgtgtgg ttgccaccag aagtacgccc tccactcaga cggtcgcacg	720
tgcacatcgaga cgtgcgcagt caataacgga ggctgcgacc ggacatgcaa ggacacagcc	780
actggcgtgc gatgcagctg ccccggttggaa ttacactgc agccggacgg gaagacatgc	840
aaagacatca acgagtgccct ggtcaacaac ggaggctgcg accacttctg ccgcaacacc	900
gtgggcagct tcgagtgccgg ctgcccggaa ggctacaago tgctcaccga cgagcgcacc	960
tgccaggaca tcgacgagtg ctcccttcgag cgacactgtg accacatctg catcaactcc	1020
ccgggcagct tccagtgccct gtgtcaccgc ggctacatcc tctacggac aaccactgc	1080
ggagatgtgg acgagtgccag catgagcaac gggagctgtg accaggctg cgtcaacacc	1140
aagggcagct acgagtgccgt ctgtcccccg gggaggccggc tccactgaa cgggaaggat	1200
tgcgtggaga caggcaagtg tctttctcgcc gccaagaccc ccccccgggc ccagctgtcc	1260
tgcagcaagg caggccggtgtt ggagagctgc ttcccttcct gcccggctca cacactcttc	1320
gtgccagact cggaaaatag ctacgtccctg agctgcggag ttccaggggcc gcagggcaag	1380
gcgcgtcaga aacgcaacgg caccagctt ggcctcg'ggc ccagctgctc agatcccccc	1440
accaccccca tcaaacagaa ggcccgttc aagatccgag atgccaagtg ccaccccccgg	1500
ccccacagcc aggcacgagc aaaggagacc gcccaggcagc cgctgcttggaa ccactgccc	1560
gtgactttcg tgaccctcaa gtgtgactcc tccaagaaga ggcccgtggcc cgcaagtcc	1620
ccatccaagg aggtgtccca catcacagca gagtttgaga tcgagacaaa gatggaagag	1680
gcctcagaca catgcgaagc ggactgttttgcgagcagc cagaacagag cctgcaggcc	1740
gccatcaaga ccctgcgcaaa gtccatcgcc cgccagcagt tctatgtccca ggtctcaggc	1800
actgagtagtcg aggtagccca gaggccagcc aaggccgtgg agggccagggg ggcattgtggc	1860
gcaggccagg tgctacagga cagcaaattgc gtgcctgtg ggctggcac ccacttcgg	1920
ggtagctcg gccagtgtgt gtcatgtatg ccaggaacat accaggacat ggaaggccag	1980
ctcagttgca caccgtgccc cagcagcgcac ggcttggtc tgcctggc tgcacacgtg	2040
tcggaatgtg gaggccagtg ttctccaggc ttcttcctcg ccgatggctt caagccctgc	2100
caggcctgccc ccgtgggcac gtaccaggct gagccgggc gcaccggctg cttccctgt	2160
ggagggggtt tgctcacccaa acacgaaggc accacccctt tccaggactg cgaggctaaa	2220
gtgcactgtc ccccccggcca ccactacaac accaccaccc accgctgcac ccgctgcccc	2280
gtcggcacct accagccca gtttggccag aaccactgca tcacctgtcc gggcaacacc	2340
agcacagact tgcgtggc tccacacgtc acacactgca aaaaccagca ctggccggcc	2400
gagcttggtg actacacccgg ctacatcgag tcccccaact accctggca ctacccagcc	2460
aacgctgaat gcgtctggca catcgccct cccccaaagc gcaggatccat catgtggc	2520
cctgagatct tccctcccat cgaggatgag tgcggcgtat ttctggcat gaggaaagagt	2580
gcctctccca cgtccatcac cacctatgag acctgcccaga cctacgagag gcccacatgc	2640
ttcacctccc gctcccgcaa gctctggatc cagttcaaat ccaatgaagg caacagcc	2700
aaaggcttcc aagtgcctta tgcacactac gatggtaaga tccactgtct tcacggccca	2760
ctgtgcacgg ctcaggccgg gcccctggaga cacagagatg agtgcacgt cccggcccc	2820
tcaggagct ggcacactggc aggtacagac ctggaaagcag aacgaacact gtcaggggcc	2880
agagccagac aggctga	2897

<210> 26
 <211> 2151
 <212> DNA
 <213> *Homo sapiens*

<400> 26

atggcttagga	tgagctttgt	tatagcagct	tgccaaattgg	tgctgggcct	actaatgact	60
tcattaaccg	agtcttccat	acagaatagt	gagtgtccac	aactttgcgt	atgtgaaatt	120
cgtccctgg	ttaccccaaca	gtcaacttac	agagaagcc	ccactgtga	ttgcaatgac	180
ctccgcttaa	caaggattcc	cagtaacctc	tctagtgaca	cacaagtgc	tctcttacag	240
agcaataaca	tcgcaaagac	tgtggatgag	ctgcagcagc	tttcaactt	gactgaacta	300
gatttctccc	aaaacaactt	tactaacatt	aaggaggtcg	ggctggccaa	cctaaccagg	360
ctcacaacgc	tgcatttgg	ggaaaatcag	attaccgaga	tgactgatta	ctgtctacaa	420
gacctcagca	accttcaaga	actctacatc	aaccacaacc	aaattagcac	tatttctgct	480
catgcttttgc	caggcttaaa	aaatctatta	agctccacc	tgaactccaa	caaattgaaa	540
gttattgata	gtcgctgg	tgattctaca	cccaacctgg	aaattctcat	gatcgagaa	600
aaccctgtga	ttgaaattct	ggatatgaac	ttcaaacc	tcgcaaattt	gagaagctt	660
gttttggcag	gaatgtatct	cactgatatt	cctggaaatg	cttgggtgg	tctggatagc	720
ctttagagcc	tgtcttttta	tgataacaaa	ctggtaaaag	tccctcaact	tgcctgca	780
aaagttccaa	atttgaaattt	cttagacctc	aacaaaaacc	ccattcacaa	aatccaagaa	840
gggacttca	aaaatatgt	tcggtaaaa	gaactggaa	tcaacaat	gggcgagctc	900
gtttctgtcg	accgctatgc	cctggataac	ttgcctgaac	tcaaaaaagct	ggaagccacc	960
aataacccta	aactctctta	catccaccgc	ttggcttcc	gaagtgtccc	tgctctggaa	1020
agcttgc	tgaacaacaa	tgcctgaat	gccatttacc	aaaagacagt	cgaatccctc	1080
cccaatctgc	gtgagatcag	tatccatagc	aatccccca	ggtgtactg	tgtgatccac	1140
tggattaact	ccaacaaaac	caacatccgc	ttcatggagc	ccctgtccat	gttctgtgcc	1200
atgccgccc	aatataaagg	gcaccagg	aaggaagttt	taatccagga	ttcgagtgaa	1260
cagtgcctcc	caatgatatac	tcacgacagc	ttcccaatc	gtttaaacgt	ggatatcgcc	1320
acgacggttt	tcctagactg	tcgagccatg	gctgagccag	aacctgaaat	ttactgggtc	1380
actccccattg	gaaataagat	aactgtggaa	accctttcag	ataaaataca	gctaagttagc	1440
gaaggtacct	tggaaatatac	taacatacaa	attgaagact	caggaagata	cacatgtgtt	1500
gcccagaatg	tccaaggggc	agacactcgg	gtggcaacaa	ttaaggtaa	tgggaccctt	1560
ctggatggta	cccaggtgt	aaaaatatac	gtcaagcaga	cagaatccc	ttccatctta	1620
gtgtcctgg	aagttaattc	caatgtcatg	acgtcaaaact	taaaatggtc	gtctgcccacc	1680
atgaagattg	ataaccctca	cataacat	actgccaggg	tcccagtcg	tgtccatgaa	1740
tacaacctaa	cgcacatgc	gccttccaca	gattatgaag	tgtgtctcac	agtgtccaat	1800
attcatcagc	agactcaaaa	gtcatgcgt	aatgtcacaa	ccaaaaatgc	cgccttcgca	1860
gtggacatct	ctgatcaaga	aaccagtaca	gcccttgctg	cagtaatggg	gtctatgttt	1920
ccgtcatta	gccttgcgtc	cattgtgt	tacttgcc	aaagatttaa	gagaaaaaaac	1980
taccaccact	cattaaaaaa	gtatatgcaa	aaaacctt	caatcccact	aatgagctg	2040
tacccaccac	tcattaac	ctgggaaggt	gacagc	gaga	tggttctgca	2100

gacaccaagc caaccaggc cgacacatcc agaagctatt acatgtggta a

2151

<210> 27

<211> 766

<212> PRT

<213> Homo sapiens

<400> 27

Met	Glu	Lys	Val	Leu	Phe	Tyr	Leu	Phe	Leu	Ile	Gly	Ile	Ala	Val	Lys
1										10				15	
Ala	Gln	Ile	Cys	Pro	Lys	Arg	Cys	Val	Cys	Gln	Ile	Leu	Ser	Pro	Asn
											20			30	
Leu	Ala	Thr	Leu	Cys	Ala	Lys	Lys	Gly	Leu	Leu	Phe	Val	Pro	Pro	Asn
										35			45		
Ile	Asp	Arg	Arg	Thr	Val	Glu	Leu	Arg	Leu	Ala	Asp	Asn	Phe	Val	Thr
										50			60		
Asn	Ile	Lys	Arg	Lys	Asp	Phe	Ala	Asn	Met	Thr	Ser	Leu	Val	Asp	Leu
									65			75		80	
Thr	Leu	Ser	Arg	Asn	Thr	Ile	Ser	Phe	Ile	Thr	Pro	His	Ala	Phe	Ala
									85			90		95	
Asp	Leu	Arg	Asn	Leu	Arg	Ala	Leu	His	Leu	Asn	Ser	Asn	Arg	Leu	Thr
									100			105		110	
Lys	Ile	Thr	Asn	Asp	Met	Phe	Ser	Gly	Leu	Ser	Asn	Leu	His	His	Leu
									115			120		125	
Ile	Leu	Asn	Asn	Asn	Gln	Leu	Thr	Leu	Ile	Ser	Ser	Thr	Ala	Phe	Asp
									130			135		140	
Asp	Val	Phe	Ala	Leu	Glu	Glu	Leu	Asp	Leu	Ser	Tyr	Asn	Asn	Leu	Glu
									145			150		155	
Thr	Ile	Pro	Trp	Asp	Ala	Val	Glu	Lys	Met	Val	Ser	Leu	His	Thr	Leu
									165			170		175	
Ser	Leu	Asp	His	Asn	Met	Ile	Asp	Asn	Ile	Pro	Lys	Gly	Thr	Phe	Ser
									180			185		190	
His	Leu	His	Lys	Met	Thr	Arg	Leu	Asp	Val	Thr	Ser	Asn	Lys	Leu	Gln
									195			200		205	
Lys	Leu	Pro	Pro	Asp	Pro	Leu	Phe	Gln	Arg	Ala	Gln	Val	Leu	Ala	Thr
									210			215		220	
Ser	Gly	Ile	Ile	Ser	Pro	Ser	Thr	Phe	Ala	Leu	Ser	Phe	Gly	Gly	Asn
									225			230		235	
Pro	Leu	His	Cys	Asn	Cys	Glu	Leu	Leu	Trp	Leu	Arg	Arg	Leu	Ser	Arg
									245			250		255	
Glu	Asp	Asp	Leu	Glu	Thr	Cys	Ala	Ser	Pro	Pro	Leu	Leu	Thr	Gly	Arg
									260			265		270	

Tyr Phe Trp Ser Ile Pro Glu Glu Glu Phe Leu Cys Glu Pro Pro Leu
 275 280 285
 Ile Thr Arg His Thr His Glu Met Arg Val Leu Glu Gly Gln Arg Ala
 290 295 300
 Thr Leu Arg Cys Lys Ala Arg Gly Asp Pro Glu Pro Ala Ile His Trp
 305 310 315 320
 Ile Ser Pro Glu Gly Lys Leu Ile Ser Asn Ala Thr Arg Ser Leu Val
 325 330 335
 Tyr Asp Asn Gly Thr Leu Asp Ile Leu Ile Thr Thr Val Lys Asp Thr
 340 345 350
 Gly Ala Phe Thr Cys Ile Ala Ser Asn Pro Ala Gly Glu Ala Thr Gln
 355 360 365
 Ile Val Asp Leu His Ile Ile Lys Leu Pro His Leu Leu Asn Ser Thr
 370 375 380
 Asn His Ile His Glu Pro Asp Pro Gly Ser Ser Asp Ile Ser Thr Ser
 385 390 395 400
 Thr Lys Ser Gly Ser Asn Thr Ser Ser Asn Gly Asp Thr Lys Leu
 405 410 415
 Ser Gln Asp Lys Ile Val Val Ala Glu Ala Thr Ser Ser Thr Ala Leu
 420 425 430
 Leu Lys Phe Asn Phe Gln Arg Asn Ile Pro Gly Ile Arg Met Phe Gln
 435 440 445
 Ile Gln Tyr Asn Gly Thr Tyr Asp Asp Thr Leu Val Tyr Arg Met Ile
 450 455 460
 Pro Pro Thr Ser Lys Thr Phe Leu Val Asn Asn Leu Ala Ala Gly Thr
 465 470 475 480
 Met Tyr Asp Leu Cys Val Leu Ala Ile Tyr Asp Asp Gly Ile Thr Ser
 485 490 495
 Leu Thr Ala Thr Arg Val Val Gly Cys Ile Gln Phe Thr Thr Glu Gln
 500 505 510
 Asp Tyr Val Arg Cys His Phe Met Gln Ser Gln Phe Leu Gly Gly Thr
 515 520 525
 Met Ile Ile Ile Ile Gly Gly Ile Ile Val Ala Ser Val Leu Val Phe
 530 535 540
 Ile Ile Ile Leu Met Ile Arg Tyr Lys Val Cys Asn Asn Asn Gly Gln
 545 550 555 560
 His Lys Val Thr Lys Val Ser Asn Val Tyr Ser Gln Thr Asn Gly Ala
 565 570 575
 Gln Ile Gln Gly Cys Ser Val Thr Leu Pro Gln Ser Val Ser Lys Gln
 580 585 590
 Ala Val Gly His Glu Glu Asn Ala Gln Cys Cys Lys Ala Thr Ser Asp
 595 600 605

Asn Val Ile Gln Ser Ser Glu Thr Cys Ser Ser Gln Asp Ser Ser Thr
 610 615 620
 Thr Thr Ser Ala Leu Pro Pro Ser Trp Thr Ser Ser Thr Ser Val Ser
 625 630 635 640
 Gln Lys Gln Lys Arg Lys Thr Gly Thr Lys Pro Ser Thr Glu Pro Gln
 645 650 655
 Asn Glu Ala Val Thr Asn Val Glu Ser Gln Asn Thr Asn Arg Asn Asn
 660 665 670
 Ser Thr Ala Leu Gln Leu Ala Ser Arg Pro Pro Asp Ser Val Thr Glu
 675 680 685
 Gly Pro Thr Ser Lys Arg Ala His Ile Lys Pro Ser Lys Phe Ile Thr
 690 695 700
 Leu Pro Ala Glu Arg Ser Gly Ala Arg His Lys Tyr Ser Leu Asn Gly
 705 710 715 720
 Glu Leu Lys Glu Tyr Tyr Cys Tyr Ile Asn Ser Pro Asn Thr Cys Gly
 725 730 735
 Leu Phe Pro Lys Arg Ser Met Ser Met Asn Val Met Phe Ile Gln Ser
 740 745 750
 Asp Cys Ser Asp Gly His Ser Gly Lys Ala Thr Leu Lys Phe
 755 760 765

<210> 28
 <211> 148
 <212> PRT
 <213> Homo sapiens

<400> 28
 Ala Met Leu Gly Leu Pro Trp Lys Gly Gly Leu Ser Trp Ala Leu Leu
 1 5 10 15
 Leu Leu Leu Gly Ser Gln Ile Leu Leu Ile Tyr Ala Trp His Phe
 20 25 30
 His Glu Gln Arg Asp Cys Asp Glu His Asn Val Met Ala Arg Tyr Leu
 35 40 45
 Pro Ala Thr Val Glu Phe Ala Val His Thr Phe Asn Gln Gln Ser Lys
 50 55 60
 Asp Tyr Tyr Ala Tyr Arg Leu Gly His Ile Leu Asn Ser Trp Lys Glu
 65 70 75 80
 Gln Val Glu Ser Lys Thr Val Phe Ser Met Glu Leu Leu Gly Arg
 85 90 95
 Thr Arg Cys Gly Lys Phe Glu Asp Asp Ile Asp Asn Cys His Phe Gln
 100 105 110
 Glu Ser Thr Glu Leu Asn Asn Thr Phe Thr Cys Phe Phe Thr Ile Ser

115	120	125
Thr Arg Pro Trp Met Thr Gln Phe Ser Leu Leu Asn Lys Thr Cys Leu		
130	135	140
Glu Gly Phe His		
145		

<210> 29
 <211> 159
 <212> PRT
 <213> Homo sapiens

<400> 29			
Asx Met Trp Ser Leu Pro Pro Ser Arg Ala Leu Ser Cys Ala Pro Leu			
1	5	10	15
Leu Leu Leu Phe Ser Phe Gln Phe Leu Val Thr Tyr Ala Trp Arg Phe			
20	25	30	
Gln Glu Glu Glu Glu Trp Asn Asp Gln Lys Gln Ile Ala Val Tyr Leu			
35	40	45	
Pro Pro Thr Leu Glu Phe Ala Val Tyr Thr Phe Asn Lys Gln Ser Lys			
50	55	60	
Asp Trp Tyr Ala Tyr Lys Leu Val Pro Val Leu Ala Ser Trp Lys Glu			
65	70	75	80
Gln Gly Tyr Asp Lys Met Thr Phe Ser Met Asn Leu Gln Leu Gly Arg			
85	90	95	
Thr Met Cys Gly Lys Phe Glu Asp Asp Ile Asp Asn Cys Pro Phe Gln			
100	105	110	
Glu Ser Pro Glu Leu Asn Asn Val Arg Gln Asp Thr Ser Phe Pro Pro			
115	120	125	
Gly Tyr Ser Cys Gly Cys Arg Met Gly Cys Gly Ala Asp Thr Asp Leu			
130	135	140	
His Leu Leu Leu His His Trp Asn Arg Ala Leu Glu Asp Thr Val			
145	150	155	

<210> 30
 <211> 148
 <212> PRT
 <213> Homo sapiens

<400> 30			
Asx Met Trp Ser Leu Pro Pro Ser Arg Ala Leu Ser Cys Ala Pro Leu			
1	5	10	15
Leu Leu Leu Phe Ser Phe Gln Phe Leu Val Thr Tyr Ala Trp Arg Phe			

20	25	30
Gln Glu Glu Glu Glu Trp Asn Asp Gln Lys Gln Ile Ala Val Tyr Leu		
35	40	45
Pro Pro Thr Leu Glu Phe Ala Val Tyr Thr Phe Asn Lys Gln Ser Lys		
50	55	60
Asp Trp Tyr Ala Tyr Lys Leu Val Pro Val Leu Ala Ser Trp Lys Glu		
65	70	75
Gln Gly Tyr Asp Lys Met Thr Phe Ser Met Asn Leu Gln Leu Gly Arg		
85	90	95
Thr Met Cys Gly Lys Phe Glu Asp Asp Ile Asp Asn Cys Pro Phe Gln		
100	105	110
Glu Ser Pro Glu Leu Asn Asn Thr Cys Thr Cys Phe Phe Thr Ile Gly		
115	120	125
Ile Glu Pro Trp Arg Thr Arg Phe Asp Leu Trp Asn Lys Thr Cys Ser		
130	135	140
Gly Gly His Ser		
145		

<210> 31
 <211> 820
 <212> PRT
 <213> Homo sapiens

<400> 31		
Met Leu Arg Leu Gly Leu Cys Ala Ala Ala Leu Leu Cys Val Cys Arg		
1	5	10
Pro Gly Ala Val Arg Ala Asp Cys Trp Leu Ile Glu Gly Asp Lys Gly		
20	25	30
Tyr Val Trp Leu Ala Ile Cys Ser Gln Asn Gln Pro Pro Tyr Glu Thr		
35	40	45
Ile Pro Gln His Ile Asn Ser Thr Val His Asp Leu Arg Leu Asn Glu		
50	55	60
Asn Lys Leu Lys Ala Val Leu Tyr Ser Ser Leu Asn Arg Phe Gly Asn		
65	70	75
Leu Thr Asp Leu Asn Leu Thr Lys Asn Glu Ile Ser Tyr Ile Glu Asp		
85	90	95
Gly Ala Phe Leu Gly Gln Ser Ser Leu Gln Val Leu Gln Leu Gly Tyr		
100	105	110
Asn Lys Leu Ser Asn Leu Thr Glu Gly Met Leu Arg Gly Met Ser Arg		
115	120	125
Leu Gln Phe Leu Phe Val Gln His Asn Leu Ile Glu Val Val Thr Pro		
130	135	140

Thr Ala Phe Ser Glu Cys Pro Ser Leu Ile Ser Ile Asp Leu Ser Ser
 145 150 155 160
 Asn Arg Leu Ser Arg Leu Asp Gly Ala Thr Phe Ala Ser Leu Ala Ser
 165 170 175
 Leu Met Val Cys Glu Leu Ala Gly Asn Pro Phe Asn Cys Glu Cys Asp
 180 185 190
 Leu Phe Gly Phe Leu Ala Trp Leu Val Val Phe Asn Asn Val Thr Lys
 195 200 205
 Asn Tyr Asp Arg Leu Gln Cys Glu Ser Pro Arg Glu Phe Ala Gly Tyr
 210 215 220
 Pro Leu Leu Val Pro Arg Pro Tyr His Ser Leu Asn Ala Ile Thr Val
 225 230 235 240
 Leu Gln Ala Lys Cys Arg Asn Gly Ser Leu Pro Ala Arg Pro Val Ser
 245 250 255
 His Pro Thr Pro Tyr Ser Thr Asp Ala Gln Arg Glu Pro Asp Glu Asn
 260 265 270
 Ser Gly Phe Asn Pro Asp Glu Ile Leu Ser Val Glu Pro Pro Ala Ser
 275 280 285
 Ser Thr Thr Asp Ala Ser Ala Gly Pro Ala Ile Lys Leu His His Val
 290 295 300
 Thr Phe Thr Ser Ala Thr Leu Val Val Ile Ile Pro His Pro Tyr Ser
 305 310 315 320
 Lys Met Tyr Ile Leu Val Gln Tyr Asn Asn Ser Tyr Phe Ser Asp Val
 325 330 335
 Met Thr Leu Lys Asn Lys Lys Glu Ile Val Thr Leu Asp Lys Leu Arg
 340 345 350
 Ala His Thr Glu Tyr Thr Phe Cys Val Thr Ser Leu Arg Asn Ser Arg
 355 360 365
 Arg Phe Asn His Thr Cys Leu Thr Phe Thr Thr Arg Asp Pro Val Pro
 370 375 380
 Gly Asp Leu Ala Pro Ser Thr Ser Thr Thr His Tyr Ile Met Thr
 385 390 395 400
 Ile Leu Gly Cys Leu Phe Gly Met Val Ile Val Leu Gly Ala Val Tyr
 405 410 415
 Tyr Cys Leu Arg Lys Arg Arg Met Gln Glu Glu Lys Gln Lys Ser Val
 420 425 430
 Asn Val Lys Lys Thr Ile Leu Glu Met Arg Tyr Gly Ala Asp Val Asp
 435 440 445
 Ala Gly Ser Ile Val His Ala Ala Gln Lys Leu Gly Glu Pro Pro Val
 450 455 460
 Leu Pro Val Ser Arg Met Ala Ser Ile Pro Ser Met Ile Gly Glu Lys
 465 470 475 480

WO 01/66690

Leu Pro Thr Ala Lys Gly Leu Glu Ala Gly Leu Asp Thr Pro Lys Val
 485 490 495
 Ala Thr Lys Gly Asn Tyr Ile Glu Val Arg Thr Gly Ala Gly Gly Asp
 500 505 510
 Gly Leu Ala Arg Pro Glu Asp Asp Leu Pro Asp Leu Glu Asn Gly Gln
 515 520 525
 Gly Ser Ala Ala Glu Ile Ser Thr Ile Ala Lys Glu Val Asp Lys Val
 530 535 540
 Asn Gln Ile Ile Asn Asn Cys Ile Asp Ala Leu Lys Leu Asp Ser Ala
 545 550 555 560
 Ser Phe Leu Gly Gly Ser Ser Ser Gly Asp Pro Glu Leu Ala Phe
 565 570 575
 Glu Cys Gln Ser Leu Pro Ala Ala Ala Ala Ser Ser Ala Thr Gly
 580 585 590
 Pro Gly Ala Leu Glu Arg Pro Ser Phe Leu Ser Pro Pro Tyr Lys Glu
 595 600 605
 Ser Ser His His Pro Leu Gln Arg Gln Leu Ser Ala Asp Ala Ala Val
 610 615 620
 Thr Arg Lys Thr Cys Ser Val Ser Ser Gly Ser Ile Lys Ser Ala
 625 630 635 640
 Lys Val Phe Ser Leu Asp Val Pro Asp His Pro Ala Ala Thr Gly Leu
 645 650 655
 Ala Lys Gly Asp Ser Lys Tyr Ile Glu Lys Gly Ser Pro Leu Asn Ser
 660 665 670
 Pro Leu Asp Arg Leu Pro Leu Val Pro Ala Gly Ser Gly Gly Ser
 675 680 685
 Gly Gly Gly Gly Ile His His Leu Glu Val Lys Pro Ala Tyr His
 690 695 700
 Cys Ser Glu His Arg His Ser Phe Pro Ala Leu Tyr Tyr Glu Glu Gly
 705 710 715 720
 Ala Asp Ser Leu Ser Gln Arg Val Ser Phe Leu Lys Pro Leu Thr Arg
 725 730 735
 Ser Lys Arg Asp Ser Thr Tyr Ser Gln Leu Ser Pro Arg His Tyr Tyr
 740 745 750
 Ser Gly Tyr Ser Ser Ser Pro Glu Tyr Ser Ser Glu Ser Thr His Lys
 755 760 765
 Ile Trp Glu Arg Phe Arg Pro Tyr Lys Lys His His Arg Glu Glu Val
 770 775 780
 Tyr Met Ala Ala Gly His Ala Leu Arg Lys Lys Val Gln Phe Ala Lys
 785 790 795 800
 Asp Glu Asp Leu His Asp Ile Leu Asp Tyr Trp Lys Gly Val Ser Ala
 805 810 815

Gln Gln Lys Leu
820

<210> 32
<211> 866
<212> PRT
<213> Homo sapiens

<400> 32
Met Thr Ile Glu Lys Met Phe Ser Phe Tyr Phe Leu Asp Tyr Phe Ser
1 5 10 15
Leu Phe Arg Ser Ile Gln Leu Phe Ala Asp Cys Lys Lys Met Phe Leu
20 25 30
Trp Leu Phe Leu Ile Leu Ser Ala Leu Ile Ser Ser Thr Asn Ala Asp
35 40 45
Ser Asp Ile Ser Val Glu Ile Cys Asn Val Cys Ser Cys Val Ser Val
50 55 60
Glu Asn Val Leu Tyr Val Asn Cys Glu Lys Val Ser Val Tyr Arg Pro
65 70 75 80
Asn Gln Leu Lys Pro Pro Trp Ser Asn Phe Tyr His Leu Asn Phe Gln
85 90 95
Asn Asn Phe Leu Asn Ile Leu Tyr Pro Asn Thr Phe Leu Asn Phe Ser
100 105 110
His Ala Val Ser Leu His Leu Gly Asn Asn Lys Leu Gln Asn Ile Glu
115 120 125
Gly Gly Ala Phe Leu Gly Leu Ser Ala Leu Lys Gln Leu His Leu Asn
130 135 140
Asn Asn Glu Leu Lys Ile Leu Arg Ala Asp Thr Phe Leu Gly Ile Glu
145 150 155 160
Asn Leu Glu Tyr Leu Gln Ala Asp Tyr Asn Leu Ile Lys Tyr Ile Glu
165 170 175
Arg Gly Ala Phe Asn Lys Leu His Lys Leu Lys Val Leu Ile Leu Asn
180 185 190
Asp Asn Leu Ile Ser Phe Leu Pro Asp Asn Ile Phe Arg Phe Ala Ser
195 200 205
Leu Thr His Leu Asp Ile Arg Gly Asn Arg Ile Gln Lys Leu Pro Tyr
210 215 220
Ile Gly Val Leu Glu His Ile Gly Arg Val Val Glu Leu Gln Leu Glu
225 230 235 240
Asp Asn Pro Trp Asn Cys Ser Cys Asp Leu Leu Pro Leu Lys Ala Trp
245 250 255
Leu Glu Asn Met Pro Tyr Asn Ile Tyr Ile Gly Glu Ala Ile Cys Glu

260	265	270
Thr Pro Ser Asp Leu Tyr Gly Arg Leu Leu Lys Glu Thr Asn Lys Gln		
275	280	285
Glu Leu Cys Pro Met Gly Thr Gly Ser Asp Phe Asp Val Arg Ile Leu		
290	295	300
Pro Pro Ser Gln Leu Glu Asn Gly Tyr Thr Thr Pro Asn Gly His Thr		
305	310	315
Thr Gln Thr Ser Leu His Arg Leu Val Thr Lys Pro Pro Lys Thr Thr		
325	330	335
Asn Pro Ser Lys Ile Ser Gly Ile Val Ala Gly Lys Ala Leu Ser Asn		
340	345	350
Arg Asn Leu Ser Gln Ile Val Ser Tyr Gln Thr Arg Val Pro Pro Leu		
355	360	365
Thr Pro Cys Pro Ala Pro Cys Phe Cys Lys Thr His Pro Ser Asp Leu		
370	375	380
Gly Leu Ser Val Asn Cys Gln Glu Lys Asn Ile Gln Ser Met Ser Glu		
385	390	395
Leu Ile Pro Lys Pro Leu Asn Ala Lys Lys Leu His Val Asn Gly Asn		
405	410	415
Ser Ile Lys Asp Val Asp Val Ser Asp Phe Thr Asp Phe Glu Gly Leu		
420	425	430
Asp Leu Leu His Leu Gly Ser Asn Gln Ile Thr Val Ile Lys Gly Asp		
435	440	445
Val Phe His Asn Leu Thr Asn Leu Arg Arg Leu Tyr Leu Asn Gly Asn		
450	455	460
Gln Ile Glu Arg Leu Tyr Pro Glu Ile Phe Ser Gly Leu His Asn Leu		
465	470	475
Gln Tyr Leu Tyr Leu Glu Tyr Asn Leu Ile Lys Glu Ile Ser Ala Gly		
485	490	495
Thr Phe Asp Ser Met Pro Asn Leu Gln Leu Leu Tyr Leu Asn Asn Asn		
500	505	510
Leu Leu Lys Ser Leu Pro Val Tyr Ile Phe Ser Gly Ala Pro Leu Ala		
515	520	525
Arg Leu Asn Leu Arg Asn Asn Lys Phe Met Tyr Leu Pro Val Ser Gly		
530	535	540
Val Leu Asp Gln Leu Gln Ser Leu Thr Gln Ile Asp Leu Glu Gly Asn		
545	550	555
Pro Trp Asp Cys Thr Cys Asp Leu Val Ala Leu Lys Leu Trp Val Glu		
565	570	575
Lys Leu Ser Asp Gly Ile Val Val Lys Glu Leu Lys Cys Glu Thr Pro		
580	585	590
Val Gln Phe Ala Asn Ile Glu Leu Lys Ser Leu Lys Asn Glu Ile Leu		

595	600	605
Cys Pro Lys Leu Leu Asn Lys Pro Ser Ala Pro Phe Thr Ser Pro Ala		
610	615	620
Pro Ala Ile Thr Phe Thr Thr Pro Leu Gly Pro Ile Arg Ser Pro Pro		
625	630	635
Gly Gly Pro Val Pro Leu Ser Ile Leu Ile Leu Ser Ile Leu Val Val		
645	650	655
Leu Ile Leu Thr Val Phe Val Ala Phe Cys Leu Leu Val Phe Val Leu		
660	665	670
Arg Arg Asn Lys Lys Pro Thr Val Lys His Glu Gly Leu Gly Asn Pro		
675	680	685
Asp Cys Gly Ser Met Gln Leu Gln Leu Arg Lys His Asp His Lys Thr		
690	695	700
Asn Lys Lys Asp Gly Leu Ser Thr Glu Ala Phe Ile Pro Gln Thr Ile		
705	710	715
Glu Gln Met Ser Lys Ser His Thr Cys Gly Leu Lys Glu Ser Glu Thr		
725	730	735
Gly Phe Met Phe Ser Asp Pro Pro Gly Gln Lys Val Val Met Arg Asn		
740	745	750
Val Ala Asp Lys Glu Lys Asp Leu Leu His Val Asp Thr Arg Lys Arg		
755	760	765
Leu Ser Thr Ile Asp Glu Leu Asp Glu Leu Phe Pro Ser Arg Asp Ser		
770	775	780
Asn Val Phe Ile Gln Asn Phe Leu Glu Ser Lys Lys Glu Tyr Asn Ser		
785	790	795
Ile Gly Val Ser Gly Phe Glu Ile Arg Tyr Pro Glu Lys Gln Pro Asp		
805	810	815
Lys Lys Ser Lys Ser Leu Ile Gly Gly Asn His Ser Lys Ile Val		
820	825	830
Val Glu Gln Arg Lys Ser Glu Tyr Phe Glu Leu Lys Ala Lys Leu Gln		
835	840	845
Ser Ser Pro Asp Tyr Leu Gln Val Leu Glu Glu Gln Thr Ala Leu Asn		
850	855	860
Lys Ile		
865		

<210> 33
 <211> 533
 <212> PRT
 <213> Homo sapiens

<400> 33

Met Ala Pro Gly Pro Phe Ser Ser Ala Leu Leu Ser Pro Pro Pro Ala
1 5 10 15
Ala Leu Pro Phe Leu Leu Leu Leu Trp Ala Gly Ala Ser Arg Gly Gln
20 25 30
Pro Cys Pro Gly Arg Cys Ile Cys Gln Asn Val Ala Pro Thr Leu Thr
35 40 45
Met Leu Cys Ala Lys Thr Gly Leu Leu Phe Val Pro Pro Ala Ile Asp
50 55 60
Arg Arg Val Val Glu Leu Arg Leu Thr Asp Asn Phe Ile Ala Ala Val
65 70 75 80
Arg Arg Arg Asp Phe Ala Asn Met Thr Ser Leu Val His Leu Thr Leu
85 90 95
Ser Arg Asn Thr Ile Gly Gln Val Ala Ala Gly Ala Phe Ala Asp Leu
100 105 110
Arg Ala Leu Arg Ala Leu His Leu Asp Ser Asn Arg Leu Ala Glu Val
115 120 125
Arg Gly Asp Gln Leu Arg Gly Leu Gly Asn Leu Arg His Leu Ile Leu
130 135 140
Gly Asn Asn Gln Ile Arg Arg Val Glu Ser Ala Ala Phe Asp Ala Phe
145 150 155 160
Leu Ser Thr Val Glu Asp Leu Asp Leu Ser Tyr Asn Asn Leu Glu Ala
165 170 175
Leu Pro Trp Glu Ala Val Gly Gln Met Val Asn Leu Asn Thr Leu Thr
180 185 190
Leu Asp His Asn Leu Ile Asp His Ile Ala Glu Gly Thr Phe Val Gln
195 200 205
Leu His Lys Leu Val Arg Leu Asp Met Thr Ser Asn Arg Leu His Lys
210 215 220
Leu Pro Pro Asp Gly Leu Phe Leu Arg Ser Gln Gly Thr Gly Pro Lys
225 230 235 240
Pro Pro Thr Pro Leu Thr Val Ser Phe Gly Gly Asn Pro Leu His Cys
245 250 255
Asn Cys Glu Leu Leu Trp Leu Arg Arg Leu Thr Arg Glu Asp Asp Leu
260 265 270
Glu Thr Cys Ala Thr Pro Glu His Leu Thr Asp Arg Tyr Phe Trp Ser
275 280 285
Ile Pro Glu Glu Glu Phe Leu Cys Glu Pro Pro Leu Ile Thr Arg Gln
290 295 300
Ala Gly Gly Arg Ala Leu Val Val Glu Gly Gln Ala Val Ser Leu Arg
305 310 315 320
Cys Arg Ala Val Gly Asp Pro Glu Pro Val Val His Trp Val Ala Pro
325 330 335

Asp Gly Arg Leu Leu Gly Asn Ser Ser Arg Thr Arg Val Arg Gly Asp
 340 345 350
 Gly Thr Leu Asp Val Thr Ile Thr Thr Leu Arg Asp Ser Gly Thr Phe
 355 360 365
 Thr Cys Ile Ala Ser Asn Ala Ala Gly Glu Ala Thr Ala Pro Val Glu
 370 375 380
 Val Cys Val Val Pro Leu Pro Leu Met Ala Pro Pro Pro Ala Ala Pro
 385 390 395 400
 Pro Pro Leu Thr Glu Pro Gly Ser Ser Asp Ile Ala Thr Pro Gly Arg
 405 410 415
 Pro Gly Ala Asn Asp Ser Ala Ala Glu Arg Arg Leu Val Ala Ala Glu
 420 425 430
 Leu Thr Ser Asn Ser Val Leu Ile Arg Trp Pro Ala Gln Arg Pro Val
 435 440 445
 Pro Gly Ile Arg Met Tyr Gln Val Gln Tyr Asn Ser Ser Val Asp Asp
 450 455 460
 Ser Leu Val Tyr Ser Ser Ala Ser Leu Met His Ile Val Glu His Gln
 465 470 475 480
 Leu Asn Ala Ser Val Ile Cys Leu Ala Ser Pro Gly Asp Ala Ser Gly
 485 490 495
 Ala Gly Ala Val Ser Leu Pro Val Glu Ser Leu Ser Ser Trp Leu Ser
 500 505 510
 Asp Leu His Arg Glu Thr Cys Leu Leu Ala Ser Ile Ser Ala Phe Pro
 515 520 525
 Val Phe Ser Trp Pro
 530

<210> 34
 <211> 771
 <212> PRT
 <213> Homo sapiens

<400> 34
 Met Ala Pro Gly Pro Phe Ser Ser Ala Leu Leu Ser Pro Pro Pro Ala
 1 5 10 15
 Ala Leu Pro Phe Leu Leu Leu Leu Trp Ala Gly Ala Ser Arg Gly Gln
 20 25 30
 Pro Cys Pro Gly Arg Cys Ile Cys Gln Asn Val Ala Pro Thr Leu Thr
 35 40 45
 Met Leu Cys Ala Lys Thr Gly Leu Leu Phe Val Pro Pro Ala Ile Asp
 50 55 60
 Arg Arg Val Val Glu Leu Arg Leu Thr Asp Asn Phe Ile Ala Ala Val

65	70	75	80
Arg Arg Arg Asp Phe Ala Asn Met Thr Ser Leu Val His Leu Thr Leu			
85	90	95	
Ser Arg Asn Thr Ile Gly Gln Val Ala Ala Gly Ala Phe Ala Asp Leu			
100	105	110	
Arg Ala Leu Arg Ala Leu His Leu Asp Ser Asn Arg Leu Ala Glu Val			
115	120	125	
Arg Gly Asp Gln Leu Arg Gly Leu Gly Asn Leu Arg His Leu Ile Leu			
130	135	140	
Gly Asn Asn Gln Ile Arg Arg Val Glu Ser Ala Ala Phe Asp Ala Phe			
145	150	155	160
Leu Ser Thr Val Glu Asp Leu Asp Leu Ser Tyr Asn Asn Leu Glu Ala			
165	170	175	
Leu Pro Trp Glu Ala Val Gly Gln Met Val Asn Leu Asn Thr Leu Thr			
180	185	190	
Leu Asp His Asn Leu Ile Asp His Ile Ala Glu Gly Thr Phe Val Gln			
195	200	205	
Leu His Lys Leu Val Arg Leu Asp Met Thr Ser Asn Arg Leu His Lys			
210	215	220	
Leu Pro Pro Asp Gly Leu Phe Leu Arg Ser Gln Gly Thr Gly Pro Lys			
225	230	235	240
Pro Pro Thr Pro Leu Thr Val Ser Phe Gly Gly Asn Pro Leu His Cys			
245	250	255	
Asn Cys Glu Leu Leu Trp Leu Arg Arg Leu Thr Arg Glu Asp Asp Leu			
260	265	270	
Glu Thr Cys Ala Thr Pro Glu His Leu Thr Asp Arg Tyr Phe Trp Ser			
275	280	285	
Ile Pro Glu Glu Glu Phe Leu Cys Glu Pro Pro Leu Ile Thr Arg Gln			
290	295	300	
Ala Gly Gly Arg Ala Leu Val Val Glu Gly Gln Ala Val Ser Leu Arg			
305	310	315	320
Cys Arg Ala Val Gly Asp Pro Glu Pro Val Val His Trp Val Ala Pro			
325	330	335	
Asp Gly Arg Leu Leu Gly Asn Ser Ser Arg Thr Arg Val Arg Gly Asp			
340	345	350	
Gly Thr Leu Asp Val Thr Ile Thr Thr Leu Arg Asp Ser Gly Thr Phe			
355	360	365	
Thr Cys Ile Ala Ser Asn Ala Ala Gly Glu Ala Thr Ala Pro Val Glu			
370	375	380	
Val Cys Val Val Pro Leu Pro Leu Met Ala Pro Pro Pro Ala Ala Pro			
385	390	395	400
Pro Pro Leu Thr Glu Pro Gly Ser Ser Asp Ile Ala Thr Pro Gly Arg			

405	410	415
Pro Gly Ala Asn Asp Ser Ala Ala Glu Arg Arg Leu Val Ala Ala Glu		
420	425	430
Leu Thr Ser Asn Ser Val Val Ile Arg Trp Pro Ala Gln Arg Pro Val		
435	440	445
Pro Gly Ile Arg Met Tyr Gln Val Gln Tyr Asn Ser Ser Val Asp Asp		
450	455	460
Ser Leu Val Tyr Arg Met Ile Pro Ser Thr Ser Gln Thr Phe Leu Val		
465	470	475
Asn Asp Leu Ala Ala Gly Arg Ala Tyr Asp Leu Cys Val Leu Ala Val		
485	490	495
Tyr Asp Asp Gly Ala Thr Ala Leu Pro Ala Thr Arg Val Val Gly Cys		
500	505	510
Val Gln Phe Thr Thr Ala Gly Asp Pro Ala Pro Cys Arg Pro Leu Arg		
515	520	525
Ala His Phe Leu Gly Gly Thr Met Ile Ile Ala Ile Gly Gly Val Ile		
530	535	540
Val Ala Ser Val Leu Val Phe Ile Val Leu Leu Met Ile Arg Tyr Lys		
545	550	555
Val Tyr Gly Asp Gly Asp Ser Arg Arg Val Lys Gly Ser Arg Ser Leu		
565	570	575
Pro Arg Val Ser His Val Cys Ser Gln Thr Asn Gly Ala Gly Thr Gly		
580	585	590
Ala Ala Gln Ala Pro Ala Leu Pro Ala Gln Asp His Tyr Glu Ala Leu		
595	600	605
Arg Glu Val Glu Ser Gln Ala Ala Pro Ala Val Ala Val Glu Ala Lys		
610	615	620
Ala Met Glu Ala Glu Thr Ala Ser Ala Glu Pro Glu Val Val Leu Gly		
625	630	635
Arg Ser Leu Gly Gly Ser Ala Thr Ser Leu Cys Leu Leu Pro Ser Glu		
645	650	655
Glu Thr Ser Gly Glu Glu Ser Arg Ala Ala Val Gly Pro Arg Arg Ser		
660	665	670
Arg Ser Gly Ala Leu Glu Pro Pro Thr Ser Ala Pro Pro Thr Leu Ala		
675	680	685
Leu Val Pro Gly Gly Ala Ala Ala Arg Pro Arg Pro Gln Gln Arg Tyr		
690	695	700
Ser Phe Asp Gly Asp Tyr Gly Ala Leu Phe Gln Ser His Ser Tyr Pro		
705	710	715
Arg Arg Ala Arg Arg Thr Lys Arg His Arg Ser Thr Pro His Leu Asp		
725	730	735
Gly Ala Gly Gly Ala Ala Gly Glu Asp Gly Asp Leu Gly Leu Gly		

740	745	750
Ser Ala Arg Ala Cys Leu Ala Phe Thr Ser Thr Glu Trp Met Leu Glu		
755	760	765
Ser Thr Val		
770		
<210> 35		
<211> 399		
<212> PRT		
<213> Homo sapiens		
<400> 35		
Met Trp Gln Leu Leu Ala Ala Cys Trp Met Leu Leu Leu Gly Ser		
1	5	10
Met Tyr Gly Tyr Asp Lys Lys Gly Asn Asn Ala Asn Pro Glu Ala Asn		
20	25	30
Met Asn Ile Ser Gln Ile Ile Ser Tyr Trp Gly Tyr Pro Tyr Glu Glu		
35	40	45
Tyr Asp Val Thr Thr Lys Asp Gly Tyr Ile Leu Gly Ile Tyr Arg Ile		
50	55	60
Pro His Gly Arg Gly Cys Pro Gly Arg Thr Ala Pro Lys Pro Ala Val		
65	70	75
Tyr Leu Gln His Gly Leu Ile Ala Ser Ala Ser Asn Trp Ile Cys Asn		
85	90	95
Leu Pro Asn Asn Ser Leu Ala Phe Leu Leu Ala Asp Ser Gly Tyr Asp		
100	105	110
Val Trp Leu Gly Asn Ser Arg Gly Asn Thr Trp Ser Arg Lys His Leu		
115	120	125
Lys Leu Ser Pro Lys Ser Pro Glu Tyr Trp Ala Phe Ser Leu Asp Glu		
130	135	140
Met Ala Lys Tyr Asp Leu Pro Ala Thr Ile Asn Phe Ile Ile Glu Lys		
145	150	155
Thr Gly Gln Lys Arg Leu Tyr Tyr Val Gly His Ser Gln Gly Thr Thr		
165	170	175
Ile Ala Phe Ile Ala Phe Ser Thr Asn Pro Glu Leu Ala Lys Lys Ile		
180	185	190
Lys Ile Phe Phe Ala Leu Ala Pro Val Val Thr Val Lys Tyr Thr Gln		
195	200	205
Ser Pro Met Lys Lys Leu Thr Thr Leu Ser Arg Arg Val Val Lys Val		
210	215	220
Leu Phe Gly Asp Lys Met Phe His Pro His Thr Leu Phe Asp Gln Phe		
225	230	235
		240

Ile Ala Thr Lys Val Cys Asn Arg Lys Leu Phe Arg Arg Ile Cys Ser
 245 250 255
 Asn Phe Leu Phe Thr Leu Ser Gly Phe Asp Pro Gln Asn Leu Asn Met
 260 265 270
 Ser Arg Leu Asp Val Tyr Leu Ser His Asn Pro Ala Gly Thr Ser Val
 275 280 285
 Gln Asn Met Leu His Trp Ala Gln Ala Val Asn Ser Gly Gln Leu Gln
 290 295 300
 Ala Phe Asp Trp Gly Asn Ser Asp Gln Asn Met Met His Phe His Gln
 305 310 315 320
 Leu Thr Pro Pro Leu Tyr Asn Ile Thr Lys Ile Glu Val Pro Thr Ala
 325 330 335
 Ile Trp Asn Gly Gly Gln Asp Ile Val Ala Asp Pro Lys Asp Val Glu
 340 345 350
 Asn Leu Leu Pro Gln Ile Ala Asn Leu Ile Tyr Tyr Lys Leu Ile Pro
 355 360 365
 His Tyr Asn His Val Asp Phe Tyr Leu Gly Glu Asp Ala Pro Gln Glu
 370 375 380
 Ile Tyr Gln Asp Leu Ile Ile Leu Met Glu Glu Tyr Leu Gln Asn
 385 390 395

<210> 36
 <211> 255
 <212> PRT
 <213> Homo sapiens

<400> 36
 Ile Val Gly Gly Ser Asn Ala Gln Pro Gly Thr Trp Pro Trp Gln Val
 1 5 10 15
 Ser Leu His His Gly Gly His Ile Cys Gly Gly Ser Leu Ile Ala
 20 25 30
 Pro Ser Trp Val Leu Ser Ala Ala His Cys Phe Met Thr Gly Arg Gln
 35 40 45
 Tyr Arg Cys Pro Glu Thr Arg Arg Thr Arg Ser Ala Leu Pro Thr Arg
 50 55 60
 Lys Arg Arg Arg Ala Tyr Asn His Tyr Ser Gln Gly Ser Asp Leu Ala
 65 70 75 80
 Leu Leu Gln Leu Ala His Pro Thr Thr His Thr Pro Leu Cys Leu Pro
 85 90 95
 Gln Pro Ala His Arg Phe Pro Phe Gly Ala Ser Cys Trp Ala Thr Gly
 100 105 110
 Trp Asp Gln Asp Thr Ser Asp Ala Pro Ser Leu Ser Pro Ala Pro Gly

115	120	125
Thr Leu Arg Asn Leu Arg Leu Arg Leu Ile Ser Arg Pro Thr Cys Asn		
130	135	140
Cys Ile Tyr Asn Gln Leu His Gln Arg His Leu Ser Asn Pro Ala Arg		
145	150	155
160		
Pro Gly Met Leu Cys Gly Gly Pro Gln Pro Gly Val Gln Gly Pro Cys		
165	170	175
Gln Gly Leu Phe Gly Ala Pro Leu Val His Glu Val Arg Gly Thr Trp		
180	185	190
Phe Leu Ala Gly Leu His Ser Phe Gly Asp Ala Cys Gln Gly Pro Ala		
195	200	205
Arg Pro Ala Val Phe Thr Ala Leu Pro Ala Met Arg Thr Gly Ser Ala		
210	215	220
Val Trp Thr Arg Gln Val Tyr Phe Ala Glu Glu Pro Glu Pro Glu Ala		
225	230	235
240		
Glu Pro Gly Ser Cys Leu Ala Asn Ile Arg Pro Phe Ser Leu Gln		
245	250	255

<210> 37

<211> 301

<212> PRT

<213> Homo sapiens

<400> 37

Met Glu Thr Ala Gly Ser Asp Trp Val Ala Gly Gly Pro Leu Thr Gln		
1	5	10
15		
Ala Ser His Pro Ser Glu Cys Gly Lys Ala Pro Arg Pro Gly Ala Trp		
20	25	30
Pro Trp Glu Ala Gln Val Met Val Pro Gly Ser Arg Pro Cys His Gly		
35	40	45
Ala Leu Val Ser Glu Ser Trp Val Leu Ala Pro Ala Ser Cys Phe Leu		
50	55	60
Glu Gln Val Thr His Thr Leu Cys Cys Cys Arg Met Thr Arg Val Gly		
65	70	75
80		
Ala Phe Cys Ala Arg Arg Gly Pro Gly Phe Trp Leu Glu Ser Glu		
85	90	95
Thr Phe Pro Val Ala Val Tyr Leu Pro Arg Ala Tyr Asn His Tyr Ser		
100	105	110
Gln Gly Ser Asp Leu Ala Leu Leu Gln Leu Ala His Pro Thr Thr His		
115	120	125
Thr Pro Leu Cys Leu Pro Gln Pro Ala His Arg Phe Pro Phe Gly Ala		
130	135	140

Ser Cys Trp Ala Thr Gly Trp Asp Gln Asp Thr Ser Asp Ala Pro Gly
 145 150 155 160
 Thr Leu Arg Asn Leu Arg Leu Arg Leu Ile Ser Arg Pro Thr Cys Asn
 165 170 175
 Cys Ile Tyr Asn Gln Leu His Gln Arg His Leu Ser Asn Pro Ala Arg
 180 185 190
 Pro Gly Met Leu Cys Gly Gly Pro Gln Pro Gly Val Gln Gly Pro Cys
 195 200 205
 Gln Gly Leu Phe Gly Ala Pro Leu Val His Glu Val Arg Gly Thr Trp
 210 215 220
 Phe Leu Ala Gly Leu His Ser Phe Gly Asp Ala Cys Gln Gly Pro Ala
 225 230 235 240
 Arg Pro Ala Val Phe Thr Ala Leu Pro Ala Met Arg Thr Gly Ser Ala
 245 250 255
 Val Trp Thr Arg Gln Val Tyr Phe Ala Glu Glu Pro Glu Pro Glu Ala
 260 265 270
 Glu Pro Gly Ser Cys Leu Ala Asn Ile Ser Met Trp Pro Arg Gly Leu
 275 280 285
 Leu Pro Asn Pro Ala Ser Pro Gly Pro Phe Ser Leu Gln
 290 295 300

<210> 38
 <211> 383
 <212> PRT
 <213> Homo sapiens

<400> 38
 Met Pro Ser Gly Cys Arg Cys Leu His Leu Val Cys Leu Leu Cys Ile
 1 5 10 15
 Leu Gly Ala Pro Gly Gln Pro Val Arg Ala Asp Asp Cys Ser Ser His
 20 25 30
 Cys Asp Leu Ala His Gly Cys Cys Ala Pro Asp Gly Ser Cys Arg Cys
 35 40 45
 Asp Pro Gly Trp Glu Gly Leu His Cys Glu Arg Cys Val Arg Met Pro
 50 55 60
 Gly Cys Gln His Gly Thr Cys His Gln Pro Trp Gln Cys Ile Cys His
 65 70 75 80
 Ser Gly Trp Ala Gly Lys Phe Cys Asp Lys Asp Glu His Ile Cys Thr
 85 90 95
 Thr Gln Ser Pro Cys Gln Asn Gly Gly Gln Cys Met Tyr Asp Gly Gly
 100 105 110
 Gly Glu Tyr His Cys Val Cys Leu Pro Gly Phe His Gly Arg Asp Cys

WO 01/66690

115 Glu Arg Lys Ala Gly Pro Cys Glu Gln Ala Gly Ser Pro Cys Arg Asn
 130 Gly Gly Gln Cys Gln Asp Asp Gln Gly Phe Ala Leu Asn Phe Thr Cys
 145 Arg Cys Leu Val Gly Phe Val Gly Ala Arg Cys Glu Val Asn Val Asp
 160 Asp Cys Leu Met Arg Pro Cys Ala Asn Gly Ala Thr Cys Leu Asp Gly
 175 Ile Asn Arg Phe Ser Cys Leu Cys Pro Glu Gly Phe Ala Gly Arg Phe
 190 Cys Thr Ile Asn Leu Asp Asp Cys Ala Ser Arg Pro Cys Gln Arg Gly
 205 Ala Arg Cys Arg Asp Arg Val His Asp Phe Asp Cys Leu Cys Pro Ser
 220 Pro Thr Thr Val Asp Thr Pro Leu Gly Pro Val Pro Asp Pro
 235 Gly Tyr Gly Gly Lys Thr Cys Glu Leu Val Pro Val Pro Asp Pro
 250 Pro Ala Thr Gly Pro Ala Pro His Ser Ala Gly Ala Gly Leu Leu Arg
 265 Ile Ser Val Lys Glu Val Val Arg Arg Gin Glu Ala Leu Thr Ala Ala Leu
 280 275 Pro Ser Leu Val Ala Leu Val Val Phe Gly Ala Leu 300 320
 295 Val Leu Ala Thr Val Leu Val Val Arg Ala Tyr Arg Gly Val
 310 305 Cys Pro Pro Gly Pro Cys Cys Tyr Pro Ala Pro His Tyr Ala Pro Ala
 325 315 330 340 355 360 375 380
 300 315 330 345 360 375 380
 320 335 350 365 380
 340 355 360 375 380
 360 375 380
 380

<210> 39
 <211> 417
 <212> PRT
 <213> Homo sapiens

<400> 39
 Met Ala Ser Tyr Leu Tyr Gly Val Leu Phe Ala Val Gly Leu Cys Ala
 10 5

40/66

Pro Ile Tyr Cys Val Ser Pro Ala Asn Ala Pro Ser Ala Tyr Pro Arg
 20 25 30
 Pro Ser Ser Thr Lys Ser Thr Pro Ala Ser Gln Val Tyr Ser Leu Asn
 35 40 45
 Thr Asp Phe Ala Phe Arg Leu Tyr Arg Arg Leu Val Leu Glu Thr Pro
 50 55 60
 Ser Gln Asn Ile Phe Phe Ser Pro Val Ser Val Ser Thr Ser Leu Ala
 65 70 75 80
 Met Leu Ser Leu Gly Ala His Ser Val Thr Lys Thr Gln Ile Leu Gln
 85 90 95
 Gly Leu Gly Phe Asn Leu Thr His Thr Pro Glu Ser Ala Ile His Gln
 100 105 110
 Gly Phe Gln His Leu Val His Ser Leu Thr Val Pro Ser Lys Asp Leu
 115 120 125
 Thr Leu Lys Met Gly Ser Ala Leu Phe Val Lys Lys Glu Leu Gln Leu
 130 135 140
 Gln Ala Asn Phe Leu Gly Asn Val Lys Arg Leu Tyr Glu Ala Glu Val
 145 150 155 160
 Phe Ser Thr Asp Phe Ser Asn Pro Ser Ile Ala Gln Ala Arg Ile Asn
 165 170 175
 Ser His Val Lys Lys Lys Thr Gln Gly Lys Val Val Asp Ile Ile Gln
 180 185 190
 Gly Leu Asp Leu Leu Thr Ala Met Val Leu Val Asn His Ile Phe Phe
 195 200 205
 Lys Ala Lys Trp Glu Lys Pro Phe His Pro Glu Tyr Thr Arg Lys Asn
 210 215 220
 Phe Pro Phe Leu Val Gly Glu Gln Val Thr Val His Val Pro Met Met
 225 230 235 240
 His Gln Lys Glu Gln Phe Ala Phe Gly Val Asp Thr Glu Leu Asn Cys
 245 250 255
 Phe Val Leu Gln Met Asp Tyr Lys Gly Asp Ala Val Ala Phe Phe Val
 260 265 270
 Leu Pro Ser Lys Gly Lys Met Arg Gln Leu Glu Gln Ala Leu Ser Ala
 275 280 285
 Arg Thr Leu Arg Lys Trp Ser His Ser Leu Gln Lys Arg Trp Ile Glu
 290 295 300
 Val Phe Ile Pro Arg Phe Ser Ile Ser Ala Ser Tyr Asn Leu Glu Thr
 305 310 315 320
 Ile Leu Pro Lys Met Gly Ile Gln Asn Val Phe Asp Lys Asn Ala Asp
 325 330 335
 Phe Ser Gly Ile Ala Lys Arg Asp Ser Leu Gln Val Ser Lys Ala Thr
 340 345 350

His Lys Ala Val Leu Asp Val Ser Glu Glu Gly Thr Glu Ala Thr Ala
 355 360 365
 Ala Thr Thr Thr Lys Phe Ile Val Arg Ser Lys Asp Gly Pro Ser Tyr
 370 375 380
 Phe Thr Val Ser Phe Asn Arg Thr Phe Leu Met Met Ile Thr Asn Lys
 385 390 395 400
 Ala Thr Asp Gly Ile Leu Phe Leu Gly Lys Val Glu Asn Pro Thr Lys
 405 410 415
 Ser

<210> 40
 <211> 243
 <212> PRT
 <213> Homo sapiens

<400> 40

Met Gly Ser Ser Ser Phe Leu Val Leu Met Val Ser Leu Val Leu Val
 1 5 10 15
 Thr Leu Val Ala Val Glu Gly Val Lys Glu Gly Ile Glu Lys Ala Gly
 20 25 30
 Val Cys Pro Ala Asp Asn Val Arg Cys Phe Lys Ser Asp Pro Pro Gln
 35 40 45
 Cys His Thr Asp Gln Asp Cys Leu Gly Glu Arg Lys Cys Cys Tyr Leu
 50 55 60
 His Cys Gly Phe Lys Cys Val Ile Pro Val Lys Glu Leu Glu Gly
 65 70 75 80
 Gln Arg Leu Leu His Asn Arg Glu Leu Pro Pro Ala Ala Ile Leu Gly
 85 90 95
 Asp Ser Leu Thr Glu Lys Ser Gly Gly Cys Pro Pro Asp Asp Gly Pro
 100 105 110
 Cys Leu Leu Ser Val Pro Asp Gln Cys Val Glu Asp Ser Gln Cys Pro
 115 120 125
 Leu Thr Arg Lys Cys Cys Tyr Arg Ala Cys Phe Arg Gln Cys Val Pro
 130 135 140
 Arg Val Ser Gly Lys Cys Leu Pro Ser Thr Leu Leu Thr Ile Gln Ala
 145 150 155 160
 Pro Ser Phe Arg Ala Ser Gly Gln Gly Arg Ser Ser Pro Ser Ser Leu
 165 170 175
 Cys Cys Ser Glu Ala Gly Gln Leu Pro Arg Gly Pro Thr Ala Leu Pro
 180 185 190
 Gln Pro His Glu Pro Pro Val Ser Gln Gly Leu Arg Leu Leu Gly Gln

195	200	205
Lys Ala Met Leu Pro Gln Arg Leu Arg Ala Gly Leu Pro Gly Ser Cys		
210	215	220
Gln Arg Tyr Gly Ser Trp Val Pro Arg Ala Gly Ala Ser Pro Leu Arg		
225	230	235
Ala Gln Leu		

<210> 41
 <211> 185
 <212> PRT
 <213> Homo sapiens

<400> 41		
Met Gly Ser Ser Ser Phe Leu Val Leu Met Val Ser Leu Val Leu Val		
1	5	10
Thr Leu Val Ala Val Glu Gly Val Lys Glu Gly Ile Glu Lys Ala Gly		
20	25	30
Val Cys Pro Ala Asp Asn Val Arg Cys Phe Lys Ser Asp Pro Pro Gln		
35	40	45
Cys His Thr Asp Gln Asp Cys Leu Gly Glu Arg Lys Cys Cys Tyr Leu		
50	55	60
His Cys Gly Phe Lys Cys Val Ile Pro Val Lys Glu Leu Glu Glu Val		
65	70	75
Pro Cys Val Ala Val Lys Leu Gly Ser Cys Pro Glu Asp Gln Leu Arg		
85	90	95
Cys Leu Ser Pro Met Asn His Leu Cys His Lys Asp Ser Asp Cys Ser		
100	105	110
Gly Lys Lys Arg Cys Cys His Ser Ala Cys Gly Arg Asp Cys Arg Asp		
115	120	125
Pro Ala Arg Gly Thr Ala Pro Gly Cys Pro Gly Gln Val Pro Pro Leu		
130	135	140
Ser Glu Pro Ser Ser Asn Thr Phe Phe Ile Ala Thr Ser Leu Thr Gly		
145	150	155
Cys Leu Pro Arg Ser Gln Asp Leu Pro Trp Pro Gly Leu Gly Asn Trp		
165	170	175
Ile Gly Val Gly Val Leu Leu Gly		
180	185	

<210> 42
 <211> 198
 <212> PRT

<213> Homo sapiens

<400> 42

Met Asn Ser Gly Arg Glu Pro Arg Thr Pro Arg Thr Leu Leu Ser Ile
 1 5 10 15
 Ala Asp Ile Leu Ala Pro Arg Met Val Pro Arg Ala Pro Ser Ala Pro
 20 25 30
 Gln Leu Pro Glu Ser Gly Pro Gly Pro Thr Ser Pro Leu Cys Ala Leu
 35 40 45
 Glu Glu Leu Thr Ser Lys Thr Phe Arg Gly Leu Asp Ala Arg Ala Leu
 50 55 60
 Gln Pro Ser Glu Gly Arg Ala Gly Pro Asp Ala Leu Gly Pro Gly Pro
 65 70 75 80
 Phe Gly Arg Lys Arg Arg Lys Ser Arg Thr Ala Phe Thr Ala Gln Gln
 85 90 95
 Val Leu Glu Leu Glu Arg Arg Phe Val Phe Gln Lys Tyr Leu Ala Pro
 100 105 110
 Ser Glu Arg Asp Gly Leu Ala Thr Arg Leu Gly Leu Ala Asn Ala Gln
 115 120 125
 Val Val Thr Trp Phe Gln Asn Arg Arg Ala Lys Leu Lys Arg Asp Val
 130 135 140
 Glu Glu Met Arg Ala Asp Val Ala Ser Leu Arg Ala Leu Ser Pro Glu
 145 150 155 160
 Val Leu Cys Ser Leu Ala Leu Pro Glu Gly Ala Pro Asp Pro Gly Leu
 165 170 175
 Cys Leu Gly Pro Ala Gly Pro Asp Ser Arg Pro His Leu Ser Asp Glu
 180 185 190
 Glu Ile Gln Val Asp Asp
 195

<210> 43

<211> 330

<212> PRT

<213> Homo sapiens

<400> 43

Met Val Trp Lys Arg Glu Asn Phe Tyr Lys Glu Val Lys Arg Gly Arg
 1 5 10 15
 Ala Leu Phe Leu Lys Arg Leu Cys Ile Phe Asn Ile Asp Thr Asp Asn
 20 25 30
 Thr Phe Gln Arg Ile Ile Glu Lys Pro Ser Trp Leu Gly Phe Leu Gly
 35 40 45

Pro Met Ile Lys Ala Glu Thr Gly Asp Phe Ile Tyr Val His Val Lys
 50 55 60
 Asn Asn Ala Ser Arg Ala Tyr Ser Tyr His Pro His Gly Leu Thr Tyr
 65 70 75 80
 Ser Lys Glu Asn Glu Gly Ala Ile Tyr Pro Asp Asn Thr Thr Gly Leu
 85 90 95
 Gln Lys Glu Asp Glu Tyr Leu Glu Pro Gly Lys Gln Tyr Thr Tyr Lys
 100 105 110
 Trp Tyr Val Glu Glu His Gln Gly Pro Gly Pro Asn Asp Ser Asn Cys
 115 120 125
 Val Thr Arg Ile Tyr His Ser His Ile Asp Thr Ala Arg Asp Val Ala
 130 135 140
 Ser Gly Leu Ile Gly Pro Ile Leu Thr Cys Lys Arg Ala Ile Asn Gly
 145 150 155 160
 Tyr Ile Tyr Gly Asn Leu Pro Asn Leu Thr Met Cys Ala Glu Asp Arg
 165 170 175
 Val Gln Trp Tyr Phe Val Gly Met Gly Gly Val Ala Asp Ile His Pro
 180 185 190
 Val Tyr Leu Arg Gly Gln Thr Leu Ile Ser Arg Asn His Arg Lys Asp
 195 200 205
 Thr Ile Met Leu Phe Pro Ser Ser Leu Glu Asp Ala Phe Met Val Ala
 210 215 220
 Lys Ala Pro Gly Val Trp Met Leu Gly Cys Gln Ile His Gly Ser Asp
 225 230 235 240
 Ile Leu Leu Leu Arg Asp Thr Lys Ser Glu Asn Phe Gln Gly Leu Ser
 245 250 255
 Pro Phe His Met His Phe Leu Thr Asn Glu Glu Thr Tyr Ile Gln Glu
 260 265 270
 Glu Ser Met Gln Ala Phe Phe Lys Val Ser Asn Cys Gln Lys Pro Ser
 275 280 285
 Thr Glu Ala Phe Val Thr Gly Thr His Val Ile His Tyr Tyr Ile Ala
 290 295 300
 Ala Lys Glu Ile Leu Trp Asn Tyr Ala Pro Ser Gly Ile Asp Phe Phe
 305 310 315 320
 Thr Lys Lys Asn Leu Thr Ala Ala Gly Arg
 325 330

<210> 44
 <211> 479
 <212> PRT
 <213> Homo sapiens

<400> 44

Met Ala Ile Leu Pro Leu Leu Leu Cys	Leu Leu Pro Leu Ala Pro Ala	
1 5 10 15		
Ser Ser Pro Pro Gln Ser Ala Thr Pro Ser Pro Cys	Pro Arg Arg Cys	
20 25 30		
Arg Cys Gln Thr Gln Ser Leu Pro Leu Ser Val	Leu Cys Pro Gly Ala	
35 40 45		
Gly Leu Leu Phe Val Pro Pro Ser Leu Asp Arg	Arg Ala Ala Glu Leu	
50 55 60		
Arg Leu Ala Asp Asn Phe Ile Ala Ser Val Arg	Arg Arg Asp Leu Ala	
65 70 75 80		
Asn Met Thr Gly Leu Leu His Leu Ser Leu Ser Arg	Asn Thr Ile Arg	
85 90 95		
His Val Ala Ala Gly Ala Phe Ala Asp Leu Arg	Ala Leu Arg Ala Leu	
100 105 110		
His Leu Asp Gly Asn Arg Leu Thr Ser Leu Gly	Glu Gly Gln Leu Arg	
115 120 125		
Gly Leu Val Asn Leu Arg His Leu Ile Leu Ser Asn	Asn Gln Leu Ala	
130 135 140		
Ala Leu Ala Ala Gly Ala Leu Asp Asp Cys	Ala Glu Thr Leu Glu Asp	
145 150 155 160		
Leu Asp Leu Ser Tyr Asn Asn Leu Glu Gln Leu	Pro Trp Glu Ala Leu	
165 170 175		
Gly Arg Leu Gly Asn Val Asn Thr Leu Gly Leu Asp	His Asn Leu Leu	
180 185 190		
Ala Ser Val Pro Ala Gly Ala Phe Ser Arg Leu His	Lys Leu Ala Arg	
195 200 205		
Leu Asp Met Thr Ser Asn Arg Leu Thr Thr Ile	Pro Pro Asp Pro Leu	
210 215 220		
Phe Ser Arg Leu Pro Leu Leu Ala Arg Pro Arg	Gly Ser Pro Ala Ser	
225 230 235 240		
Ala Leu Val Leu Ala Phe Gly Gly Asn Pro Leu His	Cys Asn Cys Glu	
245 250 255		
Leu Val Trp Leu Arg Arg Leu Ala Arg Glu Asp Asp	Leu Glu Ala Cys	
260 265 270		
Ala Ser Pro Pro Ala Leu Gly Gly Arg Tyr Phe	Trp Ala Val Gly Glu	
275 280 285		
Glu Glu Phe Val Cys Glu Pro Pro Val Val Thr	His Arg Ser Pro Pro	
290 295 300		
Leu Ala Val Pro Ala Gly Arg Pro Ala Ala Leu	Arg Cys Arg Ala Val	
305 310 315 320		
Gly Asp Pro Glu Pro Arg Val Arg Trp Val Ser	Pro Gln Gly Arg Leu	

325	330	335
Leu Gly Asn Ser Ser Arg Ala Arg Ala Phe Pro Asn Gly Thr Leu Glu		
340	345	350
Leu Leu Val Thr Glu Pro Gly Asp Gly Gly Ile Phe Thr Cys Ile Ala		
355	360	365
Ala Asn Ala Ala Gly Glu Ala Thr Ala Ala Val Glu Leu Thr Val Gly		
370	375	380
Pro Pro Pro Pro Gln Leu Ala Asn Ser Thr Ser Cys Asp Pro Pro		
385	390	395
385 Arg Asp Gly Asp Pro Asp Ala Leu Thr Pro Pro Ser Ala Ala Ser Ala		
405	410	415
Ser Ala Lys Val Ala Asp Thr Gly Pro Pro Thr Asp Arg Gly Val Gln		
420	425	430
Val Thr Glu His Gly Ala Thr Ala Ala Leu Val Gln Trp Pro Asp Gln		
435	440	445
Arg Pro Ile Pro Gly Ile Arg Met Tyr Gln Ile Gln Tyr Asn Ser Ser		
450	455	460
Ala Asp Asp Ile Leu Val Tyr Arg Cys Arg Val Gln Ala Leu Gly		
465	470	475

<210> 45

<211> 628

<212> PRT

<213> Homo sapiens

<400> 45

Met Ala Ile Leu Pro Leu Leu Leu Cys Leu Leu Pro Leu Ala Pro Ala		
1	5	10
15 Ser Ser Pro Pro Gln Ser Ala Thr Pro Ser Pro Cys Pro Arg Arg Cys		
20	25	30
Arg Cys Gln Thr Gln Ser Leu Pro Leu Ser Val Leu Cys Pro Gly Ala		
35	40	45
Gly Leu Leu Phe Val Pro Pro Ser Leu Asp Arg Arg Ala Ala Glu Leu		
50	55	60
Arg Leu Ala Asp Asn Phe Ile Ala Ser Val Arg Arg Arg Asp Leu Ala		
65	70	75
65 Asn Met Thr Gly Leu Leu His Leu Ser Leu Ser Arg Asn Thr Ile Arg		
85	90	95
His Val Ala Ala Gly Ala Phe Ala Asp Leu Arg Ala Leu Arg Ala Leu		
100	105	110
His Leu Asp Gly Asn Arg Leu Thr Ser Leu Gly Glu Gly Gln Leu Arg		
115	120	125

Gly Leu Val Asn Leu Arg His Leu Ile Leu Ser Asn Asn Gln Leu Ala
 130 135 140
 Ala Leu Ala Ala Gly Ala Leu Asp Asp Cys Ala Glu Thr Leu Glu Asp
 145 150 155 160
 Leu Asp Leu Ser Tyr Asn Asn Leu Glu Gln Leu Pro Trp Glu Ala Leu
 165 170 175
 Gly Arg Leu Gly Asn Val Asn Thr Leu Gly Leu Asp His Asn Leu Leu
 180 185 190
 Ala Ser Val Pro Ala Gly Ala Phe Ser Arg Leu His Lys Leu Ala Arg
 195 200 205
 Leu Asp Met Thr Ser Asn Arg Leu Thr Thr Ile Pro Pro Asp Pro Leu
 210 215 220
 Phe Ser Arg Leu Pro Leu Leu Ala Arg Pro Arg Gly Ser Pro Ala Ser
 225 230 235 240
 Ala Leu Val Leu Ala Phe Gly Gly Asn Pro Leu His Cys Asn Cys Glu
 245 250 255
 Leu Val Trp Leu Arg Arg Leu Ala Arg Glu Asp Asp Leu Glu Ala Cys
 260 265 270
 Ala Ser Pro Pro Ala Leu Gly Gly Arg Tyr Phe Trp Ala Val Gly Glu
 275 280 285
 Glu Glu Phe Val Cys Glu Pro Pro Val Val Thr His Arg Ser Pro Pro
 290 295 300
 Leu Ala Val Pro Ala Gly Arg Pro Ala Ala Leu Arg Cys Arg Ala Val
 305 310 315 320
 Gly Asp Pro Glu Pro Arg Val Arg Trp Val Ser Pro Gln Gly Arg Leu
 325 330 335
 Leu Gly Asn Ser Ser Arg Ala Arg Ala Phe Pro Asn Gly Thr Leu Glu
 340 345 350
 Leu Leu Val Thr Glu Pro Gly Asp Gly Gly Ile Phe Thr Cys Ile Ala
 355 360 365
 Ala Asn Ala Ala Gly Glu Ala Thr Ala Ala Val Glu Leu Thr Val Gly
 370 375 380
 Pro Pro Pro Pro Gln Leu Ala Asn Ser Thr Ser Cys Asp Pro Pro
 385 390 395 400
 Arg Asp Gly Asp Pro Asp Ala Leu Thr Pro Pro Ser Ala Ala Ser Ala
 405 410 415
 Ser Ala Lys Val Ala Asp Thr Gly Pro Pro Thr Asp Arg Gly Val Gln
 420 425 430
 Val Thr Glu His Gly Ala Thr Ala Ala Leu Val Gln Trp Pro Asp Gln
 435 440 445
 Arg Pro Ile Pro Gly Ile Arg Met Tyr Gln Ile Gln Tyr Asn Ser Ser
 450 455 460

Ala Asp Asp Ile Leu Val Tyr Arg Met Ile Pro Ala Glu Ser Arg Ser
 465 470 475 480
 Phe Leu Leu Thr Asp Leu Ala Ser Gly Arg Thr Tyr Asp Leu Cys Val
 485 490 495
 Leu Ala Val Tyr Glu Asp Ser Ala Thr Gly Leu Thr Ala Thr Arg Pro
 500 505 510
 Val Gly Cys Ala Arg Phe Ser Thr Glu Pro Ala Leu Arg Pro Cys Gly
 515 520 525
 Ala Pro His Ala Pro Phe Leu Gly Gly Thr Met Ile Ile Ala Leu Gly
 530 535 540
 Gly Val Ile Val Ala Ser Val Leu Val Phe Ile Phe Val Leu Leu Met
 545 550 555 560
 Arg Tyr Lys Val His Gly Gly Gln Pro Pro Gly Lys Ala Lys Ile Pro
 565 570 575
 Ala Pro Val Ser Ser Val Cys Ser Gln Thr Asn Gly Ala Leu Gly Pro
 580 585 590
 Thr Pro Thr Pro Ala Pro Pro Ala Pro Glu Pro Ala Ala Leu Arg Ala
 595 600 605
 His Thr Val Val Gln Leu Asp Cys Glu Pro Trp Gly Pro Gly His Glu
 610 615 620
 Pro Val Gly Pro
 625

<210> 46
 <211> 845
 <212> PRT
 <213> Homo sapiens

<400> 46
 Met Leu Ser Gly Val Trp Phe Leu Ser Val Leu Thr Val Ala Gly Ile
 1 5 10 15
 Leu Gln Thr Glu Ser Arg Lys Thr Ala Lys Asp Ile Cys Lys Ile Arg
 20 25 30
 Cys Leu Cys Glu Glu Lys Glu Asn Val Leu Asn Ile Asn Cys Glu Asn
 35 40 45
 Lys Gly Phe Thr Thr Val Ser Leu Leu Gln Pro Pro Gln Tyr Arg Ile
 50 55 60
 Tyr Gln Leu Phe Leu Asn Gly Asn Leu Leu Thr Arg Leu Tyr Pro Asn
 65 70 75 80
 Glu Phe Val Asn Tyr Ser Asn Ala Val Thr Leu His Leu Gly Asn Asn
 85 90 95
 Gly Leu Gln Glu Ile Arg Thr Gly Ala Phe Ser Gly Leu Lys Thr Leu

100	105	110
Lys Arg Leu His Leu Asn Asn Asn Lys	Leu Glu Ile	Leu Arg Glu Asp
115	120	125
Thr Phe Leu Gly Leu Glu Ser Leu Glu Tyr	Leu Gln Ala Asp Tyr Asn	
130	135	140
Tyr Ile Ser Ala Ile Glu Ala Gly Ala	Phe Ser Lys Leu Asn Lys	Leu
145	150	155
Lys Val Leu Ile Leu Asn Asp Asn Leu	Leu Ser Leu Pro Ser Asn	
165	170	175
Val Phe Arg Phe Val Leu Leu Thr His	Leu Asp Leu Arg Gly Asn Arg	
180	185	190
Leu Lys Val Met Pro Phe Ala Gly Val	Leu Glu His Ile Gly Gly Ile	
195	200	205
Met Glu Ile Gln Leu Glu Glu Asn Pro	Trp Asn Cys Thr Cys Asp	Leu
210	215	220
Leu Pro Leu Lys Ala Trp Leu Asp Thr	Ile Thr Val Phe Val Gly Glu	
225	230	235
Ile Val Cys Glu Thr Pro Phe Arg Leu	His Gly Lys Asp Val Thr Gln	
245	250	255
Leu Thr Arg Gln Asp Leu Cys Pro Arg	Lys Ser Ala Ser Asp Ser	Ser
260	265	270
Gln Arg Gly Ser His Ala Asp Thr His	Val Gln Arg Leu Ser Pro Thr	
275	280	285
Met Asn Pro Ala Leu Asn Pro Thr Arg	Ala Pro Lys Ala Ser Arg Pro	
290	295	300
Pro Lys Met Arg Asn Arg Pro Thr Pro	Arg Val Thr Val Ser Lys Asp	
305	310	315
Arg Gln Ser Phe Gly Pro Ile Met Val	Tyr Gln Thr Lys Ser Pro Val	
325	330	335
Pro Leu Thr Cys Pro Ser Ser Cys Val	Cys Thr Ser Gln Ser Ser Asp	
340	345	350
Asn Gly Leu Asn Val Asn Cys Gln	Glu Arg Lys Phe Thr Asn Ile Ser	
355	360	365
Asp Leu Gln Pro Lys Pro Thr Ser Pro	Lys Lys Leu Tyr Leu Thr Gly	
370	375	380
Asn Tyr Leu Gln Thr Val Tyr Lys Asn	Asp Leu Leu Glu Tyr Ser Ser	
385	390	395
Leu Asp Leu Leu His Leu Gly Asn Asn Arg	Ile Ala Val Ile Gln Glu	
405	410	415
Gly Ala Phe Thr Asn Leu Thr Ser Leu	Arg Arg Leu Tyr Leu Asn Gly	
420	425	430
Asn Tyr Leu Glu Val Leu Tyr Pro Ser	Met Phe Asp Gly Leu Gln Ser	

435	440	445
Leu Gln Tyr Leu Tyr Leu Glu Tyr Asn Val Ile Lys Glu Ile Lys Pro		
450	455	460
Leu Thr Phe Asp Ala Leu Ile Asn Leu Gln Leu Leu Phe Leu Asn Asn		
465	470	475
Asn Leu Leu Arg Ser Leu Pro Asp Asn Ile Phe Gly Gly Thr Ala Leu		
485	490	495
Thr Arg Leu Asn Leu Arg Asn Asn His Phe Ser His Leu Pro Val Lys		
500	505	510
Gly Val Leu Asp Gln Leu Pro Ala Phe Ile Gln Ile Asp Leu Gln Glu		
515	520	525
Asn Pro Trp Asp Cys Thr Cys Asp Ile Met Gly Leu Lys Asp Trp Thr		
530	535	540
Glu His Ala Asn Ser Pro Val Ile Ile Asn Glu Val Thr Cys Glu Ser		
545	550	555
Pro Ala Lys His Ala Gly Glu Ile Leu Lys Phe Leu Gly Arg Glu Ala		
565	570	575
Ile Cys Pro Asp Ser Pro Asn Leu Ser Asp Gly Thr Val Leu Ser Met		
580	585	590
Asn His Asn Thr Asp Thr Pro Arg Ser Leu Ser Val Ser Pro Ser Ser		
595	600	605
Tyr Pro Glu Leu His Thr Glu Val Pro Leu Ser Val Leu Ile Leu Gly		
610	615	620
Leu Leu Val Val Phe Ile Leu Ser Val Cys Phe Gly Ala Gly Leu Phe		
625	630	635
Val Phe Val Leu Lys Arg Arg Lys Gly Val Pro Ser Val Pro Arg Asn		
645	650	655
Thr Asn Asn Leu Asp Val Ser Ser Phe Gln Leu Gln Tyr Gly Ser Tyr		
660	665	670
Asn Thr Glu Thr His Asp Lys Thr Asp Gly His Val Tyr Asn Tyr Ile		
675	680	685
Pro Pro Pro Val Gly Gln Met Cys Gln Asn Pro Ile Tyr Met Gln Lys		
690	695	700
Glu Gly Asp Pro Val Ala Tyr Tyr Arg Asn Leu Gln Glu Phe Ser Tyr		
705	710	715
720		
Ser Asn Leu Glu Glu Lys Lys Glu Glu Pro Ala Thr Pro Ala Tyr Thr		
725	730	735
Ile Ser Ala Thr Glu Leu Leu Glu Lys Gln Ala Thr Pro Arg Glu Pro		
740	745	750
Glu Leu Leu Tyr Gln Asn Ile Ala Glu Arg Val Lys Glu Leu Pro Ser		
755	760	765
Ala Gly Leu Val His Tyr Asn Phe Cys Thr Leu Pro Lys Arg Gln Phe		

770	775	780
Ala Pro Ser Tyr Glu Ser Arg Arg Gln Asn Gln Asp Arg Ile Asn Lys		
785	790	795
Thr Val Leu Tyr Gly Thr Pro Arg Lys Cys Phe Val Gly Gln Ser Lys		
805	810	815
Pro Asn His Pro Leu Leu Gln Ala Lys Pro Gln Ser Glu Pro Asp Tyr		
820	825	830
Leu Glu Val Leu Glu Lys Gln Thr Ala Ile Ser Gln Leu		
835	840	845

<210> 47
 <211> 349
 <212> PRT
 <213> Homo sapiens

<400> 47		
Met Gly Ile Thr Cys Trp Ile Ala Leu Tyr Ala Val Glu Ala Leu Pro		
1	5	10
Thr Cys Pro Phe Ser Cys Lys Cys Asp Ser Arg Ser Leu Glu Val Asp		
20	25	30
Cys Ser Gly Leu Gly Leu Thr Thr Val Pro Pro Asp Val Pro Ala Ala		
35	40	45
Thr Arg Thr Leu Leu Leu Asn Asn Lys Leu Ser Ala Leu Pro Ser		
50	55	60
Trp Ala Phe Ala Asn Leu Ser Ser Leu Gln Arg Leu Asp Leu Ser Asn		
65	70	75
Asn Phe Leu Asp Arg Leu Pro Arg Ser Ile Phe Gly Asp Leu Thr Asn		
85	90	95
Leu Thr Glu Leu Gln Leu Arg Asn Asn Ser Ile Arg Thr Leu Asp Arg		
100	105	110
Asp Leu Leu Arg His Ser Pro Leu Leu Arg His Leu Asp Leu Ser Ile		
115	120	125
Asn Gly Leu Ala Gln Leu Pro Pro Gly Leu Phe Asp Gly Leu Leu Ala		
130	135	140
Leu Arg Ser Leu Ser Leu Arg Ser Asn Arg Leu Gln Asn Leu Asp Arg		
145	150	155
Leu Thr Phe Glu Pro Leu Ala Asn Leu Gln Leu Leu Gln Val Gly Asp		
165	170	175
Asn Pro Trp Glu Cys Asp Cys Asn Leu Arg Glu Phe Lys His Trp Met		
180	185	190
Glu Trp Phe Ser Tyr Arg Gly Gly Arg Leu Asp Gln Leu Ala Cys Thr		
195	200	205

Leu Pro Lys Glu Leu Arg Gly Lys Asp Met Arg Met Val Pro Met Glu
 210 215 220
 Met Phe Asn Tyr Cys Ser Gln Leu Glu Asp Glu Asn Ser Ser Ala Gly
 225 230 235 240
 Leu Asp Ile Pro Gly Pro Pro Cys Thr Lys Ala Ser Pro Glu Pro Ala
 245 250 255
 Lys Pro Lys Pro Gly Ala Glu Pro Glu Pro Ser Thr Ala Cys
 260 265 270
 Pro Gln Lys Gln Arg His Arg Pro Ala Ser Val Arg Arg Ala Met Gly
 275 280 285
 Thr Val Ile Ile Ala Gly Val Val Cys Gly Val Val Cys Ile Met Met
 290 295 300
 Val Val Ala Ala Ala Tyr Gly Cys Ile Tyr Ala Ser Leu Met Ala Lys
 305 310 315 320
 Tyr His Arg Glu Leu Lys Lys Arg Gln Pro Leu Met Gly Asp Pro Glu
 325 330 335
 Gly Glu His Glu Asp Gln Lys Gln Ile Ser Ser Val Ala
 340 345

<210> 48
 <211> 738
 <212> PRT
 <213> Homo sapiens

<400> 48
 Met Gly Met Thr Val Ile Lys Gln Ile Thr Asp Asp Leu Phe Val Trp
 1 5 10 15
 Asn Val Leu Asn Arg Glu Glu Val Asn Ile Ile Cys Cys Glu Lys Val
 20 25 30
 Glu Gln Asp Ala Ala Arg Gly Ile Ile His Met Ile Leu Lys Lys Gly
 35 40 45
 Ser Glu Ser Cys Asn Leu Phe Leu Lys Ser Leu Lys Glu Trp Asn Tyr
 50 55 60
 Pro Leu Phe Gln Asp Leu Asn Gly Gln Ser Leu Phe His Gln Thr Ser
 65 70 75 80
 Glu Gly Asp Leu Asp Asp Leu Ala Gln Asp Leu Lys Asp Leu Tyr His
 85 90 95
 Thr Pro Ser Phe Leu Asn Phe Tyr Pro Leu Gly Glu Asp Ile Asp Ile
 100 105 110
 Ile Phe Asn Leu Lys Ser Thr Phe Thr Glu Pro Val Leu Trp Arg Lys
 115 120 125
 Asp Gln His His His Arg Val Glu Gln Leu Thr Leu Asn Gly Leu Leu

130	135	140
Gln Ala Leu Gln Ser Pro Cys Ile Ile Glu Gly Glu Ser Gly Lys Gly		
145	150	155
Lys Ser Thr Leu Leu Gln Arg Ile Ala Met Leu Trp Gly Ser Gly Lys		
165	170	175
Cys Lys Ala Leu Thr Lys Phe Lys Phe Val Phe Phe Leu Arg Leu Ser		
180	185	190
Arg Ala Gln Gly Gly Leu Phe Glu Thr Leu Cys Asp Gln Leu Leu Asp		
195	200	205
Ile Pro Gly Thr Ile Arg Lys Gln Thr Phe Met Ala Met Leu Leu Lys		
210	215	220
Leu Arg Gln Arg Val Leu Phe Leu Leu Asp Gly Tyr Asn Glu Phe Lys		
225	230	235
Pro Gln Asn Cys Pro Glu Ile Glu Ala Leu Ile Lys Glu Asn His Arg		
245	250	255
Phe Lys Asn Met Val Ile Val Thr Thr Thr Glu Cys Leu Arg His		
260	265	270
Ile Arg Gln Phe Gly Ala Leu Thr Ala Glu Val Gly Asp Met Thr Glu		
275	280	285
Asp Ser Ala Gln Ala Leu Ile Arg Glu Val Leu Ile Lys Glu Leu Ala		
290	295	300
Glu Gly Leu Leu Leu Gln Ile Gln Lys Ser Arg Cys Leu Arg Asn Leu		
305	310	315
Met Lys Thr Pro Leu Phe Val Val Ile Thr Cys Ala Ile Gln Met Gly		
325	330	335
Glu Ser Glu Phe His Ser His Thr Gln Thr Thr Leu Phe His Thr Phe		
340	345	350
Tyr Asp Leu Leu Ile Gln Lys Asn Lys His Lys His Lys Gly Val Ala		
355	360	365
Ala Ser Asp Phe Ile Arg Ser Leu Asp His Cys Gly Asp Leu Ala Leu		
370	375	380
Glu Gly Val Phe Ser His Lys Phe Asp Phe Glu Leu Gln Asp Val Ser		
385	390	395
Ser Val Asn Glu Asp Val Leu Leu Thr Thr Gly Leu Leu Cys Lys Tyr		
405	410	415
Thr Ala Gln Arg Phe Lys Pro Lys Tyr Lys Phe Phe His Lys Ser Phe		
420	425	430
Gln Glu Tyr Thr Ala Gly Arg Arg Leu Ser Ser Leu Leu Thr Ser His		
435	440	445
Glu Pro Glu Glu Val Thr Lys Gly Asn Gly Tyr Leu Gln Lys Met Val		
450	455	460
Ser Ile Ser Asp Ile Thr Ser Thr Tyr Ser Ser Leu Leu Arg Tyr Thr		

465	470	475	480
Cys	Gly	Ser	Ser
Val	Glu	Ala	Thr
Arg	Ala	Val	Met
Met	Lys	His	Leu
Lys	Leu	Ala	
485		490	495
Ala	Val	Tyr	Gln
His	Gly	Cys	Leu
Leu	Gly	Leu	Ser
Ile	Ala	Lys	Arg
500		505	510
Pro	Leu	Trp	Arg
Gln	Glu	Ser	Leu
Gln	Ser	Val	Lys
Asn	Thr	Thr	Glu
515		520	525
Gln	Glu	Ile	Leu
Lys	Ala	Ile	Asn
Ile	Asn	Ile	Ser
Phe	Val	Glu	Cys
530		535	540
Ile	His	Leu	Tyr
Gln	Glu	Ser	Thr
Ser	Lys	Ser	Ala
Ala	Leu	Ser	Gln
Glu			
545		550	555
560			
Phe	Glu	Ala	Phe
Phe	Gln	Gly	Lys
Ser	Leu	Tyr	Ile
Ile	Asn	Ser	Gly
565		570	575
Ile	Pro	Asp	Tyr
Leu	Phe	Asp	Phe
Phe	Glu	His	Leu
His	Leu	Pro	Asn
Asn	Cys	Ala	
580		585	590
Ser	Ala	Leu	Asp
Phe	Ile	Lys	Leu
Asp	Phe	Tyr	Gly
Gly	Ala	Met	Ala
595		600	605
Ser	Trp	Glu	Lys
Ala	Ala	Glu	Asp
Ala	Glu	Thr	Tyr
Gly	Gly	Ile	His
Met	Glu	Glu	
610		615	620
Ala	Pro	Glu	Thr
Tyr	Ile	Pro	Ser
Arg	Ala	Val	Ser
Leu	Phe	Phe	Asn
625		630	635
640			
Trp	Lys	Gln	Glu
Phe	Arg	Thr	Leu
Glu	Val	Gly	Arg
Val	Thr	Leu	Asp
Thr	Leu	Arg	Phe
645		650	655
Lys	Leu	Asn	Lys
Gln	Asp	Ile	Arg
Ile	Tyr	Leu	Gly
Gly	Lys	Ile	Phe
660		665	670
Ala	Thr	Ser	Leu
Arg	Leu	Gln	Ile
Ile	Lys	Arg	Cys
675		680	685
Ser	Leu	Ser	Leu
Leu	Val	Leu	Ser
Thr	Cys	Lys	Asn
Ile	Tyr	Ser	Leu
690		695	700
Val	Glu	Ala	Ser
Pro	Leu	Thr	Ile
Glu	Asp	Glu	Arg
Arg	His	Ile	Thr
705		710	715
720			
Val	Thr	Asn	Leu
Lys	Thr	Leu	Ser
Ile	His	Asp	Leu
Gln	Asn	Gln	Arg
725		730	735
Leu	Pro		

<210> 49
 <211> 1070
 <212> PRT
 <213> Homo sapiens

<400> 49

Met Tyr Lys Ser Leu Asn Ile Asp Glu Cys Asp Leu His Ala Trp Leu
1 5 10 15
Asp Leu Pro Ala Glu Lys Pro Leu Gly Val Val Asn Arg Val Cys Trp
20 25 30
Gly Phe Ile Arg Phe Lys Gly Tyr Met Tyr Pro Leu Asp Tyr Leu Asn
35 40 45
Phe Ile Lys Asp Asn Ser Arg Ala Leu Ile Gln Arg Met Gly Met Thr
50 55 60
Val Ile Lys Gln Ile Thr Asp Asp Leu Phe Val Trp Asn Val Leu Asn
65 70 75 80
Arg Glu Glu Val Asn Ile Ile Cys Cys Glu Lys Val Glu Gln Asp Ala
85 90 95
Ala Arg Gly Ile Ile His Met Ile Leu Lys Lys Gly Ser Glu Ser Cys
100 105 110
Asn Leu Phe Leu Lys Ser Leu Lys Glu Trp Asn Tyr Pro Leu Phe Gln
115 120 125
Asp Leu Asn Gly Gln Ser Leu Phe His Gln Thr Ser Glu Gly Asp Leu
130 135 140
Asp Asp Leu Ala Gln Asp Leu Lys Asp Leu Tyr His Thr Pro Ser Phe
145 150 155 160
Leu Asn Phe Tyr Pro Leu Gly Glu Asp Ile Asp Ile Ile Phe Asn Leu
165 170 175
Lys Ser Thr Phe Thr Glu Pro Val Leu Trp Arg Lys Asp Gln His His
180 185 190
His Arg Val Glu Gln Leu Thr Leu Asn Gly Leu Leu Gln Ala Leu Gln
195 200 205
Ser Pro Cys Ile Ile Glu Gly Glu Ser Gly Lys Ser Thr Leu
210 215 220
Leu Gln Arg Ile Ala Met Leu Trp Gly Ser Gly Lys Cys Lys Ala Leu
225 230 235 240
Thr Lys Phe Lys Phe Val Phe Leu Arg Leu Ser Arg Ala Gln Gly
245 250 255
Gly Leu Phe Glu Thr Leu Cys Asp Gln Leu Leu Asp Ile Pro Gly Thr
260 265 270
Ile Arg Lys Gln Thr Phe Met Ala Met Leu Leu Lys Leu Arg Gln Arg
275 280 285
Val Leu Phe Leu Leu Asp Gly Tyr Asn Glu Phe Lys Pro Gln Asn Cys
290 295 300
Pro Glu Ile Glu Ala Leu Ile Lys Glu Asn His Arg Phe Lys Asn Met
305 310 315 320
Val Ile Val Thr Thr Thr Glu Cys Leu Arg His Ile Arg Gln Phe
325 330 335

Gly Ala Leu Thr Ala Glu Val Gly Asp Met Thr Glu Asp Ser Ala Gln
340 345 350
Ala Leu Ile Arg Glu Val Leu Ile Lys Glu Leu Ala Glu Gly Leu Leu
355 360 365
Leu Gln Ile Gln Lys Ser Arg Cys Leu Arg Asn Leu Met Lys Thr Pro
370 375 380
Leu Phe Val Val Ile Thr Cys Ala Ile Gln Met Gly Glu Ser Glu Phe
385 390 395 400
His Ser His Thr Gln Thr Thr Leu Phe His Thr Phe Tyr Asp Leu Leu
405 410 415
Ile Gln Lys Asn Lys His Lys His Lys Gly Val Ala Ala Ser Asp Phe
420 425 430
Ile Arg Ser Leu Asp His Cys Gly Asp Leu Ala Leu Glu Gly Val Phe
435 440 445
Ser His Lys Phe Asp Phe Glu Leu Gln Asp Val Ser Ser Val Asn Glu
450 455 460
Asp Val Leu Leu Thr Thr Gly Leu Leu Cys Lys Tyr Thr Ala Gln Arg
465 470 475 480
Phe Lys Pro Lys Tyr Lys Phe Phe His Lys Ser Phe Gln Glu Tyr Thr
485 490 495
Ala Gly Arg Arg Leu Ser Ser Leu Leu Thr Ser His Glu Pro Glu Glu
500 505 510
Val Thr Lys Gly Asn Gly Tyr Leu Gln Lys Met Val Ser Ile Ser Asp
515 520 525
Ile Thr Ser Thr Tyr Ser Ser Leu Leu Arg Tyr Thr Cys Gly Ser Ser
530 535 540
Val Glu Ala Thr Arg Ala Val Met Lys His Leu Ala Ala Val Tyr Gln
545 550 555 560
His Gly Cys Leu Leu Gly Leu Ser Ile Ala Lys Arg Pro Leu Trp Arg
565 570 575
Gln Glu Ser Leu Gln Ser Val Lys Asn Thr Thr Glu Gln Glu Ile Leu
580 585 590
Lys Ala Ile Asn Ile Asn Ser Phe Val Glu Cys Gly Ile His Leu Tyr
595 600 605
Gln Glu Ser Thr Ser Lys Ser Ala Leu Ser Gln Glu Phe Glu Ala Phe
610 615 620
Phe Gln Gly Lys Ser Leu Tyr Ile Asn Ser Gly Asn Ile Pro Asp Tyr
625 630 635 640
Leu Phe Asp Phe Phe Glu His Leu Pro Asn Cys Ala Ser Ala Leu Asp
645 650 655
Phe Ile Lys Leu Asp Phe Tyr Gly Gly Ala Met Ala Ser Trp Glu Lys
660 665 670

Ala Ala Glu Asp Thr Gly Gly Ile His Met Glu Glu Ala Pro Glu Thr
 675 680 685
 Tyr Ile Pro Ser Arg Ala Val Ser Leu Phe Phe Asn Trp Lys Gln Glu
 690 695 700
 Phe Arg Thr Leu Glu Val Thr Leu Arg Asp Phe Ser Lys Leu Asn Lys
 705 710 715 720
 Gln Asp Ile Arg Tyr Leu Gly Lys Ile Phe Ser Ser Ala Thr Ser Leu
 725 730 735
 Arg Leu Gln Ile Lys Arg Cys Ala Gly Val Ala Gly Ser Leu Ser Leu
 740 745 750
 Val Leu Ser Thr Cys Lys Asn Ile Tyr Ser Leu Met Val Glu Ala Ser
 755 760 765
 Pro Leu Thr Ile Glu Asp Glu Arg His Ile Thr Ser Val Thr Asn Leu
 770 775 780
 Lys Thr Leu Ser Ile His Asp Leu Gln Asn Gln Arg Leu Pro Gly Gly
 785 790 795 800
 Leu Thr Asp Ser Leu Gly Asn Leu Lys Asn Leu Thr Lys Leu Ile Met
 805 810 815
 Asp Asn Ile Lys Met Asn Glu Glu Asp Ala Ile Lys Leu Ala Glu Gly
 820 825 830
 Leu Lys Asn Leu Lys Lys Met Cys Leu Phe His Leu Thr His Leu Ser
 835 840 845
 Asp Ile Gly Glu Gly Met Asp Tyr Ile Val Lys Ser Leu Ser Ser Glu
 850 855 860
 Pro Cys Asp Leu Glu Glu Ile Gln Leu Val Ser Cys Cys Leu Ser Ala
 865 870 875 880
 Asn Ala Val Lys Ile Leu Ala Gln Asn Leu His Asn Leu Val Lys Leu
 885 890 895
 Ser Ile Leu Asp Leu Ser Glu Asn Tyr Leu Glu Lys Asp Gly Asn Glu
 900 905 910
 Ala Leu His Glu Leu Ile Asp Arg Met Asn Val Leu Glu Gln Leu Thr
 915 920 925
 Ala Leu Met Leu Pro Trp Gly Cys Asp Val Gln Gly Ser Leu Ser Ser
 930 935 940
 Leu Leu Lys His Leu Glu Glu Val Pro Gln Leu Val Lys Leu Gly Leu
 945 950 955 960
 Lys Asn Trp Arg Leu Thr Asp Thr Glu Ile Arg Ile Leu Gly Ala Phe
 965 970 975
 Phe Gly Lys Asn Pro Leu Lys Asn Phe Gln Gln Leu Asn Leu Ala Gly
 980 985 990
 Asn Arg Val Ser Ser Asp Gly Trp Leu Ala Phe Met Gly Val Phe Glu
 995 1000 1005

Asn Leu Lys Gln Leu Val Phe Phe Asp Phe Ser Thr Lys Glu Phe Leu
 1010 1015 1020
 Pro Asp Pro Ala Leu Val Arg Lys Leu Ser Gln Val Leu Ser Lys Leu
 1025 1030 1035 104
 Thr Phe Leu Gln Glu Ala Arg Leu Val Gly Trp Gln Phe Asp Asp Asp
 1045 1050 1055
 Asp Leu Ser Val Ile Thr Gly Ala Phe Lys Leu Val Thr Ala
 1060 1065 1070

 <210> 50
 <211> 487
 <212> PRT
 <213> Homo sapiens

<400> 50
 Met Pro Pro Leu Pro Gln Trp Ser Phe Pro Arg Pro Asp His Cys His
 1 5 10 15
 Val Thr Phe Val Thr Leu Lys Cys Asp Ser Ser Lys Lys Arg Arg Arg
 20 25 30
 Gly Arg Lys Ser Pro Ser Lys Glu Val Ser His Ile Thr Ala Glu Phe
 35 40 45
 Glu Ile Glu Thr Lys Met Glu Glu Ala Ser Asp Thr Cys Glu Ala Asp
 50 55 60
 Cys Leu Arg Lys Arg Ala Glu Gln Ser Leu Gln Ala Ala Ile Lys Thr
 65 70 75 80
 Leu Arg Lys Ser Ile Gly Arg Gln Gln Phe Tyr Val Gln Val Ser Gly
 85 90 95
 Thr Glu Tyr Glu Val Ala Gln Arg Pro Ala Lys Ala Leu Glu Gly Gln
 100 105 110
 Gly Ala Cys Gly Ala Gly Gln Val Leu Gln Asp Ser Lys Cys Val Ala
 115 120 125
 Cys Gly Pro Gly Thr His Phe Gly Gly Glu Leu Gly Gln Cys Val Ser
 130 135 140
 Cys Met Pro Gly Thr Tyr Gln Asp Met Glu Gly Gln Leu Ser Cys Thr
 145 150 155 160
 Pro Cys Pro Ser Ser Asp Gly Leu Gly Leu Pro Gly Ala Arg Asn Val
 165 170 175
 Ser Glu Cys Gly Gly Lys Cys Gly Pro Arg Arg Gly Phe Phe Ser
 180 185 190
 Ala Asp Gly Phe Lys Pro Cys Gln Ala Cys Pro Val Gly Thr Tyr Gln
 195 200 205
 Pro Glu Pro Gly Arg Thr Gly Cys Phe Pro Cys Gly Gly Leu Leu

210	215	220
Thr Lys His Glu Gly Thr Thr Ser Phe Gln Asp Cys Glu Ala Lys Val		
225	230	235
His Cys Ser Pro Gly His His Tyr Asn Thr Thr Thr His Arg Cys Ile		240
245		250
Arg Cys Pro Val Gly Thr Tyr Gln Pro Glu Phe Gly Gln Asn His Cys		255
260	265	270
Ile Thr Cys Pro Gly Asn Thr Ser Thr Asp Phe Asp Gly Ser Thr Asn		
275	280	285
Val Thr His Cys Lys Asn Gln His Cys Gly Gly Glu Leu Gly Asp Tyr		
290	295	300
Thr Gly Tyr Ile Glu Ser Pro Asn Tyr Pro Gly Asp Tyr Pro Ala Asn		
305	310	315
Ala Glu Cys Val Trp His Ile Ala Pro Pro Pro Lys Arg Arg Ile Leu		320
325	330	335
Ile Val Val Pro Glu Ile Phe Leu Pro Ile Glu Asp Glu Cys Gly Asp		
340	345	350
Val Leu Val Met Arg Lys Ser Ala Ser Pro Thr Ser Ile Thr Thr Tyr		
355	360	365
Glu Thr Cys Gln Thr Tyr Glu Arg Pro Ile Ala Phe Thr Ser Arg Ser		
370	375	380
Arg Lys Leu Trp Ile Gln Phe Lys Ser Asn Glu Gly Asn Ser Gly Lys		
385	390	395
Gly Phe Gln Val Pro Tyr Val Thr Tyr Asp Glu Asp Tyr Gln Gln Leu		400
405	410	415
Ile Glu Asp Ile Val Arg Asp Gly Arg Leu Tyr Ala Ser Glu Asn His		
420	425	430
Gln Glu Ile Leu Lys Asp Lys Lys Leu Ile Lys Ala Leu Phe Asp Val		
435	440	445
Leu Ala His Pro Gln Asn Tyr Phe Lys Tyr Thr Ala Gln Glu Ser Lys		
450	455	460
Glu Met Phe Pro Arg Ser Phe Ile Lys Leu Leu Arg Ser Lys Val Ser		
465	470	475
Arg Phe Leu Arg Pro Tyr Lys		480
	485	

<210> 51
 <211> 965
 <212> PRT
 <213> Homo sapiens

<400> 51

Met Gly Ala Ala Ala Val Arg Trp His Leu Cys Val Leu Leu Ala Leu
 1 5 10 15
 Gly Thr Arg Gly Arg Leu Ala Gly Gly Ser Gly Leu Pro Gly Ser Val
 20 25 30
 Asp Val Asp Glu Cys Ser Glu Gly Thr Asp Asp Cys His Ile Asp Ala
 35 40 45
 Ile Cys Gln Asn Thr Pro Lys Ser Tyr Lys Cys Leu Cys Lys Pro Gly
 50 55 60
 Tyr Lys Gly Glu Gly Lys Gln Cys Glu Asp Ile Asp Glu Cys Glu Asn
 65 70 75 80
 Asp Tyr Tyr Asn Gly Gly Cys Val His Glu Cys Ile Asn Ile Pro Gly
 85 90 95
 Asn Tyr Arg Cys Thr Cys Phe Asp Gly Phe Met Leu Ala His Asp Gly
 100 105 110
 His Asn Cys Leu Asp Val Asp Glu Cys Gln Asp Asn Asn Gly Gly Cys
 115 120 125
 Gln Gln Ile Cys Val Asn Ala Met Gly Ser Tyr Glu Cys Gln Cys His
 130 135 140
 Ser Gly Phe Phe Leu Ser Asp Asn Gln His Thr Cys Ile His Arg Ser
 145 150 155 160
 Asn Glu Gly Met Asn Cys Met Asn Lys Asp His Gly Cys Ala His Ile
 165 170 175
 Cys Arg Glu Thr Pro Lys Gly Gly Val Ala Cys Asp Cys Arg Pro Gly
 180 185 190
 Phe Asp Leu Ala Gln Asn Gln Lys Asp Cys Thr Leu Thr Cys Asn Tyr
 195 200 205
 Gly Asn Gly Gly Cys Gln His Ser Cys Glu Asp Thr Asp Thr Gly Pro
 210 215 220
 Thr Cys Gly Cys His Gln Lys Tyr Ala Leu His Ser Asp Gly Arg Thr
 225 230 235 240
 Cys Ile Glu Thr Cys Ala Val Asn Asn Gly Gly Cys Asp Arg Thr Cys
 245 250 255
 Lys Asp Thr Ala Thr Gly Val Arg Cys Ser Cys Pro Val Gly Phe Thr
 260 265 270
 Leu Gln Pro Asp Gly Lys Thr Cys Lys Asp Ile Asn Glu Cys Leu Val
 275 280 285
 Asn Asn Gly Gly Cys Asp His Phe Cys Arg Asn Thr Val Gly Ser Phe
 290 295 300
 Glu Cys Gly Cys Arg Lys Gly Tyr Lys Leu Leu Thr Asp Glu Arg Thr
 305 310 315 320
 Cys Gln Asp Ile Asp Glu Cys Ser Phe Glu Arg Thr Cys Asp His Ile
 325 330 335

Cys Ile Asn Ser Pro Gly Ser Phe Gln Cys Leu Cys His Arg Gly Tyr
 340 345 350
 Ile Leu Tyr Gly Thr Thr His Cys Gly Asp Val Asp Glu Cys Ser Met
 355 360 365
 Ser Asn Gly Ser Cys Asp Gln Gly Cys Val Asn Thr Lys Gly Ser Tyr
 370 375 380
 Glu Cys Val Cys Pro Pro Gly Arg Arg Leu His Trp Asn Gly Lys Asp
 385 390 395 400
 Cys Val Glu Thr Gly Lys Cys Leu Ser Arg Ala Lys Thr Ser Pro Arg
 405 410 415
 Ala Gln Leu Ser Cys Ser Lys Ala Gly Gly Val Glu Ser Cys Phe Leu
 420 425 430
 Ser Cys Pro Ala His Thr Leu Phe Val Pro Asp Ser Glu Asn Ser Tyr
 435 440 445
 Val Leu Ser Cys Gly Val Pro Gly Pro Gln Gly Lys Ala Leu Gln Lys
 450 455 460
 Arg Asn Gly Thr Ser Ser Gly Leu Gly Pro Ser Cys Ser Asp Ala Pro
 465 470 475 480
 Thr Thr Pro Ile Lys Gln Lys Ala Arg Phe Lys Ile Arg Asp Ala Lys
 485 490 495
 Cys His Leu Arg Pro His Ser Gln Ala Arg Ala Lys Glu Thr Ala Arg
 500 505 510
 Gln Pro Leu Leu Asp His Cys His Val Thr Phe Val Thr Leu Lys Cys
 515 520 525
 Asp Ser Ser Lys Lys Arg Arg Gly Arg Lys Ser Pro Ser Lys Glu
 530 535 540
 Val Ser His Ile Thr Ala Glu Phe Glu Ile Glu Thr Lys Met Glu Glu
 545 550 555 560
 Ala Ser Asp Thr Cys Glu Ala Asp Cys Leu Arg Lys Arg Ala Glu Gln
 565 570 575
 Ser Leu Gln Ala Ala Ile Lys Thr Leu Arg Lys Ser Ile Gly Arg Gln
 580 585 590
 Gln Phe Tyr Val Gln Val Ser Gly Thr Glu Tyr Glu Val Ala Gln Arg
 595 600 605
 Pro Ala Lys Ala Leu Glu Gly Gln Gly Ala Cys Gly Ala Gly Gln Val
 610 615 620
 Leu Gln Asp Ser Lys Cys Val Ala Cys Gly Pro Gly Thr His Phe Gly
 625 630 635 640
 Gly Glu Leu Gly Gln Cys Val Ser Cys Met Pro Gly Thr Tyr Gln Asp
 645 650 655
 Met Glu Gly Gln Leu Ser Cys Thr Pro Cys Pro Ser Ser Asp Gly Leu
 660 665 670

Gly Leu Pro Gly Ala Arg Asn Val Ser Glu Cys Gly Gly Gln Cys Ser
 675 680 685
 Pro Gly Phe Phe Ser Ala Asp Gly Phe Lys Pro Cys Gln Ala Cys Pro
 690 695 700
 Val Gly Thr Tyr Gln Pro Glu Pro Gly Arg Thr Gly Cys Phe Pro Cys
 705 710 715 720
 Gly Gly Gly Leu Leu Thr Lys His Glu Gly Thr Thr Ser Phe Gln Asp
 725 730 735
 Cys Glu Ala Lys Val His Cys Ser Pro Gly His His Tyr Asn Thr Thr
 740 745 750
 Thr His Arg Cys Ile Arg Cys Pro Val Gly Thr Tyr Gln Pro Glu Phe
 755 760 765
 Gly Gln Asn His Cys Ile Thr Cys Pro Gly Asn Thr Ser Thr Asp Phe
 770 775 780
 Asp Gly Ser Thr Asn Val Thr His Cys Lys Asn Gln His Cys Gly Gly
 785 790 795 800
 Glu Leu Gly Asp Tyr Thr Gly Tyr Ile Glu Ser Pro Asn Tyr Pro Gly
 805 810 815
 Asp Tyr Pro Ala Asn Ala Glu Cys Val Trp His Ile Ala Pro Pro Pro
 820 825 830
 Lys Arg Arg Ile Leu Ile Val Val Pro Glu Ile Phe Leu Pro Ile Glu
 835 840 845
 Asp Glu Cys Gly Asp Val Leu Val Met Arg Lys Ser Ala Ser Pro Thr
 850 855 860
 Ser Ile Thr Thr Tyr Glu Thr Cys Gln Thr Tyr Glu Arg Pro Ile Ala
 865 870 875 880
 Phe Thr Ser Arg Ser Arg Lys Leu Trp Ile Gln Phe Lys Ser Asn Glu
 885 890 895
 Gly Asn Ser Gly Lys Gly Phe Gln Val Pro Tyr Val Thr Tyr Asp Gly
 900 905 910
 Lys Ile His Cys Leu His Gly Pro Leu Cys Thr Ala Gln Ala Gly Pro
 915 920 925
 Trp Arg His Arg Asp Glu Ser His Val Pro Ala Pro Ser Gly Ser Cys
 930 935 940
 Asp Leu Ala Gly Thr Asp Leu Glu Ala Glu Arg Thr Leu Ser Gly Ala
 945 950 955 960
 Arg Ala Arg Gln Ala
 965

<210> 52

<211> 716

<212> PRT

<213> Homo sapiens

<400> 52

Met Ala Arg Met Ser Phe Val Ile Ala Ala Cys Gln Leu Val Leu Gly
 1 5 10 15
 Leu Leu Met Thr Ser Leu Thr Glu Ser Ser Ile Gln Asn Ser Glu Cys
 20 25 30
 Pro Gln Leu Cys Val Cys Glu Ile Arg Pro Trp Phe Thr Pro Gln Ser
 35 40 45
 Thr Tyr Arg Glu Ala Thr Thr Val Asp Cys Asn Asp Leu Arg Leu Thr
 50 55 60
 Arg Ile Pro Ser Asn Leu Ser Ser Asp Thr Gln Val Leu Leu Leu Gln
 65 70 75 80
 Ser Asn Asn Ile Ala Lys Thr Val Asp Glu Leu Gln Gln Leu Phe Asn
 85 90 95
 Leu Thr Glu Leu Asp Phe Ser Gln Asn Asn Phe Thr Asn Ile Lys Glu
 100 105 110
 Val Gly Leu Ala Asn Leu Thr Gln Leu Thr Thr Leu His Leu Glu Glu
 115 120 125
 Asn Gln Ile Thr Glu Met Thr Asp Tyr Cys Leu Gln Asp Leu Ser Asn
 130 135 140
 Leu Gln Glu Leu Tyr Ile Asn His Asn Gln Ile Ser Thr Ile Ser Ala
 145 150 155 160
 His Ala Phe Ala Gly Leu Lys Asn Leu Leu Arg Leu His Leu Asn Ser
 165 170 175
 Asn Lys Leu Lys Val Ile Asp Ser Arg Trp Phe Asp Ser Thr Pro Asn
 180 185 190
 Leu Glu Ile Leu Met Ile Gly Glu Asn Pro Val Ile Gly Ile Leu Asp
 195 200 205
 Met Asn Phe Lys Pro Leu Ala Asn Leu Arg Ser Leu Val Leu Ala Gly
 210 215 220
 Met Tyr Leu Thr Asp Ile Pro Gly Asn Ala Leu Val Gly Leu Asp Ser
 225 230 235 240
 Leu Glu Ser Leu Ser Phe Tyr Asp Asn Lys Leu Val Lys Val Pro Gln
 245 250 255
 Leu Ala Leu Gln Lys Val Pro Asn Leu Lys Phe Leu Asp Leu Asn Lys
 260 265 270
 Asn Pro Ile His Lys Ile Gln Glu Gly Asp Phe Lys Asn Met Leu Arg
 275 280 285
 Leu Lys Glu Leu Gly Ile Asn Asn Met Gly Glu Leu Val Ser Val Asp
 290 295 300
 Arg Tyr Ala Leu Asp Asn Leu Pro Glu Leu Thr Lys Leu Glu Ala Thr

305	310	315	320
Asn Asn Pro Lys Leu Ser Tyr Ile His Arg Leu Ala Phe Arg Ser Val			
325	330	335	
Pro Ala Leu Glu Ser Leu Met Leu Asn Asn Asn Ala Leu Asn Ala Ile			
340	345	350	
Tyr Gln Lys Thr Val Glu Ser Leu Pro Asn Leu Arg Glu Ile Ser Ile			
355	360	365	
His Ser Asn Pro Leu Arg Cys Asp Cys Val Ile His Trp Ile Asn Ser			
370	375	380	
Asn Lys Thr Asn Ile Arg Phe Met Glu Pro Leu Ser Met Phe Cys Ala			
385	390	395	400
Met Pro Pro Glu Tyr Lys Gly His Gln Val Lys Glu Val Leu Ile Gln			
405	410	415	
Asp Ser Ser Glu Gln Cys Leu Pro Met Ile Ser His Asp Ser Phe Pro			
420	425	430	
Asn Arg Leu Asn Val Asp Ile Gly Thr Thr Val Phe Leu Asp Cys Arg			
435	440	445	
Ala Met Ala Glu Pro Glu Pro Glu Ile Tyr Trp Val Thr Pro Ile Gly			
450	455	460	
Asn Lys Ile Thr Val Glu Thr Leu Ser Asp Lys Tyr Lys Leu Ser Ser			
465	470	475	480
Glu Gly Thr Leu Glu Ile Ser Asn Ile Gln Ile Glu Asp Ser Gly Arg			
485	490	495	
Tyr Thr Cys Val Ala Gln Asn Val Gln Gly Ala Asp Thr Arg Val Ala			
500	505	510	
Thr Ile Lys Val Asn Gly Thr Leu Leu Asp Gly Thr Gln Val Leu Lys			
515	520	525	
Ile Tyr Val Lys Gln Thr Glu Ser His Ser Ile Leu Val Ser Trp Lys			
530	535	540	
Val Asn Ser Asn Val Met Thr Ser Asn Leu Lys Trp Ser Ser Ala Thr			
545	550	555	560
Met Lys Ile Asp Asn Pro His Ile Thr Tyr Thr Ala Arg Val Pro Val			
565	570	575	
Asp Val His Glu Tyr Asn Leu Thr His Leu Gln Pro Ser Thr Asp Tyr			
580	585	590	
Glu Val Cys Leu Thr Val Ser Asn Ile His Gln Gln Thr Gln Lys Ser			
595	600	605	
Cys Val Asn Val Thr Thr Lys Asn Ala Ala Phe Ala Val Asp Ile Ser			
610	615	620	
Asp Gln Glu Thr Ser Thr Ala Leu Ala Ala Val Met Gly Ser Met Phe			
625	630	635	640
Ala Val Ile Ser Leu Ala Ser Ile Ala Val Tyr Phe Ala Lys Arg Phe			

	645	650	655
Lys Arg Lys Asn Tyr His His Ser	Leu Lys Lys Tyr Met Gln Lys Thr		
660	665	670	
Ser Ser Ile Pro Leu Asn Glu Leu Tyr Pro Pro Leu Ile Asn Leu Trp			
675	680	685	
Glu Gly Asp Ser Glu Lys Asp Lys Asp Gly Ser Ala Asp Thr Lys Pro			
690	695	700	
Thr Gln Val Asp Thr Ser Arg Ser Tyr Tyr Met Trp			
705	710	715	

